[sentNum: 1]<Annotation Id="24128" Type="Sentence" StartNode="0" EndNode="83">Importance  Breast cancer is a leading cause of premature mortality among US women. PreferredName:Leading SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Mortality, Premature SemanticType:[fndg] PreferredName:Science of Etiology SemanticType:[cnce] PreferredName:Woman SemanticType:[popg] POS:JJ POS:NN POS:NN POS:VBZ POS:DT POS:VBG POS:NN POS:IN POS:JJ POS:NN POS:IN POS:NNP POS:NNS POS:. 
[sentNum: 2]<Annotation Id="24129" Type="Sentence" StartNode="84" EndNode="183">Early detection has been shown to be associated with reduced breast cancer morbidity and mortality.PreferredName:Early Diagnosis SemanticType:[diap] PreferredName:To SemanticType:[qlco] PreferredName:Show SemanticType:[inpr] PreferredName:Reduced SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Morbidity - disease rate SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Mortality Vital Statistics SemanticType:[qnco] POS:JJ POS:NN POS:VBZ POS:VBN POS:VBN POS:TO POS:VB POS:VBN POS:IN POS:JJ POS:NN POS:NN POS:NN POS:CC POS:NN POS:. 
[sentNum: 3]<Annotation Id="24130" Type="Sentence" StartNode="185" EndNode="323">Objective  To update the American Cancer Society (ACS) 2003 breast cancer screening guideline for women at average risk for breast cancer.PreferredName:objective (goal) SemanticType:[inpr] PreferredName:American Cancer Society SemanticType:[pros] PreferredName:Update SemanticType:[tmco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:At risk SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Average SemanticType:[qnco] POS:VB POS:TO POS:VB POS:DT POS:NNP POS:NNP POS:NNP POS:( POS:NNP POS:) POS:CD POS:NN POS:NN POS:NN POS:NNS POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 4]<Annotation Id="24131" Type="Sentence" StartNode="325" EndNode="559">Process  The ACS commissioned a systematic evidence review of the breast cancer screening literature to inform the update and a supplemental analysis of mammography registry data to address questions related to the screening interval. PreferredName:Review, Systematic SemanticType:[inpr] PreferredName:Processed SemanticType:[phpr] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Publications SemanticType:[inpr, mnob] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Update SemanticType:[tmco] PreferredName:inform SemanticType:[idcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Supplement SemanticType:[ftcn] PreferredName:Data Analysis SemanticType:[ocac] PreferredName:Registries SemanticType:[inpr] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Address SemanticType:[spco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Relationships SemanticType:[qlco] PreferredName:Data Type Interval SemanticType:[inpr] POS:NNP POS:NNP POS:NNP POS:VBD POS:DT POS:JJ POS:NN POS:NN POS:IN POS:DT POS:NN POS:NN POS:NN POS:NN POS:TO POS:VB POS:DT POS:NN POS:CC POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:NNS POS:TO POS:VB POS:NNS POS:VBN POS:TO POS:DT POS:NN POS:NN POS:. 
[sentNum: 5]<Annotation Id="24132" Type="Sentence" StartNode="560" EndNode="724">Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms.PreferredName:Drug Formulation Process SemanticType:[resa] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Quality SemanticType:[qlco] PreferredName:Values SemanticType:[qlco] PreferredName:Judgment SemanticType:[menp] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:preference SemanticType:[idcn] PreferredName:Benefits SemanticType:[qnco] POS:NNP POS:IN POS:NNS POS:VBD POS:VBN POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:CC POS:NN POS:( POS:JJ POS:NNS POS:CC POS:NNS POS:) POS:IN POS:DT POS:NN POS:IN POS:NNS POS:CC POS:NNS POS:. 
[sentNum: 6]<Annotation Id="24133" Type="Sentence" StartNode="726" EndNode="995">Evidence Synthesis  Screening mammography in women aged 40 to 69 years is associated with a reduction in breast cancer deaths across a range of study designs, and inferential evidence supports breast cancer screening for women 70 years and older who are in good health. PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Synthesis SemanticType:[acty] PreferredName:Age SemanticType:[orga] PreferredName:Woman SemanticType:[popg] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:/40 SemanticType:[tmco] PreferredName:Associated with SemanticType:[qlco] PreferredName:year SemanticType:[tmco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Reduction mammaplasty SemanticType:[topp] PreferredName:Sample Range SemanticType:[qnco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Inference SemanticType:[menp] PreferredName:Research Design SemanticType:[resa] PreferredName:Supportive assistance SemanticType:[cnce] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Old SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Personal Satisfaction SemanticType:[fndg] PreferredName:are unit of measure SemanticType:[qnco] POS:NN POS:NNS POS:VBG POS:RB POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:VBZ POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:NNS POS:IN POS:DT POS:NN POS:IN POS:NN POS:NNS POS:, POS:CC POS:JJ POS:NN POS:VBZ POS:NN POS:NN POS:NN POS:IN POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:WP POS:VBP POS:IN POS:JJ POS:NN POS:. 
[sentNum: 7]<Annotation Id="24134" Type="Sentence" StartNode="996" EndNode="1220">Estimates of the cumulative lifetime risk of false-positive examination results are greater if screening begins at younger ages because of the greater number of mammograms, as well as the higher recall rate in younger women. PreferredName:Cumulative SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Largest SemanticType:[qnco] PreferredName:Young SemanticType:[tmco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Largest SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:Mammography SemanticType:[diap] PreferredName:Numbers SemanticType:[qnco] PreferredName:Recall:-:Point in time:^Patient:- SemanticType:[clna] PreferredName:High SemanticType:[qlco] PreferredName:Young SemanticType:[tmco] PreferredName:Rating (action) SemanticType:[acty] PreferredName:Woman SemanticType:[popg] POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:NN POS:IN POS:JJ POS:NN POS:NNS POS:VBP POS:JJR POS:IN POS:NN POS:VBZ POS:IN POS:JJR POS:NNS POS:RB POS:IN POS:DT POS:JJR POS:NN POS:IN POS:NNS POS:, POS:RB POS:RB POS:IN POS:DT POS:JJR POS:NN POS:NN POS:IN POS:JJR POS:NNS POS:. 
[sentNum: 8]<Annotation Id="24135" Type="Sentence" StartNode="1221" EndNode="1329">The quality of the evidence for overdiagnosis is not sufficient to estimate a lifetime risk with confidence. PreferredName:Quality SemanticType:[qlco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Sufficient SemanticType:[qlco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Confidence SemanticType:[menp] POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:VBZ POS:RB POS:JJ POS:TO POS:VB POS:DT POS:NN POS:NN POS:IN POS:NN POS:. 
[sentNum: 9]<Annotation Id="24136" Type="Sentence" StartNode="1330" EndNode="1483">Analysis examining the screening interval demonstrates more favorable tumor characteristics when premenopausal women are screened annually vs biennially. PreferredName:Analysis of substances SemanticType:[lbpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Examining SemanticType:[acty] PreferredName:Demonstrates SemanticType:[acty] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Favorable SemanticType:[qlco] PreferredName:More SemanticType:[ftcn] PreferredName:Characteristics SemanticType:[qlco] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Woman SemanticType:[popg] PreferredName:Premenopausal - menopausal status SemanticType:[tmco] PreferredName:Annual SemanticType:[tmco] PreferredName:Screening - procedure intent SemanticType:[ftcn] POS:NN POS:VBG POS:DT POS:NN POS:NN POS:VBZ POS:JJR POS:JJ POS:NN POS:NNS POS:WRB POS:JJ POS:NNS POS:VBP POS:VBG POS:RB POS:RB POS:RB POS:. 
[sentNum: 10]<Annotation Id="24137" Type="Sentence" StartNode="1484" EndNode="1594">Evidence does not support routine clinical breast examination as a screening method for women at average risk.PreferredName:Negation SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Health Checkup SemanticType:[topp] PreferredName:Supportive assistance SemanticType:[cnce] PreferredName:Screening Method SemanticType:[inpr] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Woman SemanticType:[popg] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] POS:NNS POS:VBZ POS:RB POS:VB POS:JJ POS:JJ POS:NN POS:NN POS:IN POS:DT POS:NN POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:. 
[sentNum: 11]<Annotation Id="24138" Type="Sentence" StartNode="1596" EndNode="1775">Recommendations  The ACS recommends that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years (strong recommendation). PreferredName:Recommendation SemanticType:[idcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Average SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Regular SemanticType:[qlco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Strong SemanticType:[qlco] POS:NNP POS:DT POS:NNP POS:VBZ POS:IN POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:MD POS:VB POS:JJ POS:NN POS:NN POS:VBG POS:IN POS:NN POS:CD POS:NNS POS:( POS:JJ POS:NN POS:) POS:. 
[sentNum: 12]<Annotation Id="24139" Type="Sentence" StartNode="1776" EndNode="1857">Women aged 45 to 54 years should be screened annually (qualified recommendation). PreferredName:Age SemanticType:[orga] PreferredName:Woman SemanticType:[popg] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:year SemanticType:[tmco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Annual SemanticType:[tmco] POS:RB POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:MD POS:VB POS:VBN POS:RB POS:( POS:JJ POS:NN POS:) POS:. 
[sentNum: 13]<Annotation Id="24140" Type="Sentence" StartNode="1858" EndNode="2005">Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation). PreferredName:Arabic numeral 55 SemanticType:[inpr] PreferredName:Woman SemanticType:[popg] PreferredName:Old SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Transition Mutation SemanticType:[comd] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Continuous SemanticType:[idcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Annual SemanticType:[tmco] POS:NNP POS:CD POS:NNS POS:CC POS:JJR POS:MD POS:VB POS:TO POS:JJ POS:NN POS:CC POS:VB POS:DT POS:NN POS:TO POS:VB POS:VBG POS:RB POS:( POS:JJ POS:NN POS:) POS:. 
[sentNum: 14]<Annotation Id="24141" Type="Sentence" StartNode="2006" EndNode="2129">Women should have the opportunity to begin annual screening between the ages of 40 and 44 years (qualified recommendation). PreferredName:Beginning SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:annual screening SemanticType:[diap] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Recommendation SemanticType:[idcn] POS:NNS POS:MD POS:VB POS:DT POS:NN POS:TO POS:VB POS:JJ POS:NN POS:IN POS:DT POS:NNS POS:IN POS:CD POS:CC POS:CD POS:NNS POS:( POS:JJ POS:NN POS:) POS:. 
[sentNum: 15]<Annotation Id="24142" Type="Sentence" StartNode="2130" EndNode="2295">Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation). PreferredName:Woman SemanticType:[popg] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Continuous SemanticType:[idcn] PreferredName:Long SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] PreferredName:Health SemanticType:[idcn] PreferredName:Overall SemanticType:[qlco] PreferredName:antineoplaston A10 SemanticType:[orch, phsu] PreferredName:Good SemanticType:[qlco] PreferredName:year SemanticType:[tmco] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Long SemanticType:[qlco] POS:NNS POS:MD POS:VB POS:NN POS:NN POS:RB POS:RB POS:IN POS:PRP$ POS:JJ POS:NN POS:VBZ POS:JJ POS:CC POS:PRP POS:VBP POS:DT POS:NN POS:NN POS:IN POS:CD POS:NNS POS:CC POS:JJR POS:( POS:JJ POS:NN POS:) POS:. 
[sentNum: 16]<Annotation Id="24143" Type="Sentence" StartNode="2296" EndNode="2442">The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age (qualified recommendation).PreferredName:Recommendation SemanticType:[idcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:Woman SemanticType:[popg] PreferredName:Recommendation SemanticType:[idcn] POS:DT POS:NNP POS:VBZ POS:RB POS:VB POS:JJ POS:NN POS:NN POS:IN POS:NN POS:NN POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:DT POS:NN POS:( POS:JJ POS:NN POS:) POS:. 
[sentNum: 17]<Annotation Id="24144" Type="Sentence" StartNode="2444" EndNode="2610">Conclusions and Relevance  These updated ACS guidelines provide evidence-based recommendations for breast cancer screening for women at average risk of breast cancer. PreferredName:Conclusion SemanticType:[idcn] PreferredName:Update SemanticType:[tmco] PreferredName:Relevance SemanticType:[qlco] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:NNP POS:CC POS:NNP POS:DT POS:VBN POS:NN POS:NNS POS:VBP POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 18]<Annotation Id="24145" Type="Sentence" StartNode="2611" EndNode="2723">These recommendations should be considered by physicians and women in discussions about breast cancer screening.PreferredName:Recommendation SemanticType:[idcn] PreferredName:Physicians SemanticType:[prog] PreferredName:consider SemanticType:[idcn] PreferredName:Discussion (procedure) SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] POS:DT POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:NNS POS:CC POS:NNS POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:. 
[sentNum: 19]<Annotation Id="24146" Type="Sentence" StartNode="2725" EndNode="2784">Breast cancer is the most common cancer in women worldwide.1PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:shared attribute SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] POS:JJ POS:NN POS:VBZ POS:DT POS:RBS POS:JJ POS:NN POS:IN POS:NNS POS:VBN POS:. 
[sentNum: 20]<Annotation Id="24147" Type="Sentence" StartNode="2784" EndNode="3058">1 In the United States, an estimated 231 840 women will be diagnosed with breast cancer in 2015.2 Breast cancer continues to rank second, after lung cancer, as a cause of cancer death in women in the United States, and it is a leading cause of premature mortality for women. PreferredName:United States SemanticType:[geoa] PreferredName:Woman SemanticType:[popg] PreferredName:Estimated SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Continuous SemanticType:[idcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Rank SemanticType:[inpr] PreferredName:To SemanticType:[qlco] PreferredName:Malignant neoplasm of lung SemanticType:[neop] PreferredName:seconds SemanticType:[tmco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Cause of Death SemanticType:[fndg] PreferredName:Woman SemanticType:[popg] PreferredName:Within SemanticType:[spco] PreferredName:Leading SemanticType:[ftcn] PreferredName:United States SemanticType:[geoa] PreferredName:Mortality, Premature SemanticType:[fndg] PreferredName:Science of Etiology SemanticType:[cnce] PreferredName:Woman SemanticType:[popg] POS:LS POS:IN POS:DT POS:NNP POS:NNPS POS:, POS:DT POS:VBN POS:CD POS:NNP POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:NN POS:NN POS:IN POS:CD POS:. POS:CD POS:NNP POS:NN POS:VBZ POS:TO POS:VB POS:JJ POS:, POS:IN POS:NN POS:NN POS:, POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:IN POS:NNS POS:IN POS:DT POS:NNP POS:NNPS POS:, POS:CC POS:PRP POS:VBZ POS:DT POS:VBG POS:NN POS:IN POS:JJ POS:NN POS:IN POS:NNS POS:. 
[sentNum: 21]<Annotation Id="24148" Type="Sentence" StartNode="3059" EndNode="3195">In 2012, deaths from breast cancer accounted for 783 000 years of potential life lost and an average of 19 years of life lost per death.3PreferredName:Cessation of life SemanticType:[orgf] PreferredName:account - ActClass SemanticType:[idcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Potential SemanticType:[qlco] PreferredName:year SemanticType:[tmco] PreferredName:Lost SemanticType:[ftcn] PreferredName:Life SemanticType:[idcn] PreferredName:year SemanticType:[tmco] PreferredName:Average SemanticType:[qnco] PreferredName:Lost SemanticType:[ftcn] PreferredName:Life SemanticType:[idcn] PreferredName:Cessation of life SemanticType:[orgf] POS:IN POS:CD POS:, POS:NNS POS:IN POS:NN POS:NN POS:VBD POS:IN POS:CD POS:CD POS:NNS POS:IN POS:JJ POS:NN POS:VBN POS:CC POS:DT POS:NN POS:IN POS:CD POS:NNS POS:IN POS:NN POS:VBN POS:IN POS:NN POS:. 
[sentNum: 22]<Annotation Id="24149" Type="Sentence" StartNode="3195" EndNode="3417">3 Even though mortality from breast cancer has declined steadily since 1990, largely due to improvements in early detection and treatment,4 an estimated 40 290 women in the United States will die of breast cancer in 2015.2PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:1990s SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Improvement SemanticType:[cnce] PreferredName:Due to SemanticType:[ftcn] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Early Diagnosis SemanticType:[diap] PreferredName:/40 SemanticType:[tmco] PreferredName:Estimated SemanticType:[qnco] PreferredName:United States SemanticType:[geoa] PreferredName:Woman SemanticType:[popg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Cessation of life SemanticType:[orgf] POS:CD POS:RB POS:IN POS:NN POS:IN POS:NN POS:NN POS:VBZ POS:VBN POS:RB POS:IN POS:CD POS:, POS:RB POS:JJ POS:TO POS:NNS POS:IN POS:JJ POS:NN POS:CC POS:NN POS:, POS:CD POS:DT POS:VBN POS:CD POS:CD POS:NNS POS:IN POS:DT POS:NNP POS:NNPS POS:MD POS:VB POS:IN POS:NN POS:NN POS:IN POS:CD POS:. POS:CD 
[sentNum: 23]<Annotation Id="24150" Type="Sentence" StartNode="3419" EndNode="3709">Since the last ACS breast cancer screening update for average-risk women was published in 2003,5 new evidence has accumulated from long-term follow-up of the randomized controlled trials (RCTs) and observational studies of organized, population-based screening (service screening) programs. PreferredName:Update SemanticType:[tmco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Woman SemanticType:[popg] PreferredName:New SemanticType:[tmco] PreferredName:&gt;5 SemanticType:[qnco] PreferredName:Longterm Follow-up SemanticType:[hlca] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Observational Study SemanticType:[resa] PreferredName:Randomized Controlled Trials as Topic SemanticType:[inpr, resa] PreferredName:Population Based Study SemanticType:[resa] PreferredName:Organized SemanticType:[ftcn] PreferredName:Services SemanticType:[ocac] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Programs - Publication Format SemanticType:[inpr] PreferredName:Disease Screening SemanticType:[diap] POS:IN POS:DT POS:JJ POS:NNP POS:NN POS:NN POS:NN POS:NN POS:IN POS:JJ POS:NNS POS:VBD POS:VBN POS:IN POS:CD POS:, POS:CD POS:JJ POS:NN POS:VBZ POS:VBN POS:IN POS:JJ POS:NN POS:IN POS:DT POS:JJ POS:JJ POS:NNS POS:( POS:NNP POS:) POS:CC POS:JJ POS:NNS POS:IN POS:VBN POS:, POS:JJ POS:NN POS:( POS:NN POS:NN POS:) POS:NNS POS:. 
[sentNum: 24]<Annotation Id="24151" Type="Sentence" StartNode="3710" EndNode="3947">In addition, there is now greater emphasis on estimating harms associated with screening; assessing the balance of benefits and harms; and supporting the interplay among values, preferences, informed decision making, and recommendations. PreferredName:Now (temporal qualifier) SemanticType:[tmco] PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Largest SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Associated with SemanticType:[qlco] PreferredName:Ability to balance SemanticType:[fndg] PreferredName:Assessed SemanticType:[acty] PreferredName:Supportive assistance SemanticType:[cnce] PreferredName:Benefits SemanticType:[qnco] PreferredName:preference SemanticType:[idcn] PreferredName:Values SemanticType:[qlco] PreferredName:Decision Making SemanticType:[menp] PreferredName:Informed SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] POS:IN POS:NN POS:, POS:EX POS:VBZ POS:RB POS:JJR POS:NN POS:IN POS:VBG POS:NNS POS:VBN POS:IN POS:NN POS:: POS:VBG POS:DT POS:NN POS:IN POS:NNS POS:CC POS:NNS POS:: POS:CC POS:VBG POS:DT POS:NN POS:IN POS:NNS POS:, POS:NNS POS:, POS:JJ POS:NN POS:NN POS:, POS:CC POS:NNS POS:. 
[sentNum: 25]<Annotation Id="24152" Type="Sentence" StartNode="3948" EndNode="4183">In 2011, the ACS incorporated standards recommended by the Institute of Medicine6,7 into its guidelines development protocol to ensure a more trustworthy, transparent, and consistent process for developing and communicating guidelines.8PreferredName:standards characteristics SemanticType:[inpr] PreferredName:Institutes SemanticType:[orgt] PreferredName:Recommendation SemanticType:[idcn] PreferredName:protocol development SemanticType:[resa] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:More SemanticType:[ftcn] PreferredName:Ensure (product) SemanticType:[food] PreferredName:Translucent SemanticType:[qlco] PreferredName:Trustworthiness SemanticType:[menp] PreferredName:Processed SemanticType:[phpr] PreferredName:Consistent with SemanticType:[idcn] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Does communicate SemanticType:[fndg] POS:IN POS:CD POS:, POS:DT POS:NNP POS:JJ POS:NNS POS:VBN POS:IN POS:DT POS:NNP POS:IN POS:NNP POS:CD POS:, POS:CD POS:IN POS:PRP$ POS:NNS POS:NN POS:NN POS:TO POS:VB POS:DT POS:RBR POS:JJ POS:, POS:JJ POS:, POS:CC POS:JJ POS:NN POS:IN POS:VBG POS:CC POS:VBG POS:NNS POS:. 
[sentNum: 26]<Annotation Id="24153" Type="Sentence" StartNode="4183" EndNode="4184">8POS:CD 
[sentNum: 27]<Annotation Id="24154" Type="Sentence" StartNode="4186" EndNode="4460">In accordance with the new guideline development process, the ACS organized an interdisciplinary guideline development group (GDG) consisting of clinicians (n = 4), biostatisticians (n = 2), epidemiologists (n = 2), an economist (n = 1), and patient representatives (n = 2). PreferredName:Guidelines SemanticType:[inpr] PreferredName:New SemanticType:[tmco] PreferredName:Organized SemanticType:[ftcn] PreferredName:Developmental Process SemanticType:[ortf] PreferredName:Guidelines SemanticType:[inpr] PreferredName:Interdisciplinary Studies SemanticType:[ocac] PreferredName:Groups SemanticType:[idcn] PreferredName:Development SemanticType:[ftcn] PreferredName:Clinician SemanticType:[prog] PreferredName:Consistency SemanticType:[qlco] PreferredName:Biostatistician - NUCCProviderCodes SemanticType:[inpr] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] PreferredName:Epidemiologist SemanticType:[prog] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] PreferredName:Economist SemanticType:[prog] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] PreferredName:Patient Representatives SemanticType:[prog] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] POS:IN POS:NN POS:IN POS:DT POS:JJ POS:NN POS:NN POS:NN POS:, POS:DT POS:NNP POS:VBD POS:DT POS:JJ POS:NN POS:NN POS:NN POS:( POS:NNP POS:) POS:VBG POS:IN POS:NNS POS:( POS:VBN POS:SYM POS:CD POS:) POS:, POS:NNS POS:( POS:VBN POS:SYM POS:CD POS:) POS:, POS:NNS POS:( POS:VBN POS:SYM POS:CD POS:) POS:, POS:DT POS:NN POS:( POS:VBN POS:SYM POS:CD POS:) POS:, POS:CC POS:JJ POS:NNS POS:( POS:VBN POS:SYM POS:CD POS:) POS:. 
[sentNum: 28]<Annotation Id="24155" Type="Sentence" StartNode="4461" EndNode="4647">The GDG developed 5 key questions using the general approach of specifying populations, interventions, comparisons, outcomes, timing of outcomes, and settings (PICOTS) for each question.9PreferredName:Guidelines SemanticType:[inpr] PreferredName:Groups SemanticType:[idcn] PreferredName:Development SemanticType:[ftcn] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Integer +5 SemanticType:[qnco] PreferredName:General Population SemanticType:[popg] PreferredName:Use of SemanticType:[ftcn] PreferredName:To specify SemanticType:[qlco] PreferredName:Approach SemanticType:[spco] PreferredName:Comparison SemanticType:[acty] PreferredName:Intervention regimes SemanticType:[hlca] PreferredName:Timing SemanticType:[tmco] PreferredName:Result SemanticType:[ftcn] PreferredName:{Setting} SemanticType:[qnco] PreferredName:Result SemanticType:[ftcn] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Picot SemanticType:[phsu] PreferredName:Question (inquiry) SemanticType:[inpr] POS:DT POS:NNP POS:VBD POS:CD POS:JJ POS:NNS POS:VBG POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:NNS POS:, POS:NNS POS:, POS:NNS POS:, POS:NNS POS:, POS:NN POS:IN POS:NNS POS:, POS:CC POS:NNS POS:( POS:NNP POS:) POS:IN POS:DT POS:NN POS:. 
[sentNum: 29]<Annotation Id="24156" Type="Sentence" StartNode="4647" EndNode="4845">9 After evaluating available methods to grade the evidence and the strength of recommendations, the GDG selected the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system. PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Methods SemanticType:[inpr] PreferredName:Availability of SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Grade SemanticType:[clas] PreferredName:Recommendation SemanticType:[idcn] PreferredName:STRENGTH (attribute) SemanticType:[idcn] PreferredName:Development SemanticType:[ftcn] PreferredName:Guidelines SemanticType:[inpr] PreferredName:Choose (action) SemanticType:[acty] PreferredName:Groups SemanticType:[idcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Grade SemanticType:[clas] PreferredName:Development SemanticType:[ftcn] PreferredName:Assessed SemanticType:[acty] PreferredName:System SemanticType:[ftcn] PreferredName:Evaluation SemanticType:[ftcn] POS:CD POS:IN POS:VBG POS:JJ POS:NNS POS:TO POS:VB POS:DT POS:NN POS:CC POS:DT POS:NN POS:IN POS:NNS POS:, POS:DT POS:NNP POS:VBD POS:DT POS:NNP POS:IN POS:NNP POS:, POS:NNS POS:, POS:NNP POS:, POS:CC POS:NNP POS:( POS:NNP POS:) POS:NN POS:. 
[sentNum: 30]<Annotation Id="24157" Type="Sentence" StartNode="4846" EndNode="5157">GRADE is an accepted approach with a defined analytic framework, an explicit consideration of values and preferences in addressing patient-centered outcomes, the capacity for flexibility in evaluating results from observational studies, and separation between quality of evidence and strength of recommendation.10PreferredName:Recommendation SemanticType:[idcn] PreferredName:Grade SemanticType:[clas] PreferredName:Development SemanticType:[ftcn] PreferredName:Assessed SemanticType:[acty] PreferredName:Accepted SemanticType:[qlco] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Definition SemanticType:[cnce] PreferredName:Approach SemanticType:[spco] PreferredName:Values SemanticType:[qlco] PreferredName:consideration SemanticType:[fndg] PreferredName:Address SemanticType:[spco] PreferredName:preference SemanticType:[idcn] PreferredName:Capacity SemanticType:[qnco] PreferredName:Patient-Focused Outcomes SemanticType:[resa] PreferredName:Within SemanticType:[spco] PreferredName:Pliability SemanticType:[qlco] PreferredName:research outcome SemanticType:[fndg] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Marital separation SemanticType:[socb] PreferredName:Observational Study SemanticType:[resa] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Quality SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:STRENGTH (attribute) SemanticType:[idcn] POS:NNP POS:VBZ POS:DT POS:JJ POS:NN POS:IN POS:DT POS:JJ POS:JJ POS:NN POS:, POS:DT POS:JJ POS:NN POS:IN POS:NNS POS:CC POS:NNS POS:IN POS:VBG POS:JJ POS:NNS POS:, POS:DT POS:NN POS:IN POS:NN POS:IN POS:VBG POS:NNS POS:IN POS:JJ POS:NNS POS:, POS:CC POS:NN POS:IN POS:NN POS:IN POS:NN POS:CC POS:NN POS:IN POS:NN POS:. 
[sentNum: 31]<Annotation Id="24158" Type="Sentence" StartNode="5157" EndNode="5162">10,11POS:CD POS:, POS:CD 
[sentNum: 32]<Annotation Id="24159" Type="Sentence" StartNode="5164" EndNode="5370">The ACS GDG selected the Duke University Evidence Synthesis Group to conduct an independent systematic evidence review of the breast cancer screening literature, after a response to a request for proposals. PreferredName:Duke Method for Bleeding Time Measurement SemanticType:[lbpr] PreferredName:Choose (action) SemanticType:[acty] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Universities SemanticType:[mnob, orgt] PreferredName:Population Group SemanticType:[popg] PreferredName:Synthesis SemanticType:[acty] PreferredName:Independence SemanticType:[idcn] PreferredName:Behavior SemanticType:[inbe] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Review, Systematic SemanticType:[inpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Response process SemanticType:[orga] PreferredName:Publications SemanticType:[inpr, mnob] PreferredName:proposal - intent SemanticType:[idcn] PreferredName:Request - action SemanticType:[ftcn] POS:DT POS:NNP POS:NNP POS:VBD POS:DT POS:NNP POS:NNP POS:NNP POS:NNPS POS:NNP POS:TO POS:VB POS:DT POS:JJ POS:JJ POS:NN POS:NN POS:IN POS:DT POS:NN POS:NN POS:NN POS:NN POS:, POS:IN POS:DT POS:NN POS:TO POS:DT POS:NN POS:IN POS:NNS POS:. 
[sentNum: 33]<Annotation Id="24160" Type="Sentence" StartNode="5371" EndNode="5421">This effort is referred to as the evidence review. PreferredName:Referring SemanticType:[ftcn] PreferredName:Exertion SemanticType:[orgf] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Review [Publication Type] SemanticType:[inpr] POS:DT POS:NN POS:VBZ POS:VBN POS:TO POS:IN POS:DT POS:JJ POS:NN POS:. 
[sentNum: 34]<Annotation Id="24161" Type="Sentence" StartNode="5422" EndNode="5592">In addition, the ACS commissioned the Breast Cancer Surveillance Consortium (BCSC) to update previously published analyses related to the screening interval and outcomes. PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Update SemanticType:[tmco] PreferredName:Breast Cancer Surveillance Consortium SemanticType:[prog] PreferredName:Analysis SemanticType:[resa] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Relationships SemanticType:[qlco] PreferredName:Result SemanticType:[ftcn] PreferredName:Parameterized Data Type - Interval SemanticType:[idcn] POS:IN POS:NN POS:, POS:DT POS:NNP POS:VBD POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:( POS:NNP POS:) POS:TO POS:VB POS:RB POS:VBN POS:NNS POS:VBN POS:TO POS:DT POS:NN POS:JJ POS:CC POS:JJ POS:. 
[sentNum: 35]<Annotation Id="24162" Type="Sentence" StartNode="5593" EndNode="5776">The ACS Surveillance and Health Services Research Program provided supplementary data on disease burden using data from the Surveillance, Epidemiology, and End Results (SEER) Program.3PreferredName:Health Services Research SemanticType:[resa] PreferredName:Medical Surveillance SemanticType:[hlca] PreferredName:Data SemanticType:[idcn] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Burden SemanticType:[idcn] PreferredName:breast and cervical cancer disease program SemanticType:[hcro] PreferredName:Data SemanticType:[idcn] PreferredName:Use of SemanticType:[ftcn] PreferredName:epidemiologic SemanticType:[ftcn] PreferredName:Medical Surveillance SemanticType:[hlca] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Stop (qualifier value) SemanticType:[tmco] PreferredName:Program SemanticType:[phsu] POS:DT POS:NNP POS:NNP POS:CC POS:NNP POS:NNP POS:NNP POS:NNP POS:VBD POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:VBG POS:NNS POS:IN POS:DT POS:NNP POS:, POS:NNP POS:, POS:CC POS:NNP POS:NNP POS:( POS:NNP POS:) POS:NNP POS:. 
[sentNum: 36]<Annotation Id="24163" Type="Sentence" StartNode="5776" EndNode="5777">3POS:NNP 
[sentNum: 37]<Annotation Id="24164" Type="Sentence" StartNode="5779" EndNode="6050">The GDG deliberations on the evidence and framing of the recommendations were guided by the GRADE domains: the balance between desirable and undesirable outcomes, the diversity in women’s values and preferences, and confidence in the magnitude of the effects on outcomes.12PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Reading Frames (Nucleotide Sequence) SemanticType:[nusq] PreferredName:Grade SemanticType:[clas] PreferredName:Professional guide SemanticType:[prog] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Domain (area of knowledge) SemanticType:[ftcn] PreferredName:Diversity SemanticType:[qlco] PreferredName:Result SemanticType:[ftcn] PreferredName:Values SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Self Confidence SemanticType:[menp] PreferredName:preference SemanticType:[idcn] PreferredName:Effect SemanticType:[qlco] PreferredName:Magnitude SemanticType:[qnco] PreferredName:Result SemanticType:[ftcn] POS:DT POS:NNP POS:NNS POS:IN POS:DT POS:NN POS:CC POS:NN POS:IN POS:DT POS:NNS POS:VBD POS:VBN POS:IN POS:DT POS:JJ POS:NNS POS:: POS:DT POS:NN POS:IN POS:JJ POS:CC POS:JJ POS:NNS POS:, POS:DT POS:NN POS:IN POS:NNS POS:NNS POS:VBZ POS:NNS POS:CC POS:NNS POS:, POS:CC POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:NNS POS:IN POS:NNS POS:. 
[sentNum: 38]<Annotation Id="24165" Type="Sentence" StartNode="6050" EndNode="6169">12,13Quiz Ref ID The GDG chose to assess recommendations as “strong” or “qualified,” in accordance with GRADE guidance.13PreferredName:ALYREF gene SemanticType:[gngm] PreferredName:Choose (action) SemanticType:[acty] PreferredName:Identifier SemanticType:[inpr] PreferredName:Assessed SemanticType:[acty] PreferredName:To SemanticType:[qlco] PreferredName:Strong SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Advice SemanticType:[hlca] PreferredName:Grade SemanticType:[clas] POS:CD POS:, POS:CD POS:NNP POS:NNP POS:NNP POS:DT POS:NNP POS:VBD POS:TO POS:VB POS:NNS POS:IN POS:JJ POS:JJ POS:NNS POS:CC POS:RB POS:VBN POS:, POS:VBD POS:IN POS:NN POS:IN POS:NNP POS:NN POS:. 
[sentNum: 39]<Annotation Id="24166" Type="Sentence" StartNode="6169" EndNode="6302">13 A strong recommendation conveys the consensus that the benefits of adherence to the intervention outweigh the undesirable effects. PreferredName:Recommendation SemanticType:[idcn] PreferredName:Strong SemanticType:[qlco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Consensus SemanticType:[socb] PreferredName:Intervention regimes SemanticType:[hlca] PreferredName:Adherence (attribute) SemanticType:[ftcn] PreferredName:aspects of adverse effects SemanticType:[ftcn] POS:CD POS:NN POS:JJ POS:NN POS:VBZ POS:DT POS:NN POS:IN POS:DT POS:NNS POS:IN POS:NN POS:TO POS:DT POS:NN POS:VBP POS:DT POS:JJ POS:NNS POS:. 
[sentNum: 40]<Annotation Id="24167" Type="Sentence" StartNode="6303" EndNode="6533">Qualified recommendations indicate there is clear evidence of benefit but less certainty about either the balance of benefits and harms, or about patients’ values and preferences, which could lead to different decisions (Table 1).PreferredName:Recommendation SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Clear SemanticType:[qlco] PreferredName:Less Than SemanticType:[inpr] PreferredName:Benefits SemanticType:[qnco] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Certain (qualifier value) SemanticType:[qlco] PreferredName:Patients SemanticType:[podg] PreferredName:Benefits SemanticType:[qnco] PreferredName:preference SemanticType:[idcn] PreferredName:Values SemanticType:[qlco] PreferredName:Different SemanticType:[qlco] PreferredName:Dietary Lead SemanticType:[elii] PreferredName:Table - furniture SemanticType:[mnob] PreferredName:Decision SemanticType:[menp] POS:JJ POS:NNS POS:VBP POS:EX POS:VBZ POS:JJ POS:NN POS:IN POS:NN POS:CC POS:JJR POS:NN POS:IN POS:CC POS:DT POS:NN POS:IN POS:NNS POS:CC POS:NNS POS:, POS:CC POS:IN POS:NNS POS:JJ POS:NNS POS:CC POS:NNS POS:, POS:WDT POS:MD POS:VB POS:TO POS:JJ POS:NNS POS:( POS:NNP POS:CD POS:) POS:. 
[sentNum: 41]<Annotation Id="24168" Type="Sentence" StartNode="6535" EndNode="6649">The GDG members voted on agreement or disagreement with each recommendation and on the strength of recommendation. PreferredName:Voting SemanticType:[inbe] PreferredName:member SemanticType:[popg] PreferredName:Discord SemanticType:[socb] PreferredName:Agreement SemanticType:[socb] PreferredName:And SemanticType:[idcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:STRENGTH (attribute) SemanticType:[idcn] POS:DT POS:NNP POS:NNS POS:VBD POS:IN POS:NN POS:CC POS:NN POS:IN POS:DT POS:NN POS:CC POS:IN POS:DT POS:NN POS:IN POS:NN POS:. 
[sentNum: 42]<Annotation Id="24169" Type="Sentence" StartNode="6650" EndNode="6730">A record of the vote with respect to each question was made without attribution. PreferredName:Voting SemanticType:[inbe] PreferredName:Records SemanticType:[inpr] PreferredName:Make - Instruction Imperative SemanticType:[ftcn] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Attribution SemanticType:[menp] POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:TO POS:DT POS:NN POS:VBD POS:VBN POS:IN POS:NN POS:. 
[sentNum: 43]<Annotation Id="24170" Type="Sentence" StartNode="6731" EndNode="6885">The panel attempted to achieve 100% agreement whenever possible, but a three-quarters majority was considered acceptable (see eMethods in the Supplement).PreferredName:Laboratory Order Panels SemanticType:[inpr] PreferredName:To SemanticType:[qlco] PreferredName:Attempt SemanticType:[evnt] PreferredName:Possibly Related to Intervention SemanticType:[qlco] PreferredName:Agreement SemanticType:[socb] PreferredName:Quarter SemanticType:[qnco] PreferredName:Three SemanticType:[qnco] PreferredName:consider SemanticType:[idcn] PreferredName:majority SemanticType:[socb] PreferredName:Vision SemanticType:[orgf] PreferredName:Acceptable SemanticType:[qlco] PreferredName:Supplement SemanticType:[ftcn] POS:DT POS:NN POS:VBD POS:TO POS:VB POS:CD POS:NN POS:NN POS:WRB POS:JJ POS:, POS:CC POS:DT POS:NNS POS:NN POS:VBD POS:VBN POS:JJ POS:( POS:VB POS:NNS POS:IN POS:DT POS:NNP POS:) POS:. 
[sentNum: 44]<Annotation Id="24171" Type="Sentence" StartNode="6887" EndNode="7068">Prior to submitting the final guideline for publication, 26 relevant outside organizations and 22 expert advisors were invited to participate in an external review of the guideline. PreferredName:Diagnosis Type - Final SemanticType:[idcn] PreferredName:Publications SemanticType:[inpr, mnob] PreferredName:Guidelines SemanticType:[inpr] PreferredName:Extrinsic SemanticType:[spco] PreferredName:Relevance SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Organization administrative structures SemanticType:[orgt] PreferredName:Review [Publication Type] SemanticType:[inpr] PreferredName:Extrinsic SemanticType:[spco] PreferredName:Guidelines SemanticType:[inpr] POS:RB POS:TO POS:VBG POS:DT POS:JJ POS:NN POS:IN POS:NN POS:, POS:CD POS:JJ POS:JJ POS:NNS POS:CC POS:CD POS:NN POS:NNS POS:VBD POS:VBN POS:TO POS:VB POS:IN POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NN POS:. 
[sentNum: 45]<Annotation Id="24172" Type="Sentence" StartNode="7069" EndNode="7200">Responses were documented and reviewed by the GDG to determine if modifications in the narrative or recommendations were warranted. PreferredName:Response process SemanticType:[orga] PreferredName:Reviewed SemanticType:[qlco] PreferredName:Documented SemanticType:[hlca] PreferredName:Narration SemanticType:[socb] PreferredName:ResponseLevel - modification SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] POS:NNS POS:VBD POS:VBN POS:CC POS:VBN POS:IN POS:DT POS:NNP POS:TO POS:VB POS:IN POS:NNS POS:IN POS:DT POS:NNS POS:CC POS:NNS POS:VBD POS:VBN POS:. 
[sentNum: 46]<Annotation Id="24173" Type="Sentence" StartNode="7201" EndNode="7293">Details of the guideline development process are provided in the eMethods in the Supplement.PreferredName:Details SemanticType:[qlco] PreferredName:Developmental Process SemanticType:[ortf] PreferredName:Guidelines SemanticType:[inpr] PreferredName:Supplement (document) SemanticType:[inpr] PreferredName:Providing (action) SemanticType:[acty] POS:NNS POS:IN POS:DT POS:NN POS:NN POS:NN POS:VBP POS:VBN POS:IN POS:DT POS:NNPS POS:IN POS:DT POS:NNP POS:. 
[sentNum: 47]<Annotation Id="24174" Type="Sentence" StartNode="7295" EndNode="7592">All participants in the guideline development process were required to disclose all financial and nonfinancial (personal, intellectual, practice-related) relationships and activities that might be perceived as posing a conflict of interest in development of the breast cancer screening guidelines. PreferredName:Participant SemanticType:[popg] PreferredName:All SemanticType:[qnco] PreferredName:Developmental Process SemanticType:[ortf] PreferredName:Guidelines SemanticType:[inpr] PreferredName:To SemanticType:[qlco] PreferredName:Requirement SemanticType:[ftcn] PreferredName:personal relationship SemanticType:[idcn] PreferredName:Financial (qualifier) SemanticType:[qlco] PreferredName:Relationships SemanticType:[qlco] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Perception SemanticType:[menp] PreferredName:Activities SemanticType:[acty] PreferredName:Interested SemanticType:[menp] PreferredName:Conflict (Psychology) SemanticType:[inbe] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Development SemanticType:[ftcn] PreferredName:Guidelines SemanticType:[inpr] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:DT POS:NNS POS:IN POS:DT POS:NN POS:NN POS:NN POS:VBD POS:VBN POS:TO POS:VB POS:PDT POS:JJ POS:CC POS:NNP POS:( POS:NN POS:, POS:NN POS:, POS:NN POS:) POS:NNS POS:CC POS:NNS POS:WDT POS:MD POS:VB POS:VBN POS:IN POS:VBG POS:DT POS:NN POS:IN POS:NN POS:IN POS:NN POS:IN POS:DT POS:NN POS:NN POS:NN POS:NNS POS:. 
[sentNum: 48]<Annotation Id="24175" Type="Sentence" StartNode="7593" EndNode="7733">The chairpersons of the ACS GDG had the responsibility to ensure balanced perspectives were considered in deliberations and decision making. PreferredName:Responsible to SemanticType:[fndg] PreferredName:Chairperson SemanticType:[prog] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Ensure (product) SemanticType:[food] PreferredName:Decision Making SemanticType:[menp] PreferredName:consider SemanticType:[idcn] POS:DT POS:NNS POS:IN POS:DT POS:NNP POS:NNP POS:VBD POS:DT POS:NN POS:TO POS:VB POS:JJ POS:NNS POS:VBD POS:VBN POS:IN POS:NNS POS:CC POS:NN POS:NN POS:. 
[sentNum: 49]<Annotation Id="24176" Type="Sentence" StartNode="7734" EndNode="7895">In addition to the disclosures listed in the Article Information section, nonfinancial disclosures of the authors are reported in the eMethods in the Supplement.PreferredName:List SemanticType:[cnce] PreferredName:Disclosure SemanticType:[inbe] PreferredName:Information SemanticType:[idcn] PreferredName:Article SemanticType:[inpr] PreferredName:Disclosure SemanticType:[inbe] PreferredName:section sample SemanticType:[sbst] PreferredName:Reporting SemanticType:[hlca] PreferredName:Journalist SemanticType:[prog] PreferredName:Supplement SemanticType:[ftcn] POS:IN POS:NN POS:TO POS:DT POS:NNS POS:VBN POS:IN POS:DT POS:NNP POS:NNP POS:NN POS:, POS:CD POS:NNS POS:IN POS:DT POS:NNS POS:VBP POS:VBN POS:IN POS:DT POS:NNS POS:IN POS:DT POS:NNP POS:. 
[sentNum: 50]<Annotation Id="24177" Type="Sentence" StartNode="7897" EndNode="7934">Questions Guiding the Evidence ReviewPreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Guide device SemanticType:[medd] PreferredName:Review [Publication Type] SemanticType:[inpr] POS:NNS POS:VBD POS:DT POS:NN POS:NN 
[sentNum: 51]<Annotation Id="24178" Type="Sentence" StartNode="7936" EndNode="8083">This evidence-based breast cancer screening guideline for women at average risk focuses on 3 key questions of the 5 original key questions (Box 1).PreferredName:This SemanticType:[euka] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Average SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Focal SemanticType:[spco] PreferredName:Risk SemanticType:[qlco] PreferredName:Original SemanticType:[idcn] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Protective cup SemanticType:[medd] POS:DT POS:JJ POS:NN POS:NN POS:NN POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:VBZ POS:IN POS:CD POS:JJ POS:NNS POS:IN POS:DT POS:CD POS:JJ POS:JJ POS:NNS POS:( POS:NNP POS:CD POS:) POS:. 
[sentNum: 52]<Annotation Id="24179" Type="Sentence" StartNode="8084" EndNode="8102">Box Section Ref IDPreferredName:Protective cup SemanticType:[medd] PreferredName:ALYREF gene SemanticType:[gngm] PreferredName:section sample SemanticType:[sbst] PreferredName:Identifier SemanticType:[inpr] POS:NNP POS:NNP POS:NNP POS:NNPS 
[sentNum: 53]<Annotation Id="24180" Type="Sentence" StartNode="8104" EndNode="8110">Box 1.PreferredName:Protective cup SemanticType:[medd] POS:$ POS:CD POS:. 
[sentNum: 54]<Annotation Id="24181" Type="Sentence" StartNode="8111" EndNode="8158">Key Questions (KQs) Guiding the Evidence ReviewPreferredName:Guide device SemanticType:[medd] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Review [Publication Type] SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] POS:NNP POS:NNP POS:( POS:NNP POS:) POS:NNP POS:DT POS:NNP POS:NNP 
[sentNum: 55]<Annotation Id="24182" Type="Sentence" StartNode="8159" EndNode="8207">Key Questions Addressed in This Guideline UpdatePreferredName:Address SemanticType:[spco] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Update SemanticType:[tmco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] POS:NNP POS:NNP POS:VBD POS:IN POS:DT POS:NNP POS:NNP 
[sentNum: 56]<Annotation Id="24183" Type="Sentence" StartNode="8213" EndNode="8461">KQ 1: What are the relative benefits, limitations, and harms associated with mammography screening compared with no screening among average-risk women 40 years and older, and how do they vary by age, screening interval, and prior screening history?PreferredName:Benefits SemanticType:[qnco] PreferredName:Relative SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Comparison SemanticType:[acty] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Average SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Risk SemanticType:[qlco] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Old SemanticType:[tmco] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Prior Medication Usage SemanticType:[evnt] PreferredName:History of previous events SemanticType:[fndg] POS:VB POS:CD POS:: POS:WP POS:VBP POS:DT POS:JJ POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:VBN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:, POS:CC POS:WRB POS:VBP POS:PRP POS:VB POS:IN POS:NN POS:, POS:NN POS:NN POS:, POS:CC POS:JJ POS:NN POS:NN POS:. 
[sentNum: 57]<Annotation Id="24184" Type="Sentence" StartNode="8467" EndNode="8690">KQ 2: Among average-risk women who are screened with mammography, what are the relative benefits, limitations, and harms associated with annual, biennial, triennial, or other screening interval, and how do they vary by age?PreferredName:Average SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Risk SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Relative SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Annual SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Data Type Interval SemanticType:[inpr] POS:CD POS:CD POS:: POS:IN POS:JJ POS:NNS POS:WP POS:VBP POS:VBN POS:IN POS:NN POS:, POS:WP POS:VBP POS:DT POS:JJ POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:JJ POS:, POS:JJ POS:, POS:JJ POS:, POS:CC POS:JJ POS:NN POS:NN POS:, POS:CC POS:WRB POS:VBP POS:PRP POS:VB POS:IN POS:NN POS:. 
[sentNum: 58]<Annotation Id="24185" Type="Sentence" StartNode="8696" EndNode="8952">KQ 3: What are the benefits, limitations, and harms associated with clinical breast examination (CBE) among average-risk women 20 years and older compared with no CBE, and how do they vary by age, interval, and participation rates in mammography screening?PreferredName:Limitation SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Associated with SemanticType:[qlco] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Comparison SemanticType:[acty] PreferredName:Old SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Participation SemanticType:[ftcn] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Rating (action) SemanticType:[acty] POS:VB POS:CD POS:: POS:WP POS:VBP POS:DT POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:NN POS:( POS:NNP POS:) POS:IN POS:JJ POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:VBN POS:IN POS:DT POS:NNP POS:, POS:CC POS:WRB POS:VBP POS:PRP POS:VB POS:IN POS:NN POS:, POS:NN POS:, POS:CC POS:NN POS:NNS POS:IN POS:NN POS:NN POS:. 
[sentNum: 59]<Annotation Id="24186" Type="Sentence" StartNode="8954" EndNode="8973">Other Key QuestionsPreferredName:Question (inquiry) SemanticType:[inpr] POS:NNP POS:NNP POS:NNP 
[sentNum: 60]<Annotation Id="24187" Type="Sentence" StartNode="8979" EndNode="9368">KQ 4a: Among women with an increased risk of breast cancer due to factors known prior to the onset of screening (eg, family history, BRCA mutation carrier, history of chest irradiation), what are the relative benefits, limitations, and harms associated with different screening modalities compared with no screening (ie, what ages to start and stop screening) and compared with each other?PreferredName:4a serotype SemanticType:[inpr] PreferredName:Increase SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] PreferredName:Known SemanticType:[qlco] PreferredName:Factor SemanticType:[ftcn] PreferredName:Onset of (contextual qualifier) SemanticType:[qlco] PreferredName:Before SemanticType:[tmco] PreferredName:Egypt SemanticType:[geoa] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Mutation Carrier SemanticType:[humn] PreferredName:Family History Domain SemanticType:[idcn] PreferredName:Radiotherapy to breast SemanticType:[topp] PreferredName:History of previous events SemanticType:[fndg] PreferredName:Benefits SemanticType:[qnco] PreferredName:Relative SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Different SemanticType:[qlco] PreferredName:Comparison SemanticType:[acty] PreferredName:Modality SemanticType:[idcn] PreferredName:Age SemanticType:[orga] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Beginning SemanticType:[tmco] PreferredName:To SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Stop (qualifier value) SemanticType:[tmco] PreferredName:Comparison SemanticType:[acty] POS:NNP POS:CD POS:SYM POS:: POS:IN POS:NNS POS:IN POS:DT POS:VBN POS:NN POS:IN POS:NN POS:NN POS:JJ POS:TO POS:NNS POS:VBN POS:RB POS:TO POS:DT POS:NN POS:IN POS:NN POS:( POS:NN POS:, POS:NN POS:NN POS:, POS:NNP POS:NN POS:NN POS:, POS:NN POS:IN POS:NN POS:NN POS:) POS:, POS:WP POS:VBP POS:DT POS:JJ POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:NNS POS:VBN POS:IN POS:DT POS:NN POS:( POS:VB POS:, POS:WP POS:NNS POS:TO POS:VB POS:CC POS:VB POS:NN POS:) POS:CC POS:VBN POS:IN POS:DT POS:JJ POS:. 
[sentNum: 61]<Annotation Id="24188" Type="Sentence" StartNode="9374" EndNode="9696">KQ 4b: Among women with an increased risk of breast cancer due to factors identified as the result of screening or diagnosis (eg, prior diagnosis of proliferative lesions), what are the benefits, limitations, and harms associated with different screening modalities compared with no screening and compared with each other?PreferredName:Serotype 4b SemanticType:[inpr] PreferredName:Increase SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] PreferredName:Identified SemanticType:[qlco] PreferredName:Factor SemanticType:[ftcn] PreferredName:Diagnosis Study SemanticType:[resa] PreferredName:Growth Inhibition Screening Result SemanticType:[cnce] PreferredName:Prior diagnosis SemanticType:[qlco] PreferredName:Egypt SemanticType:[geoa] PreferredName:Lesion SemanticType:[fndg] PreferredName:Proliferation (morphologic abnormality) SemanticType:[patf] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Different SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Modality SemanticType:[idcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Comparison SemanticType:[acty] PreferredName:Comparison SemanticType:[acty] POS:CD POS:CD POS:SYM POS:: POS:IN POS:NNS POS:IN POS:DT POS:VBN POS:NN POS:IN POS:NN POS:NN POS:JJ POS:TO POS:NNS POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NN POS:CC POS:NN POS:( POS:NN POS:, POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:) POS:, POS:WP POS:VBP POS:DT POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:NNS POS:VBN POS:IN POS:DT POS:NN POS:CC POS:VBN POS:IN POS:DT POS:JJ POS:. 
[sentNum: 62]<Annotation Id="24189" Type="Sentence" StartNode="9702" EndNode="10044">KQ 5a: Among women with an increased risk of breast cancer due to factors known prior to the onset of screening (eg, family history, BRCA mutation carrier, history of chest irradiation), what are the relative benefits, limitations, and harms associated with different screening modalities at different intervals, and how do these vary by age?PreferredName:Maxillary right first premolar abutment SemanticType:[medd] PreferredName:Increase SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] PreferredName:Known SemanticType:[qlco] PreferredName:Factor SemanticType:[ftcn] PreferredName:Onset of (contextual qualifier) SemanticType:[qlco] PreferredName:Before SemanticType:[tmco] PreferredName:Egypt SemanticType:[geoa] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Mutation Carrier SemanticType:[humn] PreferredName:Family history SemanticType:[fndg] PreferredName:Radiotherapy to breast SemanticType:[topp] PreferredName:History of previous events SemanticType:[fndg] PreferredName:Benefits SemanticType:[qnco] PreferredName:Relative SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Different SemanticType:[qlco] PreferredName:Different SemanticType:[qlco] PreferredName:Modality SemanticType:[idcn] PreferredName:Age SemanticType:[orga] PreferredName:Interval SemanticType:[tmco] POS:CD POS:CD POS:SYM POS:: POS:IN POS:NNS POS:IN POS:DT POS:VBN POS:NN POS:IN POS:NN POS:NN POS:JJ POS:TO POS:NNS POS:VBN POS:RB POS:TO POS:DT POS:NN POS:IN POS:NN POS:( POS:NN POS:, POS:NN POS:NN POS:, POS:NNP POS:NN POS:NN POS:, POS:NN POS:IN POS:NN POS:NN POS:) POS:, POS:WP POS:VBP POS:DT POS:JJ POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:NNS POS:IN POS:JJ POS:NNS POS:, POS:CC POS:WRB POS:VBP POS:DT POS:VB POS:IN POS:NN POS:. 
[sentNum: 63]<Annotation Id="24190" Type="Sentence" StartNode="10050" EndNode="10369">KQ 5b: Among women with an increased risk of breast cancer due to factors identified as the result of screening or diagnosis (eg, prior diagnosis of proliferative lesions), what are the benefits, limitations, and harms associated with different screening modalities at different intervals, and how do these vary by age?PreferredName:Increase SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] PreferredName:Identified SemanticType:[qlco] PreferredName:Factor SemanticType:[ftcn] PreferredName:Diagnosis Study SemanticType:[resa] PreferredName:Growth Inhibition Screening Result SemanticType:[cnce] PreferredName:Prior diagnosis SemanticType:[qlco] PreferredName:Egypt SemanticType:[geoa] PreferredName:Lesion SemanticType:[fndg] PreferredName:Proliferation (morphologic abnormality) SemanticType:[patf] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Different SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Modality SemanticType:[idcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Interval SemanticType:[tmco] PreferredName:Different SemanticType:[qlco] PreferredName:Age SemanticType:[orga] POS:CD POS:CD POS:SYM POS:: POS:IN POS:NNS POS:IN POS:DT POS:VBN POS:NN POS:IN POS:NN POS:NN POS:JJ POS:TO POS:NNS POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NN POS:CC POS:NN POS:( POS:NN POS:, POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:) POS:, POS:WP POS:VBP POS:DT POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:NNS POS:IN POS:JJ POS:NNS POS:, POS:CC POS:WRB POS:VBP POS:DT POS:VB POS:IN POS:NN POS:. 
[sentNum: 64]<Annotation Id="24191" Type="Sentence" StartNode="10375" EndNode="10614">What are the relative benefits, limitations, and harms associated with mammography screening compared with no screening in average-risk women 40 years and older, and how do they vary by age, screening interval, and prior screening history?PreferredName:Relative SemanticType:[qlco] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Associated with SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Comparison SemanticType:[acty] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:/40 SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Old SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Age SemanticType:[orga] PreferredName:Prior Medication Usage SemanticType:[evnt] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:History of previous events SemanticType:[fndg] PreferredName:Disease Screening SemanticType:[diap] POS:WP POS:VBP POS:DT POS:JJ POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:VBN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:, POS:CC POS:WRB POS:VBP POS:PRP POS:VB POS:IN POS:NN POS:, POS:NN POS:NN POS:, POS:CC POS:JJ POS:NN POS:NN POS:. 
[sentNum: 65]<Annotation Id="24192" Type="Sentence" StartNode="10620" EndNode="10837">Among average-risk women who are screened with mammography, what are the relative benefits, limitations, and harms associated with annual, biennial, triennial, or other screening interval, and how do they vary by age?PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Relative SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Annual SemanticType:[tmco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Age SemanticType:[orga] POS:IN POS:JJ POS:NNS POS:WP POS:VBP POS:VBN POS:IN POS:NN POS:, POS:WP POS:VBP POS:DT POS:JJ POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:JJ POS:, POS:JJ POS:, POS:JJ POS:, POS:CC POS:JJ POS:NN POS:NN POS:, POS:CC POS:WRB POS:VBP POS:PRP POS:VB POS:IN POS:NN POS:. 
[sentNum: 66]<Annotation Id="24193" Type="Sentence" StartNode="10843" EndNode="11093">What are the benefits, limitations, and harms associated with clinical breast examination (CBE) among average-risk women 20 years and older compared with no CBE, and how do they vary by age, interval, and participation rates in mammography screening?PreferredName:Benefits SemanticType:[qnco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Average SemanticType:[qnco] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:Risk SemanticType:[qlco] PreferredName:Old SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Comparison SemanticType:[acty] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Age SemanticType:[orga] PreferredName:Rating (action) SemanticType:[acty] PreferredName:Participation SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] POS:WP POS:VBP POS:DT POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:NN POS:( POS:NNP POS:) POS:IN POS:JJ POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:VBN POS:IN POS:DT POS:NNP POS:, POS:CC POS:WRB POS:VBP POS:PRP POS:VB POS:IN POS:NN POS:, POS:NN POS:, POS:CC POS:NN POS:NNS POS:IN POS:NN POS:NN POS:. 
[sentNum: 67]<Annotation Id="24194" Type="Sentence" StartNode="11095" EndNode="11399">Quiz Ref IDFor purposes of the evidence review, the GDG considered average risk broadly: ie, women without a personal history of breast cancer, a confirmed or suspected genetic mutation known to increase risk of breast cancer (eg, BRCA), or a history of previous radiotherapy to the chest at a young age. PreferredName:ALYREF gene SemanticType:[gngm] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Purpose SemanticType:[ftcn] PreferredName:consider SemanticType:[idcn] PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Personal Attribute SemanticType:[orga] PreferredName:Woman SemanticType:[popg] PreferredName:Confirmation SemanticType:[idcn] PreferredName:History of malignant neoplasm of breast SemanticType:[fndg] PreferredName:Mutation SemanticType:[genf] PreferredName:Suspected qualifier SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Known SemanticType:[qlco] PreferredName:Risk SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Egypt SemanticType:[geoa] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Previous SemanticType:[tmco] PreferredName:History of previous events SemanticType:[fndg] PreferredName:To SemanticType:[qlco] PreferredName:Therapeutic radiology procedure SemanticType:[topp] PreferredName:Young SemanticType:[tmco] PreferredName:Anterior thoracic region SemanticType:[blor] PreferredName:Age SemanticType:[orga] POS:VBG POS:NNP POS:NNP POS:NNS POS:IN POS:DT POS:NN POS:NN POS:, POS:DT POS:NNP POS:VBD POS:JJ POS:NN POS:RB POS:: POS:NN POS:, POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:, POS:DT POS:NN POS:CC POS:VBN POS:JJ POS:NN POS:VBN POS:TO POS:VB POS:NN POS:IN POS:NN POS:NN POS:( POS:NN POS:, POS:NNP POS:) POS:, POS:CC POS:DT POS:NN POS:IN POS:JJ POS:NN POS:TO POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NN POS:. 
[sentNum: 68]<Annotation Id="24195" Type="Sentence" StartNode="11400" EndNode="11474">Women in these risk categories constitute a small percentage of all women. PreferredName:Woman SemanticType:[popg] PreferredName:Categories SemanticType:[inpr] PreferredName:Risk SemanticType:[qlco] PreferredName:Money or percentage indicator - Percentage SemanticType:[idcn] PreferredName:A little bit SemanticType:[inpr] PreferredName:Woman SemanticType:[popg] POS:NN POS:IN POS:DT POS:NN POS:NNS POS:VBP POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NNS POS:. 
[sentNum: 69]<Annotation Id="24196" Type="Sentence" StartNode="11475" EndNode="12108">In 2014, there were an estimated 3 088 180 female survivors of invasive breast cancer 40 years and older, approximately 4% of the total population14; a 2005 prevalence estimate of those having received a diagnosis of in situ breast cancer was 570 403, expected to increase to more than 1 million by 201615; 0.2% to 0.3% of the general population and 2% of Ashkenazi Jewish women are estimated to be carriers of the BRCA1 or BRCA2 mutation,16 and overall 5.8% of mammography screening–age women have a 20% or greater lifetime risk of breast cancer based on risk assessment with specialty software, largely dependent on family history.17PreferredName:AN 3 SemanticType:[aapp] PreferredName:Woman SemanticType:[popg] PreferredName:Estimated SemanticType:[qnco] PreferredName:Invasive SemanticType:[qlco] PreferredName:Survivors SemanticType:[podg] PreferredName:/40 SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Old SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Total SemanticType:[qlco] PreferredName:Approximate SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Prevalence aspects SemanticType:[qnco] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Receive SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:In situ SemanticType:[spco] PreferredName:To SemanticType:[qlco] PreferredName:Expected SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:General Population SemanticType:[popg] PreferredName:Million SemanticType:[qnco] PreferredName:Ashkenazi Jew, follower of religion SemanticType:[popg] PreferredName:2+ Score SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Genetic Carriers SemanticType:[fndg] PreferredName:To SemanticType:[qlco] PreferredName:Overall SemanticType:[qlco] PreferredName:BRCA2 Gene Mutation SemanticType:[comd] PreferredName:Age SemanticType:[orga] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Largest SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Risk Assessment SemanticType:[hlca] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Computer software SemanticType:[inpr, mnob] PreferredName:Medical Specialities SemanticType:[bmod] PreferredName:Family history SemanticType:[fndg] PreferredName:Dependent - ability SemanticType:[qlco] POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX POS:XX 
[sentNum: 70]<Annotation Id="24197" Type="Sentence" StartNode="12108" EndNode="12305">17; and in 2010, it was estimated that there were 50 000 to 55 000 women in the United States who had been treated with moderate- to high-dose chest radiation for pediatric and young adult cancers.18PreferredName:2010s SemanticType:[tmco] PreferredName:And SemanticType:[idcn] PreferredName:Arabic numeral 55 SemanticType:[inpr] PreferredName:Estimated SemanticType:[qnco] PreferredName:United States SemanticType:[geoa] PreferredName:Woman SemanticType:[popg] PreferredName:Moderation SemanticType:[qlco] PreferredName:Treated with SemanticType:[topp] PreferredName:High-LET Radiotherapy SemanticType:[topp] PreferredName:To SemanticType:[qlco] PreferredName:Pediatric discipline SemanticType:[bmod] PreferredName:Anterior thoracic region SemanticType:[blor] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Young Adult SemanticType:[aggp] POS:CD POS:: POS:CC POS:IN POS:CD POS:, POS:PRP POS:VBD POS:VBN POS:IN POS:EX POS:VBD POS:CD POS:CD POS:TO POS:CD POS:CD POS:NNS POS:IN POS:DT POS:NNP POS:NNPS POS:WP POS:VBD POS:VBN POS:VBN POS:IN POS:CD POS:TO POS:VB POS:NN POS:NN POS:IN POS:JJ POS:CC POS:JJ POS:NN POS:NNS POS:. 
[sentNum: 71]<Annotation Id="24198" Type="Sentence" StartNode="12305" EndNode="12735">18 There also are women outside of these risk categories who are still at higher than average risk of breast cancer and for whom mammography alone may be less effective, including women with significant family histories but who do not have a high probability of being carriers of identified mutations,19 women with a prior diagnosis of benign proliferative breast disease,20 and women with significant mammographic breast density.21PreferredName:Extrinsic SemanticType:[spco] PreferredName:Woman SemanticType:[popg] PreferredName:Categories SemanticType:[inpr] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] PreferredName:And SemanticType:[idcn] PreferredName:Less Than SemanticType:[inpr] PreferredName:alone - group size SemanticType:[grpa] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Effective SemanticType:[qlco] PreferredName:Significant SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Negation SemanticType:[ftcn] PreferredName:Family history SemanticType:[fndg] PreferredName:Probability SemanticType:[qnco] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Mutation Carrier SemanticType:[humn] PreferredName:Identified SemanticType:[qlco] PreferredName:Prior diagnosis SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Proliferation (morphologic abnormality) SemanticType:[patf] PreferredName:Benign SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Breast Diseases SemanticType:[dsyn] PreferredName:Mammographic breast density SemanticType:[fndg] PreferredName:Significant SemanticType:[idcn] POS:CD POS:RB POS:RB POS:VBP POS:NNS POS:IN POS:IN POS:DT POS:NN POS:NNS POS:WP POS:VBP POS:RB POS:IN POS:JJR POS:IN POS:JJ POS:NN POS:IN POS:NN POS:NN POS:CC POS:IN POS:WP POS:NN POS:RB POS:MD POS:VB POS:RBR POS:JJ POS:, POS:VBG POS:NNS POS:IN POS:JJ POS:NN POS:NNS POS:CC POS:WP POS:VBP POS:RB POS:VB POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:NNS POS:IN POS:VBN POS:NNS POS:, POS:CD POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:JJ POS:NN POS:NN POS:, POS:CD POS:CC POS:NNS POS:IN POS:JJ POS:JJ POS:NN POS:NN POS:. 
[sentNum: 72]<Annotation Id="24199" Type="Sentence" StartNode="12735" EndNode="13003">21 At this time, there are no reliable estimates of the number of women who have 1 or more of these risk factors; nor are there widely accepted risk-based screening recommendations that differ for women in this intermediate-risk group compared with average-risk women.PreferredName:no SemanticType:[idcn] PreferredName:Time SemanticType:[tmco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Reliability (characteristic) SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Numbers SemanticType:[qnco] PreferredName:More SemanticType:[ftcn] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Accepted SemanticType:[qlco] PreferredName:risk factors SemanticType:[qnco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Intermediate Risk SemanticType:[cnce] PreferredName:Woman SemanticType:[popg] PreferredName:Comparison SemanticType:[acty] PreferredName:Population Group SemanticType:[popg] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] POS:CD POS:IN POS:DT POS:NN POS:, POS:EX POS:VBP POS:DT POS:JJ POS:NNS POS:IN POS:DT POS:NN POS:IN POS:NNS POS:WP POS:VBP POS:CD POS:CC POS:JJR POS:IN POS:DT POS:NN POS:NNS POS:: POS:CC POS:VBP POS:RB POS:RB POS:VBN POS:JJ POS:NN POS:NNS POS:WDT POS:VBP POS:IN POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:VBN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 73]<Annotation Id="24200" Type="Sentence" StartNode="13005" EndNode="13426">In 2007, the ACS provided recommendations for breast magnetic resonance imaging (MRI) screening as an adjunct to mammography for women at high risk, based on a genetic mutation known to increase risk of breast cancer, a history of radiation to the chest at ages 10 to 30 years, or an estimated lifetime risk of approximately 20% to 25% or greater, as defined by risk assessment models largely dependent on family history.22PreferredName:Providing (action) SemanticType:[acty] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] PreferredName:High risk of SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Mutation SemanticType:[genf] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Known SemanticType:[qlco] PreferredName:Risk SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:History of previous events SemanticType:[fndg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:To SemanticType:[qlco] PreferredName:Therapeutic radiology procedure SemanticType:[topp] PreferredName:Age SemanticType:[orga] PreferredName:Anterior thoracic region SemanticType:[blor] PreferredName:Estimated SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:Approximate SemanticType:[qlco] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Definition SemanticType:[cnce] PreferredName:Largest SemanticType:[qnco] PreferredName:Model SemanticType:[inpr] PreferredName:Risk Assessment SemanticType:[hlca] PreferredName:Family History Domain SemanticType:[idcn] PreferredName:Dependent - ability SemanticType:[qlco] POS:IN POS:CD POS:, POS:DT POS:NNP POS:VBD POS:NNS POS:IN POS:NN POS:JJ POS:NN POS:NN POS:( POS:NNP POS:) POS:VBG POS:IN POS:DT POS:NN POS:TO POS:VB POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:, POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:VBN POS:TO POS:VB POS:NN POS:IN POS:NN POS:NN POS:, POS:DT POS:NN POS:IN POS:NN POS:TO POS:DT POS:NN POS:IN POS:NNS POS:CD POS:TO POS:CD POS:NNS POS:, POS:CC POS:DT POS:VBN POS:NN POS:NN POS:IN POS:RB POS:CD POS:NN POS:TO POS:CD POS:NN POS:CC POS:JJR POS:, POS:RB POS:VBN POS:IN POS:NN POS:NN POS:NNS POS:RB POS:JJ POS:IN POS:NN POS:NN POS:. 
[sentNum: 74]<Annotation Id="24201" Type="Sentence" StartNode="13426" EndNode="13678">22 At that time, the ACS concluded that the evidence was insufficient to recommend for or against MRI screening for women in other categories of increased risk but recommended against use of MRI screening among women with less than a 15% lifetime risk.22PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Time SemanticType:[tmco] PreferredName:Insufficient (qualifier) SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Categories SemanticType:[inpr] PreferredName:Woman SemanticType:[popg] PreferredName:Risk SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Use of SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] POS:CD POS:IN POS:DT POS:NN POS:, POS:DT POS:NNP POS:VBD POS:IN POS:DT POS:NN POS:VBD POS:JJ POS:TO POS:VB POS:IN POS:CC POS:IN POS:NNP POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:NNS POS:IN POS:VBN POS:NN POS:CC POS:VBN POS:IN POS:NN POS:IN POS:JJ POS:NN POS:IN POS:NNS POS:IN POS:JJR POS:IN POS:DT POS:CD POS:NN POS:NN POS:NN POS:. 
[sentNum: 75]<Annotation Id="24202" Type="Sentence" StartNode="13678" EndNode="13823">22 Two additional key questions that focused on screening outcomes in women at high risk of breast cancer were considered in our evidence review.23PreferredName:Additional SemanticType:[ftcn] PreferredName:Two SemanticType:[qnco] PreferredName:Has focus SemanticType:[ftcn] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Present SemanticType:[qnco] PreferredName:Growth Inhibition Screening Result SemanticType:[cnce] PreferredName:High risk of SemanticType:[qlco] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:consider SemanticType:[idcn] PreferredName:Act Class - review SemanticType:[idcn] POS:CD POS:CD POS:JJ POS:JJ POS:NNS POS:WDT POS:VBN POS:IN POS:VBG POS:NNS POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:IN POS:NN POS:NN POS:VBD POS:VBN POS:IN POS:PRP$ POS:NN POS:NN POS:. 
[sentNum: 76]<Annotation Id="24203" Type="Sentence" StartNode="13823" EndNode="14159">23 Following the publication of this update of recommendations for women in this broad category of average risk, the ACS plans to review this and additional evidence on factors associated with increased risk (including breast density) and screening outcomes and update its screening recommendations for women at increased and high risk.PreferredName:Arabic numeral 23 SemanticType:[qnco] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Following SemanticType:[tmco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Update SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Categories SemanticType:[inpr] PreferredName:Widening SemanticType:[spco] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:To SemanticType:[qlco] PreferredName:Planned SemanticType:[ftcn] PreferredName:Additional SemanticType:[ftcn] PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Factor SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Increase SemanticType:[ftcn] PreferredName:Associated with SemanticType:[qlco] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Growth Inhibition Screening Result SemanticType:[cnce] PreferredName:Breast Density SemanticType:[clna] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Update SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Recommendation SemanticType:[idcn] PreferredName:High risk of SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] POS:CD POS:VBG POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:IN POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:, POS:DT POS:NNP POS:VBZ POS:TO POS:VB POS:DT POS:CC POS:JJ POS:NN POS:IN POS:NNS POS:VBN POS:IN POS:VBN POS:NN POS:( POS:VBG POS:NN POS:NN POS:) POS:CC POS:NN POS:NNS POS:CC POS:VB POS:PRP$ POS:NN POS:NNS POS:IN POS:NNS POS:IN POS:JJ POS:CC POS:JJ POS:NN POS:. 
[sentNum: 77]<Annotation Id="24204" Type="Sentence" StartNode="14161" EndNode="14191">The Systematic Evidence ReviewPreferredName:Evidence of SemanticType:[ftcn] PreferredName:Review, Systematic SemanticType:[inpr] POS:DT POS:NNP POS:NNPS POS:NNP 
[sentNum: 78]<Annotation Id="24205" Type="Sentence" StartNode="14193" EndNode="14327">The GDG, in consultation with a group of expert advisers (n = 22), worked with the evidence review group to develop the research plan. PreferredName:Consultation SemanticType:[hlca] PreferredName:Within SemanticType:[spco] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] PreferredName:Group A SemanticType:[clas] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Work SemanticType:[ocac] PreferredName:study planning SemanticType:[resa] PreferredName:Study Section SemanticType:[prog] POS:DT POS:NNP POS:, POS:IN POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:NNS POS:( POS:VBN POS:SYM POS:CD POS:) POS:, POS:VBD POS:IN POS:DT POS:NN POS:NN POS:NN POS:TO POS:VB POS:DT POS:NN POS:NN POS:. 
[sentNum: 79]<Annotation Id="24206" Type="Sentence" StartNode="14328" EndNode="14397">It was agreed that new meta-analyses of the RCTs would not be useful. PreferredName:New SemanticType:[tmco] PreferredName:Agree SemanticType:[inpr] PreferredName:Negation SemanticType:[ftcn] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:utilization qualifier SemanticType:[ftcn] POS:PRP POS:VBD POS:VBN POS:IN POS:JJ POS:NNS POS:IN POS:DT POS:NNPS POS:MD POS:RB POS:VB POS:JJ POS:. 
[sentNum: 80]<Annotation Id="24207" Type="Sentence" StartNode="14398" EndNode="14674">Recent meta-analyses results could be used to estimate efficacy associated with screening but not to estimate effectiveness, due to variable rates of exposure to mammography within and across the individual studies, as well as other study differences that influenced outcomes. PreferredName:Recent SemanticType:[tmco] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:To SemanticType:[qlco] PreferredName:Used by SemanticType:[fndg] PreferredName:Efficacy Study SemanticType:[resa] PreferredName:Estimated SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Associated with SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Due to SemanticType:[ftcn] PreferredName:Effectiveness SemanticType:[qlco] PreferredName:Rating (action) SemanticType:[acty] PreferredName:Variable (uniformity) SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Exposure to SemanticType:[clna] PreferredName:And SemanticType:[idcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Persons SemanticType:[popg] PreferredName:Delta (difference) SemanticType:[qnco] PreferredName:Study SemanticType:[resa] PreferredName:Result SemanticType:[ftcn] POS:JJ POS:JJ POS:NNS POS:MD POS:VB POS:VBN POS:TO POS:VB POS:RB POS:VBN POS:IN POS:NN POS:CC POS:RB POS:TO POS:VB POS:NN POS:, POS:JJ POS:TO POS:JJ POS:NNS POS:IN POS:NN POS:TO POS:VB POS:IN POS:CC POS:IN POS:DT POS:JJ POS:NNS POS:, POS:RB POS:RB POS:IN POS:JJ POS:NN POS:NNS POS:WDT POS:VBD POS:NNS POS:. 
[sentNum: 81]<Annotation Id="24208" Type="Sentence" StartNode="14675" EndNode="14971">The GDG considered that it was preferable to estimate benefits and harms of screening using contemporary data from which exposure to screening can be ascertained; observational studies, especially population-based studies of service screening derived from large national databases, were included. PreferredName:consider SemanticType:[idcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Use of SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Exposure to SemanticType:[clna] PreferredName:Data SemanticType:[idcn] PreferredName:Observational Study SemanticType:[resa] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Services SemanticType:[ocac] PreferredName:Population Based Study SemanticType:[resa] PreferredName:Derivation SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:National citizen SemanticType:[inpr] PreferredName:Large SemanticType:[qnco] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Databases SemanticType:[inpr] POS:DT POS:NNP POS:VBD POS:IN POS:PRP POS:VBD POS:JJ POS:TO POS:VB POS:NNS POS:CC POS:NNS POS:IN POS:NN POS:VBG POS:JJ POS:NNS POS:IN POS:WDT POS:NN POS:TO POS:NN POS:MD POS:VB POS:VBN POS:: POS:JJ POS:NNS POS:, POS:RB POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:VBN POS:IN POS:JJ POS:JJ POS:NNS POS:, POS:VBD POS:VBN POS:. 
[sentNum: 82]<Annotation Id="24209" Type="Sentence" StartNode="14972" EndNode="15212">While concerns about the limitations of observational studies are well established, in the case of breast cancer screening, well-designed observational studies produce results that are qualitatively consistent with the majority of the RCTs.24PreferredName:Limitation SemanticType:[ftcn] PreferredName:Concern SemanticType:[idcn] PreferredName:Good SemanticType:[qlco] PreferredName:Observational Study SemanticType:[resa] PreferredName:Within SemanticType:[spco] PreferredName:Accepted SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Clinical Study Case SemanticType:[cnce] PreferredName:Good SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Observational Study SemanticType:[resa] PreferredName:Design SemanticType:[acty] PreferredName:Consistent with SemanticType:[idcn] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:majority SemanticType:[socb] POS:IN POS:NNS POS:IN POS:DT POS:NNS POS:IN POS:JJ POS:NNS POS:VBP POS:RB POS:VBN POS:, POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:NN POS:, POS:JJ POS:JJ POS:NNS POS:VBP POS:NNS POS:WDT POS:VBP POS:RB POS:JJ POS:IN POS:DT POS:NN POS:IN POS:DT POS:NNP POS:. 
[sentNum: 83]<Annotation Id="24210" Type="Sentence" StartNode="15212" EndNode="15383">24 Once the research plan was finalized, the evidence review group had full responsibility for the literature search strategy, interpretation, and grading of the evidence. PreferredName:study planning SemanticType:[resa] PreferredName:Study Section SemanticType:[prog] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Responsibility SemanticType:[inbe] PreferredName:Full SemanticType:[qlco] PreferredName:Search - action SemanticType:[acty] PreferredName:Publications SemanticType:[inpr, mnob] PreferredName:Interpretation Process SemanticType:[inpr] PreferredName:strategy SemanticType:[menp] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Histopathologic Grade SemanticType:[clas] POS:CD POS:IN POS:DT POS:NN POS:NN POS:VBD POS:VBN POS:, POS:DT POS:NN POS:NN POS:NN POS:VBD POS:JJ POS:NN POS:IN POS:DT POS:NN POS:NN POS:NN POS:, POS:NN POS:, POS:CC POS:VBG POS:IN POS:DT POS:NN POS:. 
[sentNum: 84]<Annotation Id="24211" Type="Sentence" StartNode="15384" EndNode="15477">Studies were included in the evidence synthesis if they met the following inclusion criteria:PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Synthesis SemanticType:[acty] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Following SemanticType:[tmco] PreferredName:Fulfill SemanticType:[idcn] PreferredName:Inclusion SemanticType:[qlco] POS:NNS POS:VBD POS:VBN POS:IN POS:DT POS:NN POS:VBN POS:IN POS:PRP POS:VBD POS:DT POS:JJ POS:NN POS:NNS POS:: 
[sentNum: 85]<Annotation Id="24212" Type="Sentence" StartNode="15483" EndNode="15605">Controlled studies, including RCTs, pooled patient-level meta-analyses, systematic reviews, and study-level meta-analyses.PreferredName:Controlled Study SemanticType:[resa] PreferredName:Pooled Sample SemanticType:[sbst] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Levels (qualifier value) SemanticType:[qlco] PreferredName:Patients SemanticType:[podg] PreferredName:Review, Systematic SemanticType:[inpr] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:Levels (qualifier value) SemanticType:[qlco] PreferredName:Study SemanticType:[resa] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] POS:NN POS:NNS POS:, POS:VBG POS:NNP POS:, POS:VBD POS:JJ POS:NNS POS:, POS:JJ POS:NNS POS:, POS:CC POS:JJ POS:NNS POS:. 
[sentNum: 86]<Annotation Id="24213" Type="Sentence" StartNode="15611" EndNode="15832">Observational studies (prospective and retrospective cohort studies, incidence-based mortality studies, case-control studies, or cross-sectional studies) published since 2000 that included 1000 or more average-risk women.PreferredName:Observational Study SemanticType:[resa] PreferredName:Retrospective Cohort Study SemanticType:[resa] PreferredName:Longitudinal Studies SemanticType:[resa] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Incidence Studies SemanticType:[qnco] PreferredName:Case-Control Studies SemanticType:[resa] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Cross-Sectional Studies SemanticType:[resa] PreferredName:2000s SemanticType:[tmco] PreferredName:Since SemanticType:[tmco] PreferredName:More SemanticType:[ftcn] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] POS:JJ POS:NNS POS:( POS:JJ POS:CC POS:JJ POS:JJ POS:NNS POS:, POS:JJ POS:NN POS:NNS POS:, POS:JJ POS:NNS POS:, POS:CC POS:JJ POS:NNS POS:) POS:VBN POS:IN POS:CD POS:WDT POS:VBD POS:CD POS:CC POS:JJR POS:JJ POS:NNS POS:. 
[sentNum: 87]<Annotation Id="24214" Type="Sentence" StartNode="15838" EndNode="16066">Modeling/simulation studies, because these studies may be the only way to generate estimates of long-term outcomes associated with screening that are not adequately addressed by the RCTs or using modern technology and protocols.PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Simulation SemanticType:[resa] PreferredName:Singular SemanticType:[qnco] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Long-term SemanticType:[tmco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Result SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Use of SemanticType:[ftcn] PreferredName:Address SemanticType:[spco] PreferredName:Protocols documentation SemanticType:[inpr] PreferredName:Technology SemanticType:[ocdi] POS:VBG POS:JJ POS:NN POS:NNS POS:, POS:IN POS:DT POS:NNS POS:MD POS:VB POS:DT POS:JJ POS:NN POS:TO POS:VB POS:NNS POS:IN POS:JJ POS:NNS POS:VBN POS:IN POS:NN POS:WDT POS:VBP POS:RB POS:RB POS:VBN POS:IN POS:DT POS:NNPS POS:CC POS:VBG POS:JJ POS:NN POS:CC POS:NNS POS:. 
[sentNum: 88]<Annotation Id="24215" Type="Sentence" StartNode="16068" EndNode="16297">Critical and important outcomes considered in the review are provided in Table 2 and include the following: breast cancer mortality, quality of life, life expectancy, false-positive test results, overdiagnosis, and overtreatment. PreferredName:Result SemanticType:[ftcn] PreferredName:Critical SemanticType:[qlco] PreferredName:Act Class - review SemanticType:[idcn] PreferredName:consider SemanticType:[idcn] PreferredName:Table - furniture SemanticType:[mnob] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Following SemanticType:[tmco] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Perceived quality of life SemanticType:[fndg] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:False Positive SemanticType:[lbtr] POS:JJ POS:CC POS:JJ POS:NNS POS:VBN POS:IN POS:DT POS:NN POS:VBP POS:VBN POS:IN POS:NNP POS:CD POS:CC POS:VBP POS:DT POS:VBG POS:: POS:NN POS:NN POS:NN POS:, POS:NN POS:IN POS:NN POS:, POS:NN POS:NN POS:, POS:JJ POS:NN POS:NNS POS:, POS:NNS POS:, POS:CC POS:NN POS:. 
[sentNum: 89]<Annotation Id="24216" Type="Sentence" StartNode="16298" EndNode="16467">Other outcomes, such as morbidity related to treatment of breast cancer and radiation exposure from mammography, were considered but not included in the evidence review.PreferredName:Morbidity - disease rate SemanticType:[qnco] PreferredName:Result SemanticType:[ftcn] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Relationships SemanticType:[qlco] PreferredName:Exposure to radiation SemanticType:[phpr] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:consider SemanticType:[idcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] POS:JJ POS:NNS POS:, POS:JJ POS:IN POS:NN POS:VBN POS:TO POS:NN POS:IN POS:NN POS:NN POS:CC POS:NN POS:NN POS:IN POS:NN POS:, POS:VBD POS:VBN POS:CC POS:RB POS:VBN POS:IN POS:DT POS:NN POS:NN POS:. 
[sentNum: 90]<Annotation Id="24217" Type="Sentence" StartNode="16469" EndNode="16744">For each outcome considered for every key question, the strength of the overall body of evidence across all included study designs was rated, with consideration of risk of bias, consistency, directness, and precision, as well as strength of association (magnitude of effect). PreferredName:consider SemanticType:[idcn] PreferredName:Result SemanticType:[ftcn] PreferredName:STRENGTH (attribute) SemanticType:[idcn] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Human body SemanticType:[humn] PreferredName:Overall Publication Type SemanticType:[inpr] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Rating (action) SemanticType:[acty] PreferredName:Research Design SemanticType:[resa] PreferredName:consideration SemanticType:[fndg] PreferredName:In addition to SemanticType:[qlco] PreferredName:Biases SemanticType:[idcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Direct type of relationship SemanticType:[qlco] PreferredName:Consistency SemanticType:[qlco] PreferredName:STRENGTH (attribute) SemanticType:[idcn] PreferredName:Precision - characteristic SemanticType:[qlco] PreferredName:Magnitude SemanticType:[qnco] PreferredName:Relationship by association SemanticType:[socb] PreferredName:Effect SemanticType:[qlco] POS:IN POS:DT POS:NN POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:, POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:IN POS:DT POS:VBD POS:NN POS:NNS POS:VBD POS:VBN POS:, POS:IN POS:NN POS:IN POS:NN POS:IN POS:NN POS:, POS:NN POS:, POS:NN POS:, POS:CC POS:NN POS:, POS:RB POS:RB POS:IN POS:NN POS:IN POS:NN POS:( POS:NN POS:IN POS:NN POS:) POS:. 
[sentNum: 91]<Annotation Id="24218" Type="Sentence" StartNode="16745" EndNode="16850">Results from meta-analyses were used when evaluating consistency, precision, and strength of association. PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Used by SemanticType:[fndg] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:Consistency SemanticType:[qlco] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:STRENGTH (attribute) SemanticType:[idcn] PreferredName:Precision - characteristic SemanticType:[qlco] PreferredName:Relationship by association SemanticType:[socb] POS:NNS POS:IN POS:NNS POS:VBD POS:VBN POS:WRB POS:VBG POS:NN POS:, POS:NN POS:, POS:CC POS:NN POS:IN POS:NN POS:. 
[sentNum: 92]<Annotation Id="24219" Type="Sentence" StartNode="16851" EndNode="16981">The evidence summary and a detailed description of the evidence review methodology are published concurrently with this guideline.25PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Details SemanticType:[qlco] PreferredName:Summary (document) SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Description SemanticType:[idcn] PreferredName:Methodology aspects SemanticType:[inpr] PreferredName:Review [Publication Type] SemanticType:[inpr] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Scientific Publication SemanticType:[inpr] POS:DT POS:JJ POS:NN POS:CC POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NN POS:NN POS:NN POS:VBP POS:VBN POS:RB POS:IN POS:DT POS:NN POS:. 
[sentNum: 93]<Annotation Id="24220" Type="Sentence" StartNode="16981" EndNode="16983">25POS:CD 
[sentNum: 94]<Annotation Id="24221" Type="Sentence" StartNode="16985" EndNode="17020">Supplementary Analyses and EvidencePreferredName:Evidence of SemanticType:[ftcn] PreferredName:Analysis SemanticType:[resa] POS:VB POS:NNS POS:CC POS:NNS 
[sentNum: 95]<Annotation Id="24222" Type="Sentence" StartNode="17022" EndNode="17481">In addition to the evidence review, the ACS commissioned the BCSC to update previously published analyses26 on the association between mammography screening intervals and tumor characteristics at diagnosis by age, menopausal status, and postmenopausal hormone use, to measure the outcomes related to screening intervals closer to 12 and 24 months instead of the wider intervals used as proxies for annual and biennial screening published in previous analyses.26PreferredName:Review [Publication Type] SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Update SemanticType:[tmco] PreferredName:Breast Cancer Surveillance Consortium SemanticType:[prog] PreferredName:Relationship by association SemanticType:[socb] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Interval SemanticType:[tmco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Characteristics SemanticType:[qlco] PreferredName:neoplasm diagnosis SemanticType:[diap] PreferredName:Menopausal Status SemanticType:[clna] PreferredName:Age SemanticType:[orga] PreferredName:Hormones SemanticType:[horm] PreferredName:Postmenopausal state SemanticType:[tmco] PreferredName:To SemanticType:[qlco] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:Result SemanticType:[ftcn] PreferredName:Measurement SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Relationships SemanticType:[qlco] PreferredName:month SemanticType:[tmco] PreferredName:Interval SemanticType:[tmco] PreferredName:Used by SemanticType:[fndg] PreferredName:Kernel Bandwidth SemanticType:[inpr] PreferredName:Annual SemanticType:[tmco] PreferredName:Proxy SemanticType:[grup] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Analysis SemanticType:[resa] PreferredName:Previous SemanticType:[tmco] POS:IN POS:NN POS:TO POS:DT POS:NN POS:NN POS:, POS:DT POS:NNP POS:VBD POS:DT POS:NN POS:TO POS:VB POS:RB POS:VBN POS:NNS POS:CD POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:NNS POS:CC POS:NN POS:NNS POS:IN POS:NN POS:IN POS:NN POS:, POS:JJ POS:NN POS:, POS:CC POS:JJ POS:NN POS:NN POS:, POS:TO POS:VB POS:DT POS:NNS POS:VBN POS:TO POS:NN POS:NNS POS:RBR POS:TO POS:CD POS:CC POS:CD POS:NNS POS:RB POS:IN POS:DT POS:JJR POS:NNS POS:VBN POS:IN POS:NNS POS:IN POS:JJ POS:CC POS:JJ POS:NN POS:VBN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 96]<Annotation Id="24223" Type="Sentence" StartNode="17481" EndNode="17483">26POS:NN 
[sentNum: 97]<Annotation Id="24224" Type="Sentence" StartNode="17485" EndNode="17626">An initial consideration in the decision to offer screening to the population is the burden of disease overall and in age-specific subgroups.27PreferredName:consideration SemanticType:[fndg] PreferredName:Initial (abbreviation) SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Decision SemanticType:[menp] PreferredName:Burden SemanticType:[idcn] PreferredName:geographic population SemanticType:[qnco] PreferredName:Overall Publication Type SemanticType:[inpr] PreferredName:Disease SemanticType:[dsyn] PreferredName:Age SemanticType:[orga] PreferredName:And SemanticType:[idcn] PreferredName:Subgroup A Nepoviruses SemanticType:[virs] PreferredName:Specific qualifier value SemanticType:[qlco] POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NN POS:TO POS:VB POS:NN POS:TO POS:DT POS:NN POS:VBZ POS:DT POS:NN POS:IN POS:NN POS:RB POS:CC POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 98]<Annotation Id="24225" Type="Sentence" StartNode="17626" EndNode="17861">27 To address the question of age to begin and to stop screening, the GDG examined a range of indicators, including age-specific incidence, mortality, age-specific incidence-based mortality, and years of potential life lost (Figure 1).3PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Address SemanticType:[spco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Stop (qualifier value) SemanticType:[tmco] PreferredName:To SemanticType:[qlco] PreferredName:Examined SemanticType:[fndg] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Indicators SemanticType:[irda] PreferredName:Range SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Specific qualifier value SemanticType:[qlco] PreferredName:Age-Specific Death Rate SemanticType:[qnco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Potential SemanticType:[qlco] PreferredName:year SemanticType:[tmco] PreferredName:Lost SemanticType:[ftcn] PreferredName:Life SemanticType:[idcn] POS:CD POS:TO POS:VB POS:DT POS:NN POS:IN POS:NN POS:TO POS:VB POS:CC POS:TO POS:VB POS:NN POS:, POS:DT POS:NNP POS:VBD POS:DT POS:NN POS:IN POS:NNS POS:, POS:VBG POS:JJ POS:NN POS:, POS:NN POS:, POS:JJ POS:JJ POS:NN POS:, POS:CC POS:NNS POS:IN POS:JJ POS:NN POS:VBN POS:( POS:NN POS:CD POS:) POS:. 
[sentNum: 99]<Annotation Id="24226" Type="Sentence" StartNode="17861" EndNode="17865">3,28PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] POS:CD POS:, POS:JJ 
[sentNum: 100]<Annotation Id="24227" Type="Sentence" StartNode="17867" EndNode="17892">Results (Recommendations)PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Recommendation SemanticType:[idcn] POS:NNS POS:( POS:NN POS:) 
[sentNum: 101]<Annotation Id="24228" Type="Sentence" StartNode="17894" EndNode="18085">These recommendations are based on the GDG’s consensus judgment about when the benefits of mammography screening clearly or likely outweigh the harms in a population of women at average risk. PreferredName:Recommendation SemanticType:[idcn] PreferredName:Consensus SemanticType:[socb] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Judgment SemanticType:[menp] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Mammography SemanticType:[diap] PreferredName:geographic population SemanticType:[qnco] PreferredName:Probably SemanticType:[idcn] PreferredName:Average SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Risk SemanticType:[qlco] POS:DT POS:NNS POS:VBP POS:VBN POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:NN POS:NN POS:IN POS:WRB POS:DT POS:NNS POS:IN POS:NN POS:NN POS:RB POS:CC POS:JJ POS:VBP POS:DT POS:NNS POS:IN POS:DT POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:. 
[sentNum: 102]<Annotation Id="24229" Type="Sentence" StartNode="18086" EndNode="18342">Recognizing that individual values and preferences can lead to different decisions about the age to start and stop screening and screening intervals, some recommendations were graded as qualified to allow for informed decision making about options (Box 2).PreferredName:Individual SemanticType:[humn] PreferredName:preference SemanticType:[idcn] PreferredName:Values SemanticType:[qlco] PreferredName:Different SemanticType:[qlco] PreferredName:Dietary Lead SemanticType:[elii] PreferredName:Age SemanticType:[orga] PreferredName:Decision SemanticType:[menp] PreferredName:Stop (qualifier value) SemanticType:[tmco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Interval SemanticType:[tmco] PreferredName:To SemanticType:[qlco] PreferredName:Grade SemanticType:[clas] PreferredName:Informed SemanticType:[qlco] PreferredName:allowing SemanticType:[socb] PreferredName:Options SemanticType:[ftcn] PreferredName:Decision Making SemanticType:[menp] PreferredName:Box SemanticType:[mnob] POS:VBG POS:IN POS:JJ POS:NNS POS:CC POS:NNS POS:MD POS:VB POS:TO POS:JJ POS:NNS POS:IN POS:DT POS:NN POS:TO POS:VB POS:CC POS:VB POS:NN POS:CC POS:NN POS:NNS POS:, POS:DT POS:NNS POS:VBD POS:VBN POS:RB POS:VBN POS:TO POS:VB POS:IN POS:VBN POS:NN POS:VBG POS:IN POS:NNS POS:( POS:NNP POS:CD POS:) POS:. 
[sentNum: 103]<Annotation Id="24230" Type="Sentence" StartNode="18343" EndNode="18361">Box Section Ref IDPreferredName:Box SemanticType:[mnob] PreferredName:ALYREF gene SemanticType:[gngm] PreferredName:Sectional Distribution SemanticType:[spco] PreferredName:Identifier SemanticType:[inpr] POS:NNP POS:NNP POS:NNP POS:NNPS 
[sentNum: 104]<Annotation Id="24231" Type="Sentence" StartNode="18363" EndNode="18369">Box 2.PreferredName:Box SemanticType:[mnob] POS:$ POS:CD POS:. 
[sentNum: 105]<Annotation Id="24232" Type="Sentence" StartNode="18370" EndNode="18437">American Cancer Society Guideline for Breast Cancer Screening, 2015PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:American Cancer Society SemanticType:[pros] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] POS:NNP POS:NNP POS:NNP POS:VBZ POS:IN POS:NNP POS:NNP POS:NNP POS:, POS:CD 
[sentNum: 106]<Annotation Id="24233" Type="Sentence" StartNode="18439" EndNode="18774">These recommendations represent guidance from the American Cancer Society (ACS) for women at average risk of breast cancer: women without a personal history of breast cancer, a suspected or confirmed genetic mutation known to increase risk of breast cancer (eg, BRCA), or a history of previous radiotherapy to the chest at a young age.PreferredName:Recommendation SemanticType:[idcn] PreferredName:Spatial guidance for medical procedure SemanticType:[clna] PreferredName:Representation (action) SemanticType:[acty] PreferredName:Preposition For SemanticType:[qlco] PreferredName:American Cancer Society SemanticType:[pros] PreferredName:Average SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] PreferredName:Personal Attribute SemanticType:[orga] PreferredName:Woman SemanticType:[popg] PreferredName:Suspected qualifier SemanticType:[idcn] PreferredName:History of malignant neoplasm of breast SemanticType:[fndg] PreferredName:Mutation SemanticType:[genf] PreferredName:Confirmed by SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Known SemanticType:[qlco] PreferredName:Risk SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Egypt SemanticType:[geoa] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Previous SemanticType:[tmco] PreferredName:History of previous events SemanticType:[fndg] PreferredName:To SemanticType:[qlco] PreferredName:Therapeutic radiology procedure SemanticType:[topp] PreferredName:Young SemanticType:[tmco] PreferredName:Anterior thoracic region SemanticType:[blor] PreferredName:Age SemanticType:[orga] POS:DT POS:NNS POS:VBP POS:NN POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:( POS:NNP POS:) POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:IN POS:NN POS:NN POS:: POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:, POS:DT POS:NN POS:CC POS:VBD POS:JJ POS:NN POS:VBN POS:TO POS:VB POS:NN POS:IN POS:NN POS:NN POS:( POS:NNP POS:, POS:NNP POS:) POS:, POS:CC POS:DT POS:NN POS:IN POS:JJ POS:NN POS:TO POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NN POS:. 
[sentNum: 107]<Annotation Id="24234" Type="Sentence" StartNode="18776" EndNode="18925">The ACS recommends that all women should become familiar with the potential benefits, limitations, and harms associated with breast cancer screening.PreferredName:Recommendation SemanticType:[idcn] PreferredName:Known SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Benefits SemanticType:[qnco] PreferredName:Potential SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] POS:DT POS:NNP POS:VBZ POS:IN POS:DT POS:NNS POS:MD POS:VB POS:JJ POS:IN POS:DT POS:JJ POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:NN POS:. 
[sentNum: 108]<Annotation Id="24235" Type="Sentence" StartNode="18926" EndNode="18942">RecommendationsaPOS:NNP 
[sentNum: 109]<Annotation Id="24236" Type="Sentence" StartNode="18948" EndNode="19062">Women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years. PreferredName:Woman SemanticType:[popg] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Regular SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Beginning SemanticType:[tmco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Age-Years SemanticType:[tmco] POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:MD POS:VB POS:JJ POS:NN POS:RB POS:VBG POS:IN POS:NN POS:CD POS:NNS POS:. 
[sentNum: 110]<Annotation Id="24237" Type="Sentence" StartNode="19063" EndNode="19086">(Strong Recommendation)PreferredName:Strong SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] POS:( POS:NNP POS:NNP POS:) 
[sentNum: 111]<Annotation Id="24238" Type="Sentence" StartNode="19096" EndNode="19099">1a. PreferredName:alphanumeric label - 1A SemanticType:[inpr] POS:CD POS:DT POS:. 
[sentNum: 112]<Annotation Id="24239" Type="Sentence" StartNode="19100" EndNode="19154">Women aged 45 to 54 years should be screened annually. PreferredName:Age SemanticType:[orga] PreferredName:Woman SemanticType:[popg] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:year SemanticType:[tmco] PreferredName:Annual SemanticType:[tmco] POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:MD POS:VB POS:VBN POS:RB POS:. 
[sentNum: 113]<Annotation Id="24240" Type="Sentence" StartNode="19155" EndNode="19181">(Qualified Recommendation)PreferredName:Recommendation SemanticType:[idcn] POS:( POS:NN POS:NN POS:) 
[sentNum: 114]<Annotation Id="24241" Type="Sentence" StartNode="19191" EndNode="19194">1b. PreferredName:1B SemanticType:[inpr] POS:CD POS:RB POS:. 
[sentNum: 115]<Annotation Id="24242" Type="Sentence" StartNode="19195" EndNode="19315">Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually. PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Arabic numeral 55 SemanticType:[inpr] PreferredName:Transition Mutation SemanticType:[comd] PreferredName:Old SemanticType:[tmco] PreferredName:Continuous SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Annual SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:MD POS:VB POS:TO POS:JJ POS:NN POS:CC POS:VB POS:DT POS:NN POS:TO POS:VB POS:NN POS:RB POS:. 
[sentNum: 116]<Annotation Id="24243" Type="Sentence" StartNode="19316" EndNode="19342">(Qualified Recommendation)PreferredName:Recommendation SemanticType:[idcn] POS:( POS:NN POS:NN POS:) 
[sentNum: 117]<Annotation Id="24244" Type="Sentence" StartNode="19352" EndNode="19355">1c. POS:CD POS:RB POS:. 
[sentNum: 118]<Annotation Id="24245" Type="Sentence" StartNode="19356" EndNode="19452">Women should have the opportunity to begin annual screening between the ages of 40 and 44 years. PreferredName:Woman SemanticType:[popg] PreferredName:annual screening SemanticType:[diap] PreferredName:Beginning SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:year SemanticType:[tmco] POS:NNS POS:MD POS:VB POS:DT POS:NN POS:TO POS:VB POS:JJ POS:NN POS:IN POS:DT POS:NNS POS:IN POS:CD POS:CC POS:CD POS:NNS POS:. 
[sentNum: 119]<Annotation Id="24246" Type="Sentence" StartNode="19453" EndNode="19479">(Qualified Recommendation)PreferredName:Recommendation SemanticType:[idcn] POS:( POS:NN POS:NN POS:) 
[sentNum: 120]<Annotation Id="24247" Type="Sentence" StartNode="19485" EndNode="19623">Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer. PreferredName:Continuous SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Mammography SemanticType:[diap] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Overall SemanticType:[qlco] PreferredName:Long SemanticType:[qlco] PreferredName:Good SemanticType:[qlco] PreferredName:Health SemanticType:[idcn] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:antineoplaston A10 SemanticType:[orch, phsu] PreferredName:Long SemanticType:[qlco] PreferredName:year SemanticType:[tmco] POS:NNS POS:MD POS:VB POS:VBG POS:NN POS:RB POS:RB POS:IN POS:PRP$ POS:JJ POS:NN POS:VBZ POS:JJ POS:CC POS:PRP POS:VBP POS:DT POS:NN POS:NN POS:IN POS:CD POS:NNS POS:CC POS:RBR POS:. 
[sentNum: 121]<Annotation Id="24248" Type="Sentence" StartNode="19624" EndNode="19650">(Qualified Recommendation)PreferredName:Recommendation SemanticType:[idcn] POS:( POS:NN POS:NN POS:) 
[sentNum: 122]<Annotation Id="24249" Type="Sentence" StartNode="19656" EndNode="19775">The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age. PreferredName:Negation SemanticType:[ftcn] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Average SemanticType:[qnco] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Risk SemanticType:[qlco] PreferredName:Age SemanticType:[orga] POS:DT POS:NNP POS:VBZ POS:RB POS:VB POS:JJ POS:NN POS:NN POS:IN POS:NN POS:NN POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:DT POS:NN POS:. 
[sentNum: 123]<Annotation Id="24250" Type="Sentence" StartNode="19776" EndNode="19802">(Qualified Recommendation)PreferredName:Recommendation SemanticType:[idcn] POS:( POS:NN POS:NN POS:) 
[sentNum: 124]<Annotation Id="24251" Type="Sentence" StartNode="19804" EndNode="19967">aA strong recommendation conveys the consensus that the benefits of adherence to that intervention outweigh the undesirable effects that may result from screening. PreferredName:Strong SemanticType:[qlco] PreferredName:Aa (Plant) SemanticType:[plnt] PreferredName:Consensus SemanticType:[socb] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Adherence (attribute) SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:aspects of adverse effects SemanticType:[ftcn] PreferredName:Intervention regimes SemanticType:[hlca] PreferredName:Growth Inhibition Screening Result SemanticType:[cnce] POS:JJ POS:JJ POS:NN POS:VBZ POS:DT POS:NN POS:IN POS:DT POS:NNS POS:IN POS:NN POS:TO POS:DT POS:NN POS:VBP POS:DT POS:JJ POS:NNS POS:WDT POS:MD POS:VB POS:IN POS:NN POS:. 
[sentNum: 125]<Annotation Id="24252" Type="Sentence" StartNode="19968" EndNode="20210">Qualified recommendations indicate there is clear evidence of benefit of screening but less certainty about the balance of benefits and harms, or about patients’ values and preferences, which could lead to different decisions about screening.12PreferredName:Recommendation SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Clear SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Benefits SemanticType:[qnco] PreferredName:Certain (qualifier value) SemanticType:[qlco] PreferredName:Less Than SemanticType:[inpr] PreferredName:Benefits SemanticType:[qnco] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Values SemanticType:[qlco] PreferredName:Patients SemanticType:[podg] PreferredName:Dietary Lead SemanticType:[elii] PreferredName:preference SemanticType:[idcn] PreferredName:Decision SemanticType:[menp] PreferredName:Different SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] POS:JJ POS:NNS POS:VBP POS:EX POS:VBZ POS:JJ POS:NN POS:IN POS:NN POS:IN POS:NN POS:CC POS:JJR POS:NN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:CC POS:NNS POS:, POS:CC POS:IN POS:NNS POS:VBZ POS:NNS POS:CC POS:NNS POS:, POS:WDT POS:MD POS:VB POS:TO POS:JJ POS:NNS POS:IN POS:NN POS:. 
[sentNum: 126]<Annotation Id="24253" Type="Sentence" StartNode="20210" EndNode="20215">12,13POS:CD POS:, POS:CD 
[sentNum: 127]<Annotation Id="24254" Type="Sentence" StartNode="20217" EndNode="20331">Women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years. PreferredName:Woman SemanticType:[popg] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Regular SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Beginning SemanticType:[tmco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Age-Years SemanticType:[tmco] POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:MD POS:VB POS:JJ POS:NN POS:RB POS:VBG POS:IN POS:NN POS:CD POS:NNS POS:. 
[sentNum: 128]<Annotation Id="24255" Type="Sentence" StartNode="20332" EndNode="20355">(Strong Recommendation)PreferredName:Strong SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] POS:( POS:NNP POS:NNP POS:) 
[sentNum: 129]<Annotation Id="24256" Type="Sentence" StartNode="20357" EndNode="20430">Recommendation 1a: Women aged 45 to 54 years should be screened annually. PreferredName:Recommendation SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:alphanumeric label - 1A SemanticType:[inpr] PreferredName:year SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Annual SemanticType:[tmco] PreferredName:Screening - procedure intent SemanticType:[ftcn] POS:NNP POS:CD POS:SYM POS:: POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:MD POS:VB POS:VBN POS:RB POS:. 
[sentNum: 130]<Annotation Id="24257" Type="Sentence" StartNode="20431" EndNode="20457">(Qualified Recommendation)PreferredName:Recommendation SemanticType:[idcn] POS:( POS:NN POS:NN POS:) 
[sentNum: 131]<Annotation Id="24258" Type="Sentence" StartNode="20459" EndNode="20598">Recommendation 1b: Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually. PreferredName:Recommendation SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:1B SemanticType:[inpr] PreferredName:year SemanticType:[tmco] PreferredName:Arabic numeral 55 SemanticType:[inpr] PreferredName:Transition Mutation SemanticType:[comd] PreferredName:Old SemanticType:[tmco] PreferredName:Continuous SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Annual SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] POS:NNP POS:CD POS:SYM POS:: POS:RB POS:CD POS:NNS POS:CC POS:JJR POS:MD POS:VB POS:TO POS:JJ POS:NN POS:CC POS:VB POS:DT POS:NN POS:TO POS:VB POS:NN POS:RB POS:. 
[sentNum: 132]<Annotation Id="24259" Type="Sentence" StartNode="20599" EndNode="20625">(Qualified Recommendation)PreferredName:Recommendation SemanticType:[idcn] POS:( POS:NN POS:NN POS:) 
[sentNum: 133]<Annotation Id="24260" Type="Sentence" StartNode="20627" EndNode="20742">Recommendation 1c: Women should have the opportunity to begin annual screening between the ages of 40 and 44 years. PreferredName:Recommendation SemanticType:[idcn] PreferredName:Beginning SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:annual screening SemanticType:[diap] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] POS:CD POS:CD POS:SYM POS:: POS:NNS POS:MD POS:VB POS:DT POS:NN POS:TO POS:VB POS:JJ POS:NN POS:IN POS:DT POS:NNS POS:IN POS:CD POS:CC POS:CD POS:NNS POS:. 
[sentNum: 134]<Annotation Id="24261" Type="Sentence" StartNode="20743" EndNode="20769">(Qualified Recommendation)PreferredName:Recommendation SemanticType:[idcn] POS:( POS:NN POS:NN POS:) 
[sentNum: 135]<Annotation Id="24262" Type="Sentence" StartNode="20771" EndNode="20984">Various key topics were considered by the GDG in making this these recommendations, beginning with the results of the evidence review regarding the benefits and harms associated with regular screening mammography. PreferredName:Various patch test substance SemanticType:[irda] PreferredName:consider SemanticType:[idcn] PreferredName:topic - ActClassContainer SemanticType:[idcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Make - Instruction Imperative SemanticType:[ftcn] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Beginning SemanticType:[tmco] PreferredName:Review [Publication Type] SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Associated with SemanticType:[qlco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Regular SemanticType:[qlco] POS:JJ POS:JJ POS:NNS POS:VBD POS:VBN POS:IN POS:DT POS:NNP POS:IN POS:VBG POS:DT POS:DT POS:NNS POS:, POS:VBG POS:IN POS:DT POS:NNS POS:IN POS:DT POS:NN POS:NN POS:VBG POS:DT POS:NNS POS:CC POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:NN POS:. 
[sentNum: 136]<Annotation Id="24263" Type="Sentence" StartNode="20985" EndNode="21147">To determine the age to begin screening, the GDG reviewed the burden of disease across age groups while considering the harm-benefit trade-off for each age group. PreferredName:Age SemanticType:[orga] PreferredName:To SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Beginning SemanticType:[tmco] PreferredName:Burden SemanticType:[idcn] PreferredName:Reviewed SemanticType:[qlco] PreferredName:Human Age Group SemanticType:[aggp] PreferredName:Disease SemanticType:[dsyn] PreferredName:Benefits SemanticType:[qnco] PreferredName:consider SemanticType:[idcn] PreferredName:Human Age Group SemanticType:[aggp] POS:TO POS:VB POS:DT POS:NN POS:TO POS:VB POS:NN POS:, POS:DT POS:NNP POS:VBN POS:DT POS:NN POS:IN POS:NN POS:IN POS:NN POS:NNS POS:IN POS:VBG POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NN POS:NN POS:. 
[sentNum: 137]<Annotation Id="24264" Type="Sentence" StartNode="21148" EndNode="21326">In addition, when developing the recommendations for interval of screening, the GDG evaluated the findings of the BCSC analysis in addition to the results of the evidence review.PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Breast Cancer Surveillance Consortium SemanticType:[prog] PreferredName:Procedure findings:Finding:Point in time:^Patient:Narrative SemanticType:[clna] PreferredName:In addition to SemanticType:[qlco] PreferredName:Analysis SemanticType:[resa] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Review [Publication Type] SemanticType:[inpr] POS:IN POS:NN POS:, POS:WRB POS:VBG POS:DT POS:NNS POS:IN POS:NN POS:IN POS:NN POS:, POS:DT POS:NNP POS:VBD POS:DT POS:NNS POS:IN POS:DT POS:NNP POS:NN POS:IN POS:NN POS:TO POS:DT POS:NNS POS:IN POS:DT POS:NN POS:NN POS:. 
[sentNum: 138]<Annotation Id="24265" Type="Sentence" StartNode="21328" EndNode="21361">Outcomes of Screening MammographyPreferredName:Growth Inhibition Screening Result SemanticType:[cnce] PreferredName:Mammography SemanticType:[diap] POS:NNS POS:IN POS:NN POS:NNP 
[sentNum: 139]<Annotation Id="24266" Type="Sentence" StartNode="21363" EndNode="21559">The evidence review considered 5 critical outcomes of screening mammography: breast cancer mortality, life expectancy, false-positive findings, overdiagnosis, and quality-adjusted life expectancy.PreferredName:Evidence of SemanticType:[ftcn] PreferredName:consider SemanticType:[idcn] PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Critical SemanticType:[qlco] PreferredName:Integer +5 SemanticType:[qnco] PreferredName:Mammography SemanticType:[diap] PreferredName:Growth Inhibition Screening Result SemanticType:[cnce] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Quality SemanticType:[qlco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Adjustment Action SemanticType:[ftcn] POS:DT POS:NN POS:NN POS:VBD POS:CD POS:JJ POS:NNS POS:IN POS:VBG POS:NN POS:: POS:NN POS:NN POS:NN POS:, POS:NN POS:NN POS:, POS:JJ POS:NNS POS:, POS:NNS POS:, POS:CC POS:JJ POS:NN POS:NN POS:. 
[sentNum: 140]<Annotation Id="24267" Type="Sentence" StartNode="21561" EndNode="21857">Mammography screening has been shown to be associated with a reduction in breast cancer mortality across a range of study designs, including RCTs and observational studies (trend analyses, cohort studies, and case-control studies), with most studies demonstrating a significant benefit (Table 3).4PreferredName:Show SemanticType:[inpr] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Associated with SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Cancer Death Rate SemanticType:[qnco] PreferredName:Reduction mammaplasty SemanticType:[topp] PreferredName:Research Design SemanticType:[resa] PreferredName:Range SemanticType:[qnco] PreferredName:Observational Study SemanticType:[resa] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Cohort Studies SemanticType:[qnco] PreferredName:trend analysis SemanticType:[inpr] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Case-Control Studies SemanticType:[resa] PreferredName:Benefits SemanticType:[qnco] PreferredName:Statistical Significance SemanticType:[qnco] PreferredName:Table - furniture SemanticType:[mnob] POS:JJ POS:NN POS:VBZ POS:VBN POS:VBN POS:TO POS:VB POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:NNS POS:, POS:VBG POS:NNP POS:CC POS:JJ POS:NNS POS:( POS:NN POS:NNS POS:, POS:NN POS:NNS POS:, POS:CC POS:JJ POS:NNS POS:) POS:, POS:IN POS:JJS POS:NNS POS:VBG POS:DT POS:JJ POS:NN POS:( POS:CD POS:CD POS:) POS:. 
[sentNum: 141]<Annotation Id="24268" Type="Sentence" StartNode="21857" EndNode="22247">4,29,30 The strength of the evidence that invitation or exposure to mammography screening compared with usual care or no screening was associated with reduced breast cancer mortality was judged to be high in the evidence review, although effect sizes differed depending on a range of factors, including the study design, protocol, population undergoing screening, and duration of follow-up.PreferredName:STRENGTH (attribute) SemanticType:[idcn] PreferredName:Invitation SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Exposure to SemanticType:[clna] PreferredName:Usual SemanticType:[qlco] PreferredName:Comparison SemanticType:[acty] PreferredName:Disease Screening SemanticType:[diap] PreferredName:care activity SemanticType:[acty] PreferredName:Reduced SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:To SemanticType:[qlco] PreferredName:Judge SemanticType:[prog] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:effect size SemanticType:[qnco] PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Range SemanticType:[qnco] PreferredName:depend SemanticType:[medd] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:factor A SemanticType:[orch] PreferredName:Clinical trial protocol document SemanticType:[inpr] PreferredName:Research Design SemanticType:[resa] PreferredName:Disease Screening SemanticType:[diap] PreferredName:geographic population SemanticType:[qnco] PreferredName:follow-up SemanticType:[hlca] PreferredName:Duration (temporal concept) SemanticType:[tmco] POS:CD POS:, POS:CD POS:, POS:CD POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:CC POS:NN POS:TO POS:NN POS:NN POS:VBN POS:IN POS:JJ POS:NN POS:CC POS:DT POS:NN POS:VBD POS:VBN POS:IN POS:VBN POS:NN POS:NN POS:NN POS:VBD POS:VBN POS:TO POS:VB POS:JJ POS:IN POS:DT POS:NN POS:NN POS:, POS:IN POS:NN POS:NNS POS:VBD POS:VBG POS:IN POS:DT POS:NN POS:IN POS:NNS POS:, POS:VBG POS:DT POS:NN POS:NN POS:, POS:NN POS:, POS:NN POS:VBG POS:NN POS:, POS:CC POS:NN POS:IN POS:NN POS:. 
[sentNum: 142]<Annotation Id="24269" Type="Sentence" StartNode="22249" EndNode="22647">Pooled estimates for relative breast cancer mortality reductions after approximately 13 years of follow-up were similar for 2 meta-analyses of RCTs using random-effects models (UK Independent Panel,31 relative risk [RR], 0.80; 95% CI, 0.73-0.89; and Canadian Task Force,32 RR, 0.82; 95% CI, 0.74-0.94) and for the Cochrane analysis,30 which used a fixed-effects model (RR, 0.81; 95% CI, 0.74-0.87).PreferredName:Estimated SemanticType:[qnco] PreferredName:Pool (action) SemanticType:[ftcn] PreferredName:Encounter due to breast reduction SemanticType:[fndg] PreferredName:Relative SemanticType:[qlco] PreferredName:Approximate SemanticType:[qlco] PreferredName:Cancer Death Rate SemanticType:[qnco] PreferredName:follow-up SemanticType:[hlca] PreferredName:year SemanticType:[tmco] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:Similarity SemanticType:[qlco] PreferredName:Randomization SemanticType:[resa] PreferredName:Use of SemanticType:[ftcn] PreferredName:Model SemanticType:[inpr] PreferredName:Effect SemanticType:[qlco] PreferredName:Laboratory Order Panels SemanticType:[inpr] PreferredName:Independence SemanticType:[idcn] PreferredName:Relative Risk SemanticType:[qnco] PreferredName:Arabic numeral 31 SemanticType:[inpr] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:CANADIAN SemanticType:[fndg] PreferredName:And SemanticType:[idcn] PreferredName:Relative Risk SemanticType:[qnco] PreferredName:Used by SemanticType:[fndg] PreferredName:Analysis SemanticType:[resa] PreferredName:Effect SemanticType:[qlco] PreferredName:Immobile SemanticType:[fndg] PreferredName:Relative Risk SemanticType:[qnco] PreferredName:Model SemanticType:[inpr] POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:NN POS:NNS POS:IN POS:RB POS:CD POS:NNS POS:IN POS:NN POS:VBD POS:JJ POS:IN POS:CD POS:NNS POS:IN POS:NNP POS:VBG POS:JJ POS:NNS POS:( POS:NNP POS:NNP POS:NNP POS:, POS:CD POS:JJ POS:NN POS:NNP POS:NNP POS:NNS POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:NN POS:NNP POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:: POS:CC POS:NNP POS:NNP POS:NNP POS:, POS:CD POS:NN POS:, POS:CD POS:. POS:: POS:: POS:CD POS:NN POS:RB POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:) POS:CC POS:IN POS:DT POS:NNP POS:NN POS:, POS:CD POS:WDT POS:VBD POS:DT POS:JJ POS:NN POS:( POS:RB POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:NN POS:NNP POS:, POS:SYM POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:) POS:. 
[sentNum: 143]<Annotation Id="24270" Type="Sentence" StartNode="22649" EndNode="22821">Pooled effects from trend studies comparing mortality rates before and after the introduction of a screening program have reported a range of risk reductions of 28% to 36%.29PreferredName:Effect SemanticType:[qlco] PreferredName:Pool (action) SemanticType:[ftcn] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:trend SemanticType:[tmco] PreferredName:Death Rate SemanticType:[qnco] PreferredName:Comparison SemanticType:[acty] PreferredName:Introduction procedure SemanticType:[hlca] PreferredName:And SemanticType:[idcn] PreferredName:Program SemanticType:[phsu] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Range SemanticType:[qnco] PreferredName:Reporting SemanticType:[hlca] PreferredName:To SemanticType:[qlco] PreferredName:Risk Reduction SemanticType:[inbe] POS:JJ POS:NNS POS:IN POS:NN POS:NNS POS:VBG POS:NN POS:NNS POS:IN POS:CC POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:NN POS:VBP POS:VBN POS:DT POS:NN POS:IN POS:NN POS:NNS POS:IN POS:CD POS:NN POS:TO POS:CD POS:NN POS:. 
[sentNum: 144]<Annotation Id="24271" Type="Sentence" StartNode="22821" EndNode="23034">29 In incidence-based mortality studies, the pooled mortality reduction was 25% (RR, 0.75; 95% CI, 0.69-0.81) among women invited to screening and 38% (RR, 0.62; 95% CI, 0.56-0.69) among those attending screening.29PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Incidence Studies SemanticType:[qnco] PreferredName:Pool (action) SemanticType:[ftcn] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Attending (provider role) SemanticType:[prog] POS:CD POS:IN POS:JJ POS:NN POS:NNS POS:, POS:DT POS:JJ POS:NN POS:NN POS:VBD POS:CD POS:NN POS:( POS:RB POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:NN POS:NNP POS:, POS:SYM POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:) POS:IN POS:NNS POS:VBN POS:TO POS:NN POS:CC POS:CD POS:NN POS:( POS:RB POS:, POS:NNP POS:. POS:CD POS:: POS:CD POS:NN POS:NNP POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:) POS:IN POS:DT POS:VBG POS:NN POS:. 
[sentNum: 145]<Annotation Id="24272" Type="Sentence" StartNode="23034" EndNode="23212">29 The corresponding pooled estimates from case-control studies were 31% (OR, 0.69; 95% CI, 0.57-0.83), and 48% (OR, 0.52; 95% CI, 0.42-0.65) after adjustment for self-selection.29PreferredName:Estimated SemanticType:[qnco] PreferredName:Pool (action) SemanticType:[ftcn] PreferredName:Arabic numeral 31 SemanticType:[inpr] PreferredName:Case-Control Studies SemanticType:[resa] PreferredName:Arabic numeral 65 SemanticType:[inpr] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:subscriber - self SemanticType:[inpr] PreferredName:Individual Adjustment SemanticType:[inbe] PreferredName:Selection, Genetic SemanticType:[genf] POS:CD POS:DT POS:JJ POS:JJ POS:NNS POS:IN POS:JJ POS:NNS POS:VBD POS:CD POS:NN POS:( POS:RB POS:, POS:NNP POS:. POS:CD POS:: POS:CD POS:NN POS:NNP POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:) POS:, POS:CC POS:CD POS:NN POS:( POS:RB POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:NN POS:NNP POS:, POS:SYM POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:) POS:IN POS:NN POS:IN POS:NN POS:. 
[sentNum: 146]<Annotation Id="24273" Type="Sentence" StartNode="23212" EndNode="23214">29POS:NNP 
[sentNum: 147]<Annotation Id="24274" Type="Sentence" StartNode="23216" EndNode="23490">The magnitude of these estimates was influenced by a number of factors, including whether the estimate was based on invitation to screening or exposure to screening and the degree of heterogeneity of individual studies in meta-analyses or pooled observational study results. PreferredName:Magnitude SemanticType:[qnco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:factor A SemanticType:[orch] PreferredName:Basis - conceptual entity SemanticType:[ftcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Invitation SemanticType:[inpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Exposure to SemanticType:[clna] PreferredName:Heterogeneity SemanticType:[qlco] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Persons SemanticType:[popg] PreferredName:Pooled Sample SemanticType:[sbst] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:research outcome SemanticType:[fndg] PreferredName:Observation - diagnostic procedure SemanticType:[diap] POS:DT POS:NN POS:IN POS:DT POS:NNS POS:VBD POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:, POS:VBG POS:IN POS:DT POS:NN POS:VBD POS:VBN POS:IN POS:NN POS:TO POS:NN POS:CC POS:NN POS:TO POS:NN POS:CC POS:DT POS:NN POS:IN POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:NNS POS:CC POS:VBN POS:JJ POS:NN POS:NNS POS:. 
[sentNum: 148]<Annotation Id="24275" Type="Sentence" StartNode="23491" EndNode="23590">The analyses of RCTs follow the principle of intention-to-treat to reduce known and unknown biases. PreferredName:Followed by SemanticType:[tmco] PreferredName:Analysis SemanticType:[resa] PreferredName:Treatment intent SemanticType:[ftcn] PreferredName:intent SemanticType:[qlco] PreferredName:Known SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Biases SemanticType:[idcn] PreferredName:Unknown SemanticType:[qlco] POS:DT POS:NNS POS:IN POS:NNP POS:VBP POS:DT POS:NN POS:IN POS:NN POS:TO POS:VB POS:VBN POS:CC POS:JJ POS:NNS POS:. 
[sentNum: 149]<Annotation Id="24276" Type="Sentence" StartNode="23591" EndNode="23734">Observational studies may be evaluated by either invitation to screening or exposure to screening with appropriate adjustment for known biases. PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Observational Study SemanticType:[resa] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Invitation SemanticType:[inpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Exposure to SemanticType:[clna] PreferredName:Appropriate SemanticType:[qlco] PreferredName:In addition to SemanticType:[qlco] PreferredName:Known SemanticType:[qlco] PreferredName:Individual Adjustment SemanticType:[inbe] PreferredName:Biases SemanticType:[idcn] POS:JJ POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:DT POS:NN POS:TO POS:NN POS:CC POS:NN POS:TO POS:VBG POS:IN POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 150]<Annotation Id="24277" Type="Sentence" StartNode="23735" EndNode="23992">Although RCTs are the foundation of the supporting evidence for mammography screening, the GDG also concluded that contemporary, large well-designed observational studies provided valuable information on the effectiveness associated with modern mammography.PreferredName:Foundations SemanticType:[orgt] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Supportive assistance SemanticType:[cnce] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Good SemanticType:[qlco] PreferredName:Large SemanticType:[qnco] PreferredName:Observational Study SemanticType:[resa] PreferredName:Design SemanticType:[acty] PreferredName:Information SemanticType:[idcn] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Associated with SemanticType:[qlco] PreferredName:Effectiveness SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] POS:IN POS:NNP POS:VBP POS:DT POS:NN POS:IN POS:DT POS:VBG POS:NN POS:IN POS:NN POS:NN POS:, POS:DT POS:NNP POS:RB POS:VBD POS:IN POS:JJ POS:, POS:JJ POS:JJ POS:JJ POS:NNS POS:VBD POS:JJ POS:NN POS:IN POS:DT POS:NN POS:VBN POS:IN POS:JJ POS:NN POS:. 
[sentNum: 151]<Annotation Id="24278" Type="Sentence" StartNode="23994" EndNode="24208">In contrast to RRs, estimates of absolute benefit, measured by the number needed to invite (NNI) or the number needed to screen (NNS) to prevent 1 death are increasingly relied on as meaningful measures of benefit. PreferredName:Robinow syndrome, autosomal recessive SemanticType:[dsyn] PreferredName:Absolute SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Measured to (attribute) SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Needs SemanticType:[qlco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Needs SemanticType:[qlco] PreferredName:Numbers SemanticType:[qnco] PreferredName:To SemanticType:[qlco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:1+ Score SemanticType:[qnco] PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:Meaning SemanticType:[idcn] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Benefits SemanticType:[qnco] PreferredName:Measures SemanticType:[qnco] POS:IN POS:NN POS:TO POS:NNP POS:, POS:NNS POS:IN POS:JJ POS:NN POS:, POS:VBN POS:IN POS:DT POS:NN POS:VBN POS:TO POS:VB POS:( POS:NNP POS:) POS:CC POS:DT POS:NN POS:VBN POS:TO POS:NN POS:( POS:NNP POS:) POS:TO POS:VB POS:CD POS:NN POS:VBP POS:RB POS:VBN POS:IN POS:RB POS:JJ POS:NNS POS:IN POS:NN POS:. 
[sentNum: 152]<Annotation Id="24279" Type="Sentence" StartNode="24209" EndNode="24450">The magnitude of the absolute benefit in the published literature is influenced by the RR, duration of follow-up, underlying mortality risk in the population from which the estimate is derived, and whether the estimate is the NNI or the NNS. PreferredName:Absolute SemanticType:[qlco] PreferredName:Magnitude SemanticType:[qnco] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Benefits SemanticType:[qnco] PreferredName:Duration (temporal concept) SemanticType:[tmco] PreferredName:Publications SemanticType:[inpr, mnob] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:follow-up SemanticType:[hlca] PreferredName:Estimated SemanticType:[qnco] PreferredName:Population at Risk SemanticType:[popg] PreferredName:Estimated SemanticType:[qnco] PreferredName:Derivation SemanticType:[qlco] PreferredName:Needs SemanticType:[qlco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Needs SemanticType:[qlco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Screening - procedure intent SemanticType:[ftcn] POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NN POS:IN POS:DT POS:VBN POS:NN POS:VBZ POS:VBN POS:IN POS:DT POS:NNP POS:, POS:NN POS:IN POS:NN POS:, POS:VBG POS:NN POS:NN POS:IN POS:DT POS:NN POS:IN POS:WDT POS:DT POS:NN POS:VBZ POS:VBN POS:, POS:CC POS:IN POS:DT POS:NN POS:VBZ POS:DT POS:NNP POS:CC POS:DT POS:NNP POS:. 
[sentNum: 153]<Annotation Id="24280" Type="Sentence" StartNode="24451" EndNode="24662">Although NNI can be estimated from RCTs or observational studies, it is not a very useful indicator because this estimate will be inflated by deaths among women invited to screening who never attended screening.33PreferredName:Numbers SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Needs SemanticType:[qlco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Observational Study SemanticType:[resa] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:Very SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Indicator SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:No formal education SemanticType:[fndg] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:IN POS:NNP POS:MD POS:VB POS:VBN POS:IN POS:NNP POS:CC POS:NN POS:NNS POS:, POS:PRP POS:VBZ POS:RB POS:DT POS:RB POS:JJ POS:NN POS:IN POS:DT POS:NN POS:MD POS:VB POS:VBN POS:IN POS:NNS POS:IN POS:NNS POS:VBN POS:TO POS:NN POS:WP POS:RB POS:VBD POS:NN POS:. 
[sentNum: 154]<Annotation Id="24281" Type="Sentence" StartNode="24662" EndNode="24785">33 However, use of either NNI or NNS and other model inputs have resulted in quite disparate estimates of absolute benefit. PreferredName:Use of SemanticType:[ftcn] PreferredName:Needs SemanticType:[qlco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Needs SemanticType:[qlco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Model SemanticType:[inpr] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Result SemanticType:[ftcn] PreferredName:Input SemanticType:[cnce] PreferredName:Absolute SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] POS:CD POS:RB POS:, POS:NN POS:IN POS:CC POS:NNP POS:CC POS:NNP POS:CC POS:JJ POS:NN POS:NNS POS:VBP POS:VBN POS:IN POS:RB POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:. 
[sentNum: 155]<Annotation Id="24282" Type="Sentence" StartNode="24786" EndNode="24979">For example, the Cochrane Systematic Review estimated that 2000 women would need to be invited to screening and followed up for mortality over a 10-year period to prevent 1 breast cancer death.30PreferredName:Example SemanticType:[cnce] PreferredName:Estimated SemanticType:[qnco] PreferredName:Review, Systematic SemanticType:[inpr] PreferredName:Woman SemanticType:[popg] PreferredName:2000s SemanticType:[tmco] PreferredName:To SemanticType:[qlco] PreferredName:Needs SemanticType:[qlco] PreferredName:follow-up SemanticType:[hlca] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Period (temporal qualifier) SemanticType:[tmco] PreferredName:per year SemanticType:[tmco] PreferredName:1+ Score SemanticType:[qnco] PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:IN POS:NN POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:VBD POS:IN POS:CD POS:NNS POS:MD POS:VB POS:TO POS:VB POS:VBN POS:TO POS:NN POS:CC POS:VBD POS:RP POS:IN POS:NN POS:IN POS:DT POS:CD POS:: POS:NN POS:NN POS:TO POS:VB POS:CD POS:NN POS:NN POS:NN POS:. 
[sentNum: 156]<Annotation Id="24283" Type="Sentence" StartNode="24979" EndNode="25169">30 The UK Independent Review estimated that 180 women needed to be screened over a 20-year period beginning at age 50 years, with follow-up to age 79 years, to prevent 1 breast cancer death.31PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Independence SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Estimated SemanticType:[qnco] PreferredName:To SemanticType:[qlco] PreferredName:Needs SemanticType:[qlco] PreferredName:per year SemanticType:[tmco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Beginning SemanticType:[tmco] PreferredName:Period (temporal qualifier) SemanticType:[tmco] PreferredName:In addition to SemanticType:[qlco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:follow-up SemanticType:[hlca] PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:To SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Cessation of life SemanticType:[orgf] POS:CD POS:DT POS:NNP POS:NNP POS:NNP POS:VBD POS:IN POS:CD POS:NNS POS:VBD POS:TO POS:VB POS:VBN POS:IN POS:DT POS:CD POS:: POS:NN POS:NN POS:VBG POS:IN POS:NN POS:CD POS:NNS POS:, POS:IN POS:NN POS:TO POS:NN POS:CD POS:NNS POS:, POS:TO POS:VB POS:CD POS:NN POS:NN POS:NN POS:. 
[sentNum: 157]<Annotation Id="24284" Type="Sentence" StartNode="25169" EndNode="25548">31 The main distinction between the Cochrane Systematic Review30 and UK Independent Review31 estimates is that the former was based on a less favorable mortality reduction (RR, 0.85 vs 0.80) over a shorter duration of the screening program (10 years vs 20 years), use of NNI, and a follow-up period that is contemporaneous with and limited to the period of the screening program.PreferredName:Arabic numeral 31 SemanticType:[inpr] PreferredName:systematic SemanticType:[ftcn] PreferredName:Main SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Independence SemanticType:[idcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:FORMER SemanticType:[idcn] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Favorable SemanticType:[qlco] PreferredName:Over (spatial) SemanticType:[spco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Duration of screening SemanticType:[tmco] PreferredName:Short SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:Program SemanticType:[phsu] PreferredName:Use of SemanticType:[ftcn] PreferredName:year SemanticType:[tmco] PreferredName:Needs SemanticType:[qlco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Period (temporal qualifier) SemanticType:[tmco] PreferredName:follow-up SemanticType:[hlca] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Definite time SemanticType:[tmco] PreferredName:Program SemanticType:[phsu] POS:CD POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:CD POS:CC POS:NNPS POS:NNP POS:NNP POS:CD POS:NNS POS:VBZ POS:IN POS:DT POS:JJ POS:VBD POS:VBN POS:IN POS:DT POS:RBR POS:JJ POS:NN POS:NN POS:( POS:RB POS:, POS:JJ POS:. POS:NNP POS:NN POS:CD POS:. POS:CD POS:) POS:IN POS:DT POS:JJR POS:NN POS:IN POS:DT POS:NN POS:NN POS:( POS:CD POS:NNS POS:CD POS:CD POS:NNS POS:) POS:, POS:NN POS:IN POS:NNP POS:, POS:CC POS:DT POS:NN POS:NN POS:WDT POS:VBZ POS:JJ POS:IN POS:CC POS:VBN POS:TO POS:DT POS:NN POS:IN POS:DT POS:NN POS:NN POS:. 
[sentNum: 158]<Annotation Id="24285" Type="Sentence" StartNode="25550" EndNode="26105">As shown by Duffy et al,34 when widely different estimates of absolute benefit are standardized to a common RR, number of screening rounds, and duration of follow-up, and then applied to a standard population and baseline risk (specifically, in this example, the UK Independent Review scenario described above),31 to estimate the NNS, a nearly 20-fold difference (from 111 to 2000) found in 4 well-known estimates29- 31,35 of the NNS/NNI to prevent 1 breast cancer death was reduced to a range of 96 to 257 women screened to prevent 1 breast cancer death.34PreferredName:Show SemanticType:[inpr] PreferredName:Absolute Change SemanticType:[idcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:shared attribute SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Numbers SemanticType:[qnco] PreferredName:Duration (temporal concept) SemanticType:[tmco] PreferredName:Round shape SemanticType:[spco] PreferredName:Then SemanticType:[tmco] PreferredName:follow-up SemanticType:[hlca] PreferredName:Standard Population SemanticType:[qnco] PreferredName:Application procedure SemanticType:[hlca] PreferredName:Risk SemanticType:[qlco] PreferredName:Baseline SemanticType:[qnco] PreferredName:Independence SemanticType:[idcn] PreferredName:Example SemanticType:[cnce] PreferredName:scenario SemanticType:[ftcn] PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Upper SemanticType:[spco] PreferredName:described SemanticType:[idcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Arabic numeral 31 SemanticType:[inpr] PreferredName:From SemanticType:[qlco] PreferredName:Fold Change SemanticType:[qnco] PreferredName:Present SemanticType:[qnco] PreferredName:2000s SemanticType:[tmco] PreferredName:Known SemanticType:[qlco] PreferredName:Good SemanticType:[qlco] PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:Arabic numeral 31 SemanticType:[inpr] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Woman SemanticType:[popg] PreferredName:Sample Range SemanticType:[qnco] PreferredName:To SemanticType:[qlco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:1+ Score SemanticType:[qnco] PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:IN POS:VBN POS:IN POS:NNP POS:CC POS:NNP POS:, POS:CD POS:WRB POS:RB POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:VBP POS:JJ POS:TO POS:DT POS:JJ POS:NN POS:, POS:NN POS:IN POS:NN POS:NNS POS:, POS:CC POS:NN POS:IN POS:NN POS:, POS:CC POS:RB POS:VBN POS:TO POS:DT POS:JJ POS:NN POS:CC POS:NN POS:NN POS:( POS:UH POS:, POS:IN POS:DT POS:NN POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:NN POS:VBN POS:IN POS:) POS:, POS:CD POS:TO POS:VB POS:DT POS:NNP POS:, POS:DT POS:RB POS:CD POS:: POS:VB POS:NN POS:( POS:IN POS:CD POS:TO POS:CD POS:) POS:VBN POS:IN POS:CD POS:JJ POS:NNS POS:CD POS:: POS:CD POS:, POS:CD POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:TO POS:VB POS:CD POS:NN POS:NN POS:NN POS:VBD POS:VBN POS:TO POS:DT POS:NN POS:IN POS:CD POS:TO POS:CD POS:NNS POS:VBD POS:TO POS:VB POS:CD POS:NN POS:NN POS:NN POS:. 
[sentNum: 159]<Annotation Id="24286" Type="Sentence" StartNode="26105" EndNode="26520">34 The importance of long-term follow-up in estimating the NNS is evident in the 29-year follow-up of the Swedish Two County Trial, in which the investigators observed that 922 women aged 40 to 74 years needed to be screened 2 to 3 times over a 7-year period to prevent 1 breast cancer death at 10 years of follow-up, which decreased to 464 women at 20 years of follow-up, and to 414 women at 29 years of follow-up.36PreferredName:Estimated SemanticType:[qnco] PreferredName:Longterm Follow-up SemanticType:[hlca] PreferredName:per year SemanticType:[tmco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Swedish SemanticType:[popg] PreferredName:follow-up SemanticType:[hlca] PreferredName:County SemanticType:[geoa] PreferredName:Two SemanticType:[qnco] PreferredName:Research Personnel SemanticType:[prog] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Woman SemanticType:[popg] PreferredName:Observed SemanticType:[ftcn] PreferredName:/40 SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Needs SemanticType:[qlco] PreferredName:year SemanticType:[tmco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:per year SemanticType:[tmco] PreferredName:Time 2 SemanticType:[fndg] PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:Period (temporal qualifier) SemanticType:[tmco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Decreased SemanticType:[qnco] PreferredName:Follow-up 1 year SemanticType:[fndg] PreferredName:At SemanticType:[spco] PreferredName:Woman SemanticType:[popg] PreferredName:follow-up SemanticType:[hlca] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:And SemanticType:[idcn] PreferredName:year SemanticType:[tmco] PreferredName:At SemanticType:[spco] PreferredName:follow-up SemanticType:[hlca] POS:CD POS:DT POS:NN POS:IN POS:JJ POS:NN POS:IN POS:VBG POS:DT POS:NNP POS:VBZ POS:JJ POS:IN POS:DT POS:CD POS:: POS:NN POS:NN POS:IN POS:DT POS:JJ POS:CD POS:NNP POS:NN POS:, POS:IN POS:WDT POS:DT POS:NNS POS:VBD POS:IN POS:CD POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:VBD POS:TO POS:VB POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:IN POS:DT POS:CD POS:: POS:NN POS:NN POS:TO POS:VB POS:CD POS:NN POS:NN POS:NN POS:IN POS:CD POS:NNS POS:IN POS:NN POS:, POS:WDT POS:VBD POS:TO POS:CD POS:NNS POS:IN POS:CD POS:NNS POS:IN POS:NN POS:, POS:CC POS:TO POS:CD POS:NNS POS:IN POS:CD POS:NNS POS:IN POS:NN POS:. 
[sentNum: 160]<Annotation Id="24287" Type="Sentence" StartNode="26520" EndNode="26522">36POS:JJR 
[sentNum: 161]<Annotation Id="24288" Type="Sentence" StartNode="26524" EndNode="26871">To assess the absolute benefits of screening over a 15-year time period, the evidence review group used the prevalence of screening every 2 years of 65% (derived from the National Health Interview Survey) and incidence-based mortality from SEER to estimate the NNS to prevent 1 breast cancer death based on different relative mortality reductions. PreferredName:To SemanticType:[qlco] PreferredName:Absolute SemanticType:[qlco] PreferredName:Assessed SemanticType:[acty] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Time periods SemanticType:[tmco] PreferredName:per year SemanticType:[tmco] PreferredName:Study Section SemanticType:[prog] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Prevalence aspects SemanticType:[qnco] PreferredName:Used by SemanticType:[fndg] PreferredName:Annual SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Derivation SemanticType:[qlco] PreferredName:Arabic numeral 65 SemanticType:[inpr] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:National Health Interview Survey SemanticType:[inpr] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Surveillance, Epidemiology, and End Results (SEER) Program SemanticType:[hcro] PreferredName:1+ Score, WHO SemanticType:[clas] PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Different SemanticType:[qlco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Relative SemanticType:[qlco] PreferredName:Reduction - action SemanticType:[topp] POS:TO POS:VB POS:DT POS:JJ POS:NNS POS:IN POS:NN POS:IN POS:DT POS:CD POS:JJ POS:NN POS:NN POS:NN POS:, POS:DT POS:NN POS:NN POS:NN POS:VBD POS:DT POS:NN POS:IN POS:VBG POS:DT POS:CD POS:NNS POS:IN POS:CD POS:NN POS:( POS:VBN POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:) POS:CC POS:JJ POS:NN POS:IN POS:NNP POS:TO POS:VB POS:DT POS:NNP POS:TO POS:VB POS:CD POS:NN POS:NN POS:NN POS:VBN POS:IN POS:JJ POS:JJ POS:NN POS:NNS POS:. 
[sentNum: 162]<Annotation Id="24289" Type="Sentence" StartNode="26872" EndNode="26997">For women aged 40 to 49 years, the NNS ranged from 753 with a 40% mortality reduction to 1770 with a 20% mortality reduction. PreferredName:Woman SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Range SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:In addition to SemanticType:[qlco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:1770s SemanticType:[tmco] PreferredName:Reduction - action SemanticType:[topp] POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:, POS:DT POS:NNP POS:VBD POS:IN POS:CD POS:IN POS:DT POS:CD POS:NN POS:NN POS:NN POS:TO POS:CD POS:IN POS:DT POS:CD POS:NN POS:NN POS:NN POS:. 
[sentNum: 163]<Annotation Id="24290" Type="Sentence" StartNode="26998" EndNode="27123">For women aged 50 to 59 years, the NNS ranged from 462 with a 40% mortality reduction to 1087 with a 20% mortality reduction. PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:In addition to SemanticType:[qlco] PreferredName:Range SemanticType:[qnco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:/40 SemanticType:[tmco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Reduction - action SemanticType:[topp] POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:, POS:DT POS:NNP POS:VBD POS:IN POS:CD POS:IN POS:DT POS:CD POS:NN POS:NN POS:NN POS:TO POS:CD POS:IN POS:DT POS:CD POS:NN POS:NN POS:NN POS:. 
[sentNum: 164]<Annotation Id="24291" Type="Sentence" StartNode="27124" EndNode="27248">For women aged 60 to 69 years, the NNS ranged from 355 with a 40% mortality reduction to 835 with a 20% mortality reduction.25PreferredName:Woman SemanticType:[popg] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Range SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:In addition to SemanticType:[qlco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:20/25 SemanticType:[fndg] PreferredName:Reduction - action SemanticType:[topp] POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:, POS:DT POS:NNP POS:VBD POS:IN POS:CD POS:IN POS:DT POS:CD POS:NN POS:NN POS:NN POS:TO POS:CD POS:IN POS:DT POS:CD POS:NN POS:NN POS:NN POS:. 
[sentNum: 165]<Annotation Id="24292" Type="Sentence" StartNode="27248" EndNode="27430">25 As in other estimates of the NNI vs NNS, absolute benefit is more favorable when based on exposure to screening and is increasingly more favorable as disease prevalence increases. PreferredName:Estimated SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Absolute SemanticType:[qlco] PreferredName:Favorable SemanticType:[qlco] PreferredName:More SemanticType:[ftcn] PreferredName:Exposure to SemanticType:[clna] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Favorable SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Increase SemanticType:[ftcn] PreferredName:disorder prevalence SemanticType:[qnco] POS:CD POS:RB POS:IN POS:JJ POS:NNS POS:IN POS:DT POS:NNP POS:NNPS POS:NNP POS:, POS:JJ POS:NN POS:VBZ POS:RBR POS:JJ POS:WRB POS:VBN POS:IN POS:NN POS:TO POS:NN POS:CC POS:VBZ POS:RB POS:RBR POS:JJ POS:IN POS:NN POS:NN POS:NNS POS:. 
[sentNum: 166]<Annotation Id="24293" Type="Sentence" StartNode="27431" EndNode="27534">The estimates presented also would be more favorable if follow-up were projected to 25 years or longer.PreferredName:Presentation SemanticType:[idcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Favorable SemanticType:[qlco] PreferredName:More SemanticType:[ftcn] PreferredName:Projections and Predictions SemanticType:[inpr] PreferredName:follow-up SemanticType:[hlca] PreferredName:Long SemanticType:[qlco] PreferredName:year SemanticType:[tmco] POS:DT POS:NNS POS:VBN POS:RB POS:MD POS:VB POS:RBR POS:JJ POS:IN POS:NN POS:VBD POS:VBN POS:TO POS:CD POS:NNS POS:CC POS:RB POS:. 
[sentNum: 167]<Annotation Id="24294" Type="Sentence" StartNode="27536" EndNode="27700">The evidence review judged the quality of the evidence as high that reducing breast cancer mortality through mammographic screening should increase life expectancy. PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Quality SemanticType:[qlco] PreferredName:Judge SemanticType:[prog] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Views screening:Find:Pt:Breast:Doc:Mam SemanticType:[clna] PreferredName:Reduced SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Cancer Death Rate SemanticType:[qnco] PreferredName:Life Expectancy SemanticType:[grpa] POS:DT POS:NN POS:NN POS:VBN POS:DT POS:NN POS:IN POS:DT POS:NN POS:RB POS:JJ POS:IN POS:VBG POS:NN POS:NN POS:NN POS:IN POS:JJ POS:NN POS:MD POS:VB POS:NN POS:NN POS:. 
[sentNum: 168]<Annotation Id="24295" Type="Sentence" StartNode="27701" EndNode="28059">However, based on considerable uncertainty about several parameters important for estimating these gains (in particular, the magnitude of mortality reduction associated with screening at different ages and intervals), the quality of evidence for the magnitude of the strength of the association between screening and life expectancy was considered to be low. PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Numerous SemanticType:[qnco] PreferredName:Uncertainty SemanticType:[idcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Observation parameter SemanticType:[fndg] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Different SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Interval SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Quality SemanticType:[qlco] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Relationships SemanticType:[qlco] PreferredName:STRENGTH (attribute) SemanticType:[idcn] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:consider SemanticType:[idcn] PreferredName:low SemanticType:[qlco] POS:RB POS:, POS:VBN POS:IN POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:JJ POS:IN POS:VBG POS:DT POS:NNS POS:( POS:IN POS:JJ POS:, POS:DT POS:NN POS:IN POS:NN POS:NN POS:VBN POS:IN POS:VBG POS:IN POS:JJ POS:NNS POS:CC POS:NNS POS:) POS:, POS:DT POS:NN POS:IN POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:CC POS:NN POS:NN POS:VBD POS:VBN POS:TO POS:VB POS:JJ POS:. 
[sentNum: 169]<Annotation Id="24296" Type="Sentence" StartNode="28060" EndNode="28255">Estimates of life expectancy gains are by definition indirect and, when expressed across the entire population, have limited meaning when considered outside of the context of other interventions. PreferredName:Estimated SemanticType:[qnco] PreferredName:are unit of measure SemanticType:[qnco] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Indirect SemanticType:[qlco] PreferredName:Definition SemanticType:[cnce] PreferredName:geographic population SemanticType:[qnco] PreferredName:Entire SemanticType:[qnco] PreferredName:Meaning SemanticType:[idcn] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Extrinsic SemanticType:[spco] PreferredName:consider SemanticType:[idcn] PreferredName:Procedure context SemanticType:[idcn] POS:NNS POS:IN POS:NN POS:NN POS:NNS POS:VBP POS:IN POS:NN POS:JJ POS:CC POS:, POS:WRB POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:, POS:VBP POS:VBN POS:VBG POS:WRB POS:VBN POS:IN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 170]<Annotation Id="24297" Type="Sentence" StartNode="28256" EndNode="28517">In contrast, gains in life expectancy for individual women who avoid a premature death from breast cancer can be significant, given that the average and total years of life lost are greater for breast compared with other high-prevalence cancers affecting women.3PreferredName:Contrast SemanticType:[qlco] PreferredName:Present SemanticType:[qnco] PreferredName:Gain SemanticType:[qnco] PreferredName:Individual SemanticType:[humn] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Mortality, Premature SemanticType:[fndg] PreferredName:Woman SemanticType:[popg] PreferredName:Significant SemanticType:[idcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Average SemanticType:[qnco] PreferredName:Given name SemanticType:[inpr] PreferredName:year SemanticType:[tmco] PreferredName:Total SemanticType:[qlco] PreferredName:Lost SemanticType:[ftcn] PreferredName:Life SemanticType:[idcn] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Greater SemanticType:[qnco] PreferredName:High Prevalence SemanticType:[qnco] PreferredName:Comparison SemanticType:[acty] PreferredName:Involvement with SemanticType:[ftcn] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Woman SemanticType:[popg] POS:IN POS:NN POS:, POS:NNS POS:IN POS:NN POS:NN POS:IN POS:JJ POS:NNS POS:WP POS:VBP POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:MD POS:VB POS:JJ POS:, POS:VBN POS:IN POS:DT POS:JJ POS:CC POS:JJ POS:NNS POS:IN POS:NN POS:VBD POS:VBP POS:JJR POS:IN POS:NN POS:VBN POS:IN POS:JJ POS:JJ POS:NNS POS:VBG POS:NNS POS:. 
[sentNum: 171]<Annotation Id="24298" Type="Sentence" StartNode="28517" EndNode="28518">3POS:NNP 
[sentNum: 172]<Annotation Id="24299" Type="Sentence" StartNode="28520" EndNode="28582">False-positive findings are common in breast cancer screening. PreferredName:False Positive SemanticType:[lbtr] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:shared attribute SemanticType:[ftcn] POS:JJ POS:NNS POS:VBP POS:JJ POS:IN POS:NN POS:NN POS:NN POS:. 
[sentNum: 173]<Annotation Id="24300" Type="Sentence" StartNode="28583" EndNode="28676">The most common outcome of a false-positive finding is being recalled for additional imaging. PreferredName:False Positive Result Medical Device Problem SemanticType:[fndg] PreferredName:shared attribute SemanticType:[ftcn] PreferredName:Mental Recall SemanticType:[menp] PreferredName:Experimental Finding SemanticType:[fndg] PreferredName:Diagnostic Imaging SemanticType:[diap] PreferredName:Additional SemanticType:[ftcn] POS:DT POS:RBS POS:JJ POS:NN POS:IN POS:DT POS:NN POS:NN POS:VBZ POS:VBG POS:VBN POS:IN POS:JJ POS:NN POS:. 
[sentNum: 174]<Annotation Id="24301" Type="Sentence" StartNode="28677" EndNode="28797">A smaller percentage of women who are recalled go on to biopsy, and a majority of these women will have benign findings. PreferredName:Money or percentage indicator - Percentage SemanticType:[idcn] PreferredName:A little bit SemanticType:[inpr] PreferredName:Mental Recall SemanticType:[menp] PreferredName:Woman SemanticType:[popg] PreferredName:biopsy characteristics SemanticType:[ftcn] PreferredName:GORAB gene SemanticType:[gngm] PreferredName:Woman SemanticType:[popg] PreferredName:majority SemanticType:[socb] PreferredName:findings aspects SemanticType:[ftcn] PreferredName:Benign SemanticType:[qlco] POS:DT POS:JJR POS:NN POS:IN POS:NNS POS:WP POS:VBP POS:VBN POS:VB POS:RP POS:TO POS:NN POS:, POS:CC POS:DT POS:NN POS:IN POS:DT POS:NNS POS:MD POS:VB POS:JJ POS:NNS POS:. 
[sentNum: 175]<Annotation Id="24302" Type="Sentence" StartNode="28798" EndNode="28887">In weighing harm, the GDG placed greater emphasis on false positives leading to a biopsy.PreferredName:Place SemanticType:[spco] PreferredName:Weighing patient SemanticType:[diap] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Greater SemanticType:[qnco] PreferredName:biopsy characteristics SemanticType:[ftcn] PreferredName:Leading SemanticType:[ftcn] POS:IN POS:VBG POS:NNS POS:, POS:DT POS:NNP POS:VBD POS:JJR POS:NN POS:IN POS:JJ POS:NNS POS:VBG POS:TO POS:DT POS:NN POS:. 
[sentNum: 176]<Annotation Id="24303" Type="Sentence" StartNode="28889" EndNode="29202">Hubbard et al37 reported that among women in the BCSC who initiated screening at age 40 years and had undergone either screen-film or digital mammography, the unadjusted cumulative probability of at least 1 false-positive recall after 10 years of screening was 61.3% with annual and 41.6% with biennial screening. PreferredName:Woman SemanticType:[popg] PreferredName:Reporting SemanticType:[hlca] PreferredName:Initiate (source type) SemanticType:[idcn] PreferredName:Breast Cancer Surveillance Consortium SemanticType:[prog] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:/40 SemanticType:[tmco] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:film (photographic) SemanticType:[mnob] PreferredName:Cumulative SemanticType:[qlco] PreferredName:unadjusted SemanticType:[ftcn] PreferredName:SLC33A1 gene SemanticType:[gngm] PreferredName:Probability SemanticType:[qnco] PreferredName:Recall:-:Point in time:^Patient:- SemanticType:[clna] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:year SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Annual SemanticType:[tmco] POS:NNP POS:CC POS:NNP POS:CD POS:VBD POS:IN POS:IN POS:NNS POS:IN POS:DT POS:NN POS:WP POS:VBD POS:NN POS:IN POS:NN POS:CD POS:NNS POS:CC POS:VBD POS:VBN POS:DT POS:NN POS:CC POS:JJ POS:NN POS:, POS:DT POS:JJ POS:JJ POS:NN POS:IN POS:IN POS:JJS POS:CD POS:NN POS:VBP POS:IN POS:CD POS:NNS POS:IN POS:NN POS:VBD POS:CD POS:. POS:CD POS:NN POS:IN POS:JJ POS:CC POS:CD POS:. POS:CD POS:NN POS:IN POS:JJ POS:NN POS:. 
[sentNum: 177]<Annotation Id="24304" Type="Sentence" StartNode="29203" EndNode="29380">The 10-year cumulative probability of a false-positive mammogram leading to a biopsy recommendation within the same cohort was 7.0% with annual and 4.8% with biennial screening. PreferredName:Cumulative SemanticType:[qlco] PreferredName:per year SemanticType:[tmco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Probability SemanticType:[qnco] PreferredName:Leading SemanticType:[ftcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Advice SemanticType:[hlca] PreferredName:Biopsy SemanticType:[diap] PreferredName:Cohort SemanticType:[popg] PreferredName:Same SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Annual SemanticType:[tmco] POS:DT POS:CD POS:JJ POS:NN POS:JJ POS:NN POS:IN POS:DT POS:JJ POS:NN POS:VBG POS:TO POS:DT POS:JJ POS:NN POS:IN POS:DT POS:JJ POS:NN POS:VBD POS:CD POS:. POS:CD POS:NN POS:IN POS:JJ POS:CC POS:LS POS:. POS:CD POS:NN POS:IN POS:JJ POS:NN POS:. 
[sentNum: 178]<Annotation Id="24305" Type="Sentence" StartNode="29381" EndNode="29564">Thus, screening every 2 years rather than every year reduced the cumulative incidence of at least 1 false-positive recall and false-positive biopsy by about 32% and 31%, respectively.37PreferredName:Integer +2 SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:per year SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Cumulative SemanticType:[qlco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Less Than SemanticType:[inpr] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Recall:-:Point in time:^Patient:- SemanticType:[clna] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Biopsy SemanticType:[diap] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Arabic numeral 31 SemanticType:[inpr] POS:RB POS:, POS:VBG POS:DT POS:CD POS:NNS POS:RB POS:IN POS:DT POS:NN POS:VBD POS:DT POS:JJ POS:NN POS:IN POS:IN POS:JJS POS:CD POS:JJ POS:NN POS:CC POS:JJ POS:NN POS:IN POS:RB POS:CD POS:NN POS:CC POS:CD POS:NN POS:, POS:RB POS:. 
[sentNum: 179]<Annotation Id="24306" Type="Sentence" StartNode="29564" EndNode="30039">37,38Quiz Ref ID A number of factors appear to be associated with an increased likelihood of false-positive results, including the first mammogram, greater mammographic breast density, use of postmenopausal hormone therapy, use of digital vs screen-film mammography, longer time intervals between screening, and lack of comparison mammography images (from previous examination), suggesting some clear opportunities to reduce the harms associated with false-positive findings.37PreferredName:ALYREF gene SemanticType:[gngm] PreferredName:A-factor (Streptomyces) SemanticType:[bacs, orch] PreferredName:Identifier SemanticType:[inpr] PreferredName:Appearance SemanticType:[qlco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Associated with SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Probability SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Mammography SemanticType:[diap] PreferredName:First (number) SemanticType:[qnco] PreferredName:Mammographic breast density SemanticType:[fndg] PreferredName:Greater SemanticType:[qnco] PreferredName:Postmenopausal state SemanticType:[tmco] PreferredName:Use of SemanticType:[ftcn] PreferredName:Use of SemanticType:[ftcn] PreferredName:Hormone Therapy SemanticType:[topp] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Digital X-ray SemanticType:[inpr] PreferredName:Long SemanticType:[qlco] PreferredName:Film Mammography SemanticType:[diap] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Time Interval SemanticType:[tmco] PreferredName:Comparison SemanticType:[acty] PreferredName:Lacking SemanticType:[qlco] PreferredName:Image SemanticType:[enty] PreferredName:Mammography SemanticType:[diap] PreferredName:suggestion SemanticType:[idcn] PreferredName:Previous SemanticType:[tmco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Clear SemanticType:[qlco] PreferredName:False Positive SemanticType:[lbtr] POS:CD POS:, POS:CD POS:NNP POS:NNP POS:NNP POS:DT POS:NN POS:IN POS:NNS POS:VBP POS:TO POS:VB POS:VBN POS:IN POS:DT POS:VBN POS:NN POS:IN POS:JJ POS:NNS POS:, POS:VBG POS:DT POS:JJ POS:NN POS:, POS:JJR POS:JJ POS:NN POS:NN POS:, POS:NN POS:IN POS:JJ POS:NN POS:NN POS:, POS:NN POS:IN POS:JJ POS:NN POS:NN POS:NN POS:, POS:JJR POS:NN POS:NNS POS:IN POS:NN POS:, POS:CC POS:NN POS:IN POS:NN POS:NN POS:NNS POS:( POS:IN POS:JJ POS:NN POS:) POS:, POS:VBG POS:DT POS:JJ POS:NNS POS:TO POS:VB POS:DT POS:NNS POS:VBN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 180]<Annotation Id="24307" Type="Sentence" StartNode="30039" EndNode="30044">37,38POS:JJ POS:, POS:JJ 
[sentNum: 181]<Annotation Id="24308" Type="Sentence" StartNode="30046" EndNode="30178">An overdiagnosed cancer is a screen-detected cancer that would not have led to symptomatic breast cancer if undetected by screening. PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Detection SemanticType:[topp] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Symptomatic SemanticType:[ftcn] PreferredName:Light Emitting Diode Device Component SemanticType:[mnob] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:DT POS:JJ POS:NN POS:VBZ POS:DT POS:JJ POS:NN POS:WDT POS:MD POS:RB POS:VB POS:VBN POS:TO POS:JJ POS:NN POS:NN POS:IN POS:JJ POS:IN POS:NN POS:. 
[sentNum: 182]<Annotation Id="24309" Type="Sentence" StartNode="30179" EndNode="30367">Most published studies of overdiagnosis base their estimates on empirical comparisons of disease incidence under screening with observed or projected incidence in the absence of screening. PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Most SemanticType:[qnco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Estimated SemanticType:[qnco] PreferredName:Base SemanticType:[chvf] PreferredName:Comparison SemanticType:[acty] PreferredName:Empiric SemanticType:[qlco] PreferredName:Inferior SemanticType:[spco] PreferredName:Morbidity - disease rate SemanticType:[qnco] PreferredName:Observed SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Projections and Predictions SemanticType:[inpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Absence (morphologic abnormality) SemanticType:[anab] POS:RBS POS:VBN POS:NNS POS:IN POS:NNS POS:VBP POS:PRP$ POS:NNS POS:IN POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:IN POS:NN POS:IN POS:JJ POS:CC POS:JJ POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:. 
[sentNum: 183]<Annotation Id="24310" Type="Sentence" StartNode="30368" EndNode="30471">However, estimates available from the literature vary widely, from less than 5%39- 42 to more than 50%.43PreferredName:Availability of SemanticType:[ftcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:From SemanticType:[qlco] PreferredName:Publications SemanticType:[inpr, mnob] PreferredName:To SemanticType:[qlco] POS:RB POS:, POS:NNS POS:JJ POS:IN POS:DT POS:NN POS:VBP POS:RB POS:, POS:IN POS:JJR POS:IN POS:CD POS:NN POS:CD POS:: POS:CD POS:TO POS:JJR POS:IN POS:CD POS:NN POS:. 
[sentNum: 184]<Annotation Id="24311" Type="Sentence" StartNode="30471" EndNode="30589">43,44 Estimates of overdiagnosis produced from modeling studies generally are lower than those from empirical studies.41PreferredName:Estimated SemanticType:[qnco] PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Lower - spatial qualifier SemanticType:[spco] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:empirical study SemanticType:[resa] POS:CD POS:, POS:CD POS:NNS POS:IN POS:NNS POS:VBN POS:IN POS:NN POS:NNS POS:RB POS:VBP POS:JJR POS:IN POS:DT POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 185]<Annotation Id="24312" Type="Sentence" StartNode="30589" EndNode="30902">41,45 While modeling studies extrapolate beyond the empirical data to simulate disease natural history and derive estimates of overdiagnosis based on a comparison of the estimated risks of clinical diagnosis and other-cause death, these studies require their own assumptions pertaining to the times to key events. PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Empiric SemanticType:[qlco] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Simulate composite resin SemanticType:[bodm] PreferredName:Data SemanticType:[idcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:natural history of disease SemanticType:[fndg] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Risk SemanticType:[qlco] PreferredName:Comparison SemanticType:[acty] PreferredName:Diagnosis Study SemanticType:[resa] PreferredName:Clinical.estimated SemanticType:[lbpr] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Science of Etiology SemanticType:[cnce] PreferredName:Time SemanticType:[tmco] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Event SemanticType:[evnt] POS:CD POS:, POS:CD POS:IN POS:NN POS:NNS POS:VBP POS:IN POS:DT POS:JJ POS:NNS POS:TO POS:CD POS:NN POS:JJ POS:NN POS:CC POS:NN POS:NNS POS:IN POS:NNS POS:VBN POS:IN POS:DT POS:NN POS:IN POS:DT POS:VBN POS:NNS POS:IN POS:JJ POS:NN POS:CC POS:JJ POS:NN POS:, POS:DT POS:NNS POS:VBP POS:PRP$ POS:JJ POS:NNS POS:VBG POS:TO POS:DT POS:NNS POS:TO POS:JJ POS:NNS POS:. 
[sentNum: 186]<Annotation Id="24313" Type="Sentence" StartNode="30903" EndNode="31148">Regardless of the study design, practically all estimates require unverifiable assumptions or use methods that are biased by inadequate follow-up or failure to properly adjust for trends in incidence and lead time, leading to inflated estimates.42PreferredName:Research Design SemanticType:[resa] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Biases SemanticType:[idcn] PreferredName:Methods SemanticType:[inpr] PreferredName:follow-up SemanticType:[hlca] PreferredName:Inadequate (qualifier) SemanticType:[qlco] PreferredName:trends qualifier SemanticType:[tmco] PreferredName:Personal failure SemanticType:[inbe] PreferredName:Dietary Lead SemanticType:[elii] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Leading SemanticType:[ftcn] PreferredName:Time SemanticType:[tmco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Economic Inflation SemanticType:[qnco] POS:RB POS:IN POS:DT POS:NN POS:NN POS:, POS:RB POS:DT POS:NNS POS:VBP POS:JJ POS:NNS POS:CC POS:NN POS:NNS POS:WDT POS:VBP POS:VBN POS:IN POS:JJ POS:NN POS:CC POS:NN POS:TO POS:RB POS:VB POS:IN POS:NNS POS:IN POS:NN POS:CC POS:NN POS:NN POS:, POS:VBG POS:TO POS:JJ POS:NNS POS:. 
[sentNum: 187]<Annotation Id="24314" Type="Sentence" StartNode="31148" EndNode="31558">42,46- 50 No published study directly provides reliable, policy-relevant measurements of overdiagnosis, although lower estimates of the fraction of cancers that were overdiagnosed tended to be based on studies that included adequate follow-up, had a control group or data on the incidence expected in the absence of screening, and properly adjusted for lead time as well as age and other potential confounders.42PreferredName:Study SemanticType:[resa] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Direct (qualifier) SemanticType:[qlco] PreferredName:Policy SemanticType:[inpr] PreferredName:Reliability (characteristic) SemanticType:[qnco] PreferredName:Measurement SemanticType:[ftcn] PreferredName:Relevance SemanticType:[qlco] PreferredName:Lower - spatial qualifier SemanticType:[spco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Fraction of SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:To SemanticType:[qlco] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Sufficient SemanticType:[qlco] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Control Groups SemanticType:[grup] PreferredName:follow-up SemanticType:[hlca] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Data SemanticType:[idcn] PreferredName:Absence (morphologic abnormality) SemanticType:[anab] PreferredName:Expected SemanticType:[idcn] PreferredName:Adjustment Action SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Time SemanticType:[tmco] PreferredName:Dietary Lead SemanticType:[elii] PreferredName:Potential SemanticType:[qlco] PreferredName:Age SemanticType:[orga] POS:CD POS:, POS:CD POS:: POS:CD POS:DT POS:VBN POS:NN POS:RB POS:VBZ POS:JJ POS:, POS:JJ POS:NNS POS:IN POS:NNS POS:, POS:IN POS:JJR POS:NNS POS:IN POS:DT POS:NN POS:IN POS:NNS POS:WDT POS:VBD POS:VBN POS:VBD POS:TO POS:VB POS:VBN POS:IN POS:NNS POS:WDT POS:VBD POS:JJ POS:NN POS:, POS:VBD POS:DT POS:NN POS:NN POS:CC POS:NN POS:IN POS:DT POS:NN POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NN POS:, POS:CC POS:RB POS:VBN POS:IN POS:JJ POS:NN POS:RB POS:RB POS:IN POS:NN POS:CC POS:JJ POS:JJ POS:NNS POS:. 
[sentNum: 188]<Annotation Id="24315" Type="Sentence" StartNode="31558" EndNode="31560">42POS:NN 
[sentNum: 189]<Annotation Id="24316" Type="Sentence" StartNode="31562" EndNode="31849">The quality of evidence that overdiagnosis is a consequence of mammographic screening was judged to be high in the evidence review, but given the very wide range of estimates, the quality of the evidence for a quantitative estimate of the magnitude of overdiagnosis was judged to be low. PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Quality SemanticType:[qlco] PreferredName:Consequence of SemanticType:[ftcn] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Judge SemanticType:[prog] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Very SemanticType:[qlco] PreferredName:GIVEN SemanticType:[cnce] PreferredName:Range SemanticType:[qnco] PreferredName:Widening SemanticType:[spco] PreferredName:Quality SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Quantitative SemanticType:[qnco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Magnitude SemanticType:[qnco] PreferredName:To SemanticType:[qlco] PreferredName:Judge SemanticType:[prog] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] POS:DT POS:NN POS:IN POS:NN POS:IN POS:NNS POS:VBZ POS:DT POS:NN POS:IN POS:JJ POS:NN POS:VBD POS:VBN POS:TO POS:VB POS:JJ POS:IN POS:DT POS:NN POS:NN POS:, POS:CC POS:VBN POS:DT POS:RB POS:JJ POS:NN POS:IN POS:NNS POS:, POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:VBD POS:VBN POS:TO POS:VB POS:JJ POS:. 
[sentNum: 190]<Annotation Id="24317" Type="Sentence" StartNode="31850" EndNode="32185">While the GDG recognizes that overdiagnosis represents the greatest possible harm associated with screening because it would result in overtreatment, uncertainty about the magnitude of the risk of overdiagnosis poses a challenge to providing complete and accurate information to women about what to expect from breast cancer screening.PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Most SemanticType:[qnco] PreferredName:Representation (action) SemanticType:[acty] PreferredName:Associated with SemanticType:[qlco] PreferredName:Possible diagnosis SemanticType:[qlco] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Magnitude SemanticType:[qnco] PreferredName:Uncertainty SemanticType:[idcn] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Risk SemanticType:[qlco] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Challenge SemanticType:[hlca] PreferredName:Accurate (qualifier) SemanticType:[qlco] PreferredName:Complete SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Information SemanticType:[idcn] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:To SemanticType:[qlco] POS:IN POS:DT POS:NNP POS:VBZ POS:IN POS:NNS POS:VBZ POS:DT POS:JJS POS:JJ POS:NN POS:VBN POS:IN POS:VBG POS:IN POS:PRP POS:MD POS:VB POS:IN POS:NN POS:, POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:VBZ POS:DT POS:NN POS:TO POS:VBG POS:JJ POS:CC POS:JJ POS:NN POS:TO POS:NNS POS:IN POS:WP POS:TO POS:VB POS:IN POS:NN POS:NN POS:NN POS:. 
[sentNum: 191]<Annotation Id="24318" Type="Sentence" StartNode="32187" EndNode="32219">Quality-Adjusted Life ExpectancyPreferredName:Adjustment Action SemanticType:[ftcn] PreferredName:Quality SemanticType:[qlco] PreferredName:Life Expectancy SemanticType:[grpa] POS:NNP POS:NNP POS:NNP POS:NNP 
[sentNum: 192]<Annotation Id="24319" Type="Sentence" StartNode="32221" EndNode="32471">There are no clinical trials or observational studies that assess the effect of breast cancer screening on women’s quality-adjusted life-years (QALYs) throughout the lifetime; all information available in the literature was based on modeling studies.51PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Assessed SemanticType:[acty] PreferredName:Observational Study SemanticType:[resa] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Effect SemanticType:[qlco] PreferredName:Upon - dosing instruction fragment SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Quality-Adjusted Life Years SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Availability of SemanticType:[ftcn] PreferredName:Information SemanticType:[idcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Publications SemanticType:[inpr, mnob] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Modeling SemanticType:[inpr, resa] POS:EX POS:VBP POS:DT POS:JJ POS:NNS POS:CC POS:JJ POS:NNS POS:WDT POS:VBP POS:DT POS:NN POS:IN POS:NN POS:NN POS:NN POS:IN POS:NNS POS:NNP POS:VBZ POS:JJ POS:NNS POS:( POS:NNP POS:) POS:IN POS:DT POS:NN POS:: POS:DT POS:NN POS:JJ POS:IN POS:DT POS:NN POS:VBD POS:VBN POS:IN POS:NN POS:NNS POS:. 
[sentNum: 193]<Annotation Id="24320" Type="Sentence" StartNode="32471" EndNode="32840">51- 58 Most of these studies showed that compared with no screening, mammography screening was associated with a modest increase in QALY, although the magnitude of increase varied by screening intervals, the starting and stopping age of screening, and most importantly whether the model incorporated decrements in health utilities associated with mammography screening. PreferredName:Comparison SemanticType:[acty] PreferredName:Show SemanticType:[inpr] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Increase SemanticType:[ftcn] PreferredName:Associated with SemanticType:[qlco] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Quality-Adjusted Life Years SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Increase SemanticType:[ftcn] PreferredName:Beginning SemanticType:[tmco] PreferredName:Interval SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Stop brand of fluoride SemanticType:[inch, phsu] PreferredName:Most SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Health SemanticType:[idcn] PreferredName:Model SemanticType:[inpr] PreferredName:Associated with SemanticType:[qlco] PreferredName:Utilities (organization) SemanticType:[orgt] PreferredName:Screening mammography SemanticType:[topp] POS:CD POS:: POS:CD POS:RBS POS:IN POS:DT POS:NNS POS:VBD POS:IN POS:VBN POS:IN POS:DT POS:NN POS:, POS:JJ POS:NN POS:VBD POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NNP POS:, POS:IN POS:DT POS:NN POS:IN POS:NN POS:VBD POS:IN POS:NN POS:NNS POS:, POS:DT POS:VBG POS:CC POS:NN POS:NN POS:IN POS:NN POS:, POS:CC POS:RBS POS:RB POS:IN POS:DT POS:NN POS:JJ POS:NNS POS:IN POS:NN POS:NNS POS:VBN POS:IN POS:NN POS:NN POS:. 
[sentNum: 194]<Annotation Id="24321" Type="Sentence" StartNode="32841" EndNode="33215">The quality of evidence on QALY was subject to the limitations common to all modeling studies and to the quality of data used for modeling parameters related to health utilities, especially those capturing the negative effect of screening, which commonly rely on a single study59 published in 1991 that was limited by a small sample size and outdated mammography technology. PreferredName:Quality SemanticType:[qlco] PreferredName:Quality-Adjusted Life Years SemanticType:[tmco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Study Subject SemanticType:[grup] PreferredName:Wiskott-Aldrich Syndrome SemanticType:[dsyn] PreferredName:shared attribute SemanticType:[ftcn] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Data Quality SemanticType:[qlco] PreferredName:And SemanticType:[idcn] PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Used by SemanticType:[fndg] PreferredName:Relationships SemanticType:[qlco] PreferredName:Observation parameter SemanticType:[fndg] PreferredName:Utilities (organization) SemanticType:[orgt] PreferredName:Health SemanticType:[idcn] PreferredName:Effect SemanticType:[qlco] PreferredName:Negative SemanticType:[qlco] PreferredName:Unmarried person SemanticType:[popg] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Biospecimen SemanticType:[cnce] PreferredName:small size SemanticType:[fndg] PreferredName:Mammography SemanticType:[diap] PreferredName:Outdated SemanticType:[inpr] PreferredName:Technology SemanticType:[ocdi] POS:DT POS:NN POS:IN POS:NN POS:IN POS:NNP POS:VBD POS:JJ POS:TO POS:DT POS:NNS POS:JJ POS:TO POS:DT POS:NN POS:NNS POS:CC POS:TO POS:DT POS:NN POS:IN POS:NNS POS:VBN POS:IN POS:NN POS:NNS POS:VBN POS:TO POS:NN POS:NNS POS:, POS:RB POS:DT POS:VBG POS:DT POS:JJ POS:NN POS:IN POS:NN POS:, POS:WDT POS:RB POS:VBP POS:IN POS:DT POS:JJ POS:NN POS:CD POS:VBN POS:IN POS:CD POS:WDT POS:VBD POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:NN POS:CC POS:JJ POS:NN POS:NN POS:. 
[sentNum: 195]<Annotation Id="24322" Type="Sentence" StartNode="33216" EndNode="33557">Although a recent study has collected more contemporary health utility information on false positives among women in the United States,60 it did not explore the duration applicable to screening-related short-term reduction in health utilities, nor did it differentiate between women who underwent biopsy vs those who had repeat examinations. PreferredName:Recent SemanticType:[tmco] PreferredName:Collection (action) SemanticType:[ftcn] PreferredName:Study SemanticType:[resa] PreferredName:health information SemanticType:[hlca] PreferredName:More SemanticType:[ftcn] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Utilities (organization) SemanticType:[orgt] PreferredName:United States SemanticType:[geoa] PreferredName:Woman SemanticType:[popg] PreferredName:Duration (temporal concept) SemanticType:[tmco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Not Applicable SemanticType:[qlco] PreferredName:Short-term SemanticType:[tmco] PreferredName:Relationships SemanticType:[qlco] PreferredName:Health SemanticType:[idcn] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Well Differentiated SemanticType:[qlco] PreferredName:Utilities (organization) SemanticType:[orgt] PreferredName:biopsy characteristics SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Physical Examination SemanticType:[hlca] PreferredName:Repeat SemanticType:[ftcn] POS:IN POS:DT POS:JJ POS:NN POS:VBZ POS:VBN POS:RBR POS:JJ POS:NN POS:NN POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:NNS POS:IN POS:DT POS:NNP POS:NNPS POS:, POS:CD POS:PRP POS:VBD POS:RB POS:VB POS:DT POS:NN POS:JJ POS:TO POS:JJ POS:JJ POS:NN POS:IN POS:NN POS:NNS POS:, POS:CC POS:VBD POS:PRP POS:VB POS:IN POS:NNS POS:WP POS:VBD POS:RB POS:VBP POS:DT POS:WP POS:VBD POS:NN POS:NNS POS:. 
[sentNum: 196]<Annotation Id="24323" Type="Sentence" StartNode="33558" EndNode="33707">Thus, in the evidence review, the quality of evidence for the magnitude of the effect of different screening strategies on QALY was judged to be low.PreferredName:Review [Publication Type] SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Quality SemanticType:[qlco] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Different SemanticType:[qlco] PreferredName:Effect SemanticType:[qlco] PreferredName:strategy SemanticType:[menp] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Judge SemanticType:[prog] PreferredName:Quality-Adjusted Life Years SemanticType:[tmco] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:To SemanticType:[qlco] POS:RB POS:, POS:IN POS:DT POS:NN POS:NN POS:, POS:DT POS:NN POS:IN POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:NNS POS:IN POS:NNP POS:VBD POS:VBN POS:TO POS:VB POS:JJ POS:. 
[sentNum: 197]<Annotation Id="24324" Type="Sentence" StartNode="33709" EndNode="33918">To determine the age at which to recommend the initiation of screening, the burden of disease was examined by 5-year age categories, in addition to the evidence of benefits and harms within the age categories. PreferredName:Age SemanticType:[orga] PreferredName:To SemanticType:[qlco] PreferredName:Cognitive function: initiation SemanticType:[menp] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Burden SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Examined SemanticType:[fndg] PreferredName:Disease SemanticType:[dsyn] PreferredName:Age Categories [Disease/Finding] SemanticType:[aggp] PreferredName:per year SemanticType:[tmco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:In addition to SemanticType:[qlco] PreferredName:Age Categories [Disease/Finding] SemanticType:[aggp] PreferredName:Benefits SemanticType:[qnco] POS:TO POS:VB POS:DT POS:NN POS:IN POS:WDT POS:TO POS:VB POS:DT POS:NN POS:IN POS:NN POS:, POS:DT POS:NN POS:IN POS:NN POS:VBD POS:VBN POS:IN POS:CD POS:: POS:NN POS:NN POS:NNS POS:, POS:IN POS:NN POS:TO POS:DT POS:NN POS:IN POS:NNS POS:CC POS:NNS POS:IN POS:DT POS:NN POS:NNS POS:. 
[sentNum: 198]<Annotation Id="24325" Type="Sentence" StartNode="33919" EndNode="34061">The incidence of breast cancer noticeably begins to increase after age 25 years and continues to increase until ages 75 to 79 years (Table 4). PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Increase SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Continuous SemanticType:[idcn] PreferredName:Age SemanticType:[orga] PreferredName:Increase SemanticType:[ftcn] PreferredName:Table - furniture SemanticType:[mnob] PreferredName:year SemanticType:[tmco] POS:DT POS:NN POS:IN POS:NN POS:NN POS:RB POS:VBZ POS:TO POS:VB POS:IN POS:NN POS:CD POS:NNS POS:CC POS:VBZ POS:TO POS:VB POS:IN POS:NNS POS:CD POS:TO POS:CD POS:NNS POS:( POS:NNP POS:CD POS:) POS:. 
[sentNum: 199]<Annotation Id="24326" Type="Sentence" StartNode="34062" EndNode="34279">Historically, the age to begin screening has been influenced by the majority of RCT designs, which included women aged 40 to 49 years (based on the burden of disease)61 and also by differing outcomes reported in RCTs. PreferredName:Beginning SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:majority SemanticType:[socb] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Design SemanticType:[acty] PreferredName:Old age SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Burden SemanticType:[idcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Result SemanticType:[ftcn] PreferredName:Disease SemanticType:[dsyn] PreferredName:Reporting SemanticType:[hlca] POS:RB POS:, POS:DT POS:NN POS:TO POS:VB POS:NN POS:VBZ POS:VBN POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NNP POS:NNS POS:, POS:WDT POS:VBD POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:( POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NN POS:) POS:CD POS:CC POS:RB POS:IN POS:VBG POS:NNS POS:VBN POS:IN POS:NNP POS:. 
[sentNum: 200]<Annotation Id="24327" Type="Sentence" StartNode="34280" EndNode="34565">Evidence from the RCTs and observational data have shown similar relative benefits associated with invitation and exposure to screening among women in their 40s and 50s,29,62- 64 and rates of recall and biopsy among women screened with screen-film and digital mammography were similar.37PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Data SemanticType:[idcn] PreferredName:Observation - diagnostic procedure SemanticType:[diap] PreferredName:Similarity SemanticType:[qlco] PreferredName:Show SemanticType:[inpr] PreferredName:Benefits SemanticType:[qnco] PreferredName:Relative (related person) SemanticType:[famg] PreferredName:Invitation SemanticType:[inpr] PreferredName:Associated with SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Exposure to SemanticType:[clna] PreferredName:/40 SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Recall:-:Point in time:^Patient:- SemanticType:[clna] PreferredName:Rate SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Biopsy SemanticType:[diap] PreferredName:film (photographic) SemanticType:[mnob] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Similarity SemanticType:[qlco] PreferredName:Digital Mammography SemanticType:[diap] POS:NN POS:IN POS:DT POS:NNPS POS:CC POS:JJ POS:NNS POS:VBP POS:VBN POS:JJ POS:JJ POS:NNS POS:VBN POS:IN POS:NN POS:CC POS:NN POS:TO POS:NN POS:IN POS:NNS POS:IN POS:PRP$ POS:CD POS:CD POS:CC POS:CD POS:CD POS:, POS:CD POS:, POS:CD POS:: POS:CD POS:CC POS:NNS POS:IN POS:NN POS:CC POS:NN POS:IN POS:NNS POS:VBD POS:IN POS:NN POS:CC POS:JJ POS:NN POS:VBD POS:JJ POS:. 
[sentNum: 201]<Annotation Id="24328" Type="Sentence" StartNode="34565" EndNode="34780">37,65 However, judgments about the absolute benefit of mammography in 10-year age groups, or for women in their 40s compared with women aged 50 to 74 years, have defined modern debates about when to begin screening. PreferredName:Judgment SemanticType:[menp] PreferredName:Arabic numeral 65 SemanticType:[inpr] PreferredName:Benefits SemanticType:[qnco] PreferredName:Absolute SemanticType:[qlco] PreferredName:per year SemanticType:[tmco] PreferredName:Mammography SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Human Age Group SemanticType:[aggp] PreferredName:Comparison SemanticType:[acty] PreferredName:/40 SemanticType:[tmco] PreferredName:Old age SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:Definition SemanticType:[cnce] PreferredName:year SemanticType:[tmco] PreferredName:To SemanticType:[qlco] PreferredName:debate SemanticType:[acty] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Beginning SemanticType:[tmco] POS:CD POS:, POS:CD POS:RB POS:, POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:IN POS:CD POS:: POS:NN POS:NN POS:NNS POS:, POS:CC POS:IN POS:NNS POS:IN POS:PRP$ POS:CD POS:NNS POS:VBN POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:, POS:VBP POS:VBN POS:JJ POS:NNS POS:IN POS:WRB POS:TO POS:VB POS:NN POS:. 
[sentNum: 202]<Annotation Id="24329" Type="Sentence" StartNode="34781" EndNode="35041">While the 5-year absolute risk of breast cancer increases steadily over this age span, the 5-year risk among women aged 45 to 49 years (0.9%) and women aged 50 to 54 years (1.1%) is similar, and greater than that for women aged 40 to 44 years (0.6%) (Table 4). PreferredName:Risk Estimate SemanticType:[qnco] PreferredName:per year SemanticType:[tmco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Span - parameter SemanticType:[cnce] PreferredName:Age SemanticType:[orga] PreferredName:Risk SemanticType:[qlco] PreferredName:per year SemanticType:[tmco] PreferredName:Old age SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Old age SemanticType:[popg] PreferredName:Similarity SemanticType:[qlco] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Greater Than SemanticType:[qnco] PreferredName:/40 SemanticType:[tmco] PreferredName:Old age SemanticType:[popg] PreferredName:Table - furniture SemanticType:[mnob] PreferredName:year SemanticType:[tmco] POS:IN POS:DT POS:CD POS:JJ POS:NN POS:JJ POS:NN POS:IN POS:NN POS:NN POS:VBZ POS:RB POS:IN POS:DT POS:NN POS:NN POS:, POS:DT POS:CD POS:: POS:NN POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:( POS:NNP POS:. POS:CD POS:NN POS:) POS:CC POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:( POS:CD POS:. POS:CD POS:NN POS:) POS:VBZ POS:JJ POS:, POS:CC POS:JJR POS:IN POS:DT POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:( POS:NNP POS:. POS:CD POS:NN POS:) POS:( POS:CD POS:CD POS:) POS:. 
[sentNum: 203]<Annotation Id="24330" Type="Sentence" StartNode="35042" EndNode="35405">The proportion of all incident breast cancers in the population also is similar for ages 45 to 49 years and 50 to 54 years (10% and 12%, respectively), compared with women aged 40 to 44 years (6%) (Figure 1A), as is the distribution of breast cancer deaths by age at diagnosis (10% and 11%, respectively), compared with women aged 40 to 44 years (7%) (Figure 1B). PreferredName:incident SemanticType:[idcn] PreferredName:Proportion SemanticType:[qnco] PreferredName:geographic population SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Age SemanticType:[orga] PreferredName:Similarity SemanticType:[qlco] PreferredName:year SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Comparison SemanticType:[acty] PreferredName:/40 SemanticType:[tmco] PreferredName:Old age SemanticType:[popg] PreferredName:alphanumeric label - 1A SemanticType:[inpr] PreferredName:year SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Distribution SemanticType:[ftcn] PreferredName:Belarus SemanticType:[geoa] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Comparison SemanticType:[acty] PreferredName:Age at diagnosis SemanticType:[clna] PreferredName:Old age SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:1B SemanticType:[inpr] POS:DT POS:NN POS:IN POS:DT POS:NN POS:NN POS:NNS POS:IN POS:DT POS:NN POS:RB POS:VBZ POS:JJ POS:IN POS:NNS POS:CD POS:TO POS:CD POS:NNS POS:CC POS:CD POS:TO POS:CD POS:NNS POS:( POS:CD POS:NN POS:CC POS:CD POS:NN POS:, POS:RB POS:) POS:, POS:VBN POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:( POS:CD POS:NN POS:) POS:( POS:NN POS:CD POS:NNP POS:) POS:, POS:IN POS:VBZ POS:DT POS:NN POS:IN POS:NN POS:NN POS:NNS POS:IN POS:NN POS:IN POS:NN POS:( POS:CD POS:NN POS:CC POS:CD POS:NN POS:, POS:RB POS:) POS:, POS:VBN POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:( POS:CD POS:NN POS:) POS:( POS:NN POS:CD POS:NNP POS:) POS:. 
[sentNum: 204]<Annotation Id="24331" Type="Sentence" StartNode="35406" EndNode="35691">In addition, the age-specific incidence-based person-years of life lost were similar for women aged 45 to 49 years and 50 to 54 years at the time of diagnosis (approximately 15% each) and together accounted for 30% of all person-years of life lost at 20 years of follow-up (Figure 1C). PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Specific qualifier value SemanticType:[qlco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Life SemanticType:[idcn] PreferredName:Persons SemanticType:[popg] PreferredName:Similarity SemanticType:[qlco] PreferredName:Lost SemanticType:[ftcn] PreferredName:Old age SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Time SemanticType:[tmco] PreferredName:At SemanticType:[spco] PreferredName:Approximate SemanticType:[qlco] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Account number:Identifier:Point in time:^Patient:Nominal SemanticType:[clna] PreferredName:Together SemanticType:[qlco] PreferredName:year SemanticType:[tmco] PreferredName:Persons SemanticType:[popg] PreferredName:Lost SemanticType:[ftcn] PreferredName:Life SemanticType:[idcn] PreferredName:Follow-up status SemanticType:[fndg] PreferredName:year SemanticType:[tmco] POS:IN POS:NN POS:, POS:DT POS:JJ POS:JJ POS:NNS POS:IN POS:NN POS:VBN POS:VBD POS:JJ POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:CC POS:CD POS:TO POS:CD POS:NNS POS:IN POS:DT POS:NN POS:IN POS:NN POS:( POS:RB POS:CD POS:NN POS:DT POS:) POS:CC POS:RB POS:VBN POS:IN POS:CD POS:NN POS:IN POS:DT POS:NNS POS:IN POS:NN POS:VBN POS:IN POS:CD POS:NNS POS:IN POS:NN POS:( POS:NN POS:CD POS:NNP POS:) POS:. 
[sentNum: 205]<Annotation Id="24332" Type="Sentence" StartNode="35692" EndNode="35906">This examination of the burden of disease indicated that traditional comparisons of women in their 40s with women in their 50s, or with women 50 years and older, obscured similarities in adjacent 5-year age groups.PreferredName:Burden SemanticType:[idcn] PreferredName:This SemanticType:[euka] PreferredName:Indicated SemanticType:[fndg] PreferredName:Disease SemanticType:[dsyn] PreferredName:Comparison SemanticType:[acty] PreferredName:Traditional origin SemanticType:[ftcn] PreferredName:Present SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Similarity SemanticType:[qlco] PreferredName:Older Population SemanticType:[popg] PreferredName:per year SemanticType:[tmco] PreferredName:Adjacent SemanticType:[spco] PreferredName:Age SemanticType:[orga] POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:VBD POS:IN POS:JJ POS:NNS POS:IN POS:NNS POS:IN POS:PRP$ POS:CD POS:NNS POS:IN POS:NNS POS:IN POS:PRP$ POS:CD POS:NNS POS:, POS:CC POS:IN POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:, POS:VBD POS:NNS POS:IN POS:JJ POS:CD POS:: POS:NN POS:NN POS:NNS POS:. 
[sentNum: 206]<Annotation Id="24333" Type="Sentence" StartNode="35908" EndNode="36148">The evidence review judged the quality of evidence for a relative mortality reduction associated with screening mammography among women younger than 50 years to be high and the quality of the evidence of the magnitude of effect as moderate. PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Judge SemanticType:[prog] PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Quality SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Relative SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:Screening mammography SemanticType:[topp] PreferredName:year SemanticType:[tmco] PreferredName:Young SemanticType:[tmco] PreferredName:Quality SemanticType:[qlco] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Magnitude SemanticType:[qnco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Moderation SemanticType:[qlco] PreferredName:Effect, Appearance SemanticType:[qlco] POS:DT POS:NN POS:NN POS:VBN POS:DT POS:NN POS:IN POS:NN POS:IN POS:DT POS:JJ POS:NN POS:NN POS:VBN POS:IN POS:VBG POS:JJ POS:IN POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:TO POS:VB POS:JJ POS:CC POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:IN POS:JJ POS:. 
[sentNum: 207]<Annotation Id="24334" Type="Sentence" StartNode="36149" EndNode="36446">Systematic reviews of RCTs have generally reported that invitation to screening for women 40 years and older is associated with reduction in breast cancer mortality, with a larger magnitude of benefits observed in women aged 50 to 69 years at randomization compared with women aged 40 to 49 years.30PreferredName:Reporting SemanticType:[hlca] PreferredName:Review, Systematic SemanticType:[inpr] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Invitation SemanticType:[inpr] PreferredName:/40 SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Old SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Reduction mammaplasty SemanticType:[topp] PreferredName:Associated with SemanticType:[qlco] PreferredName:In addition to SemanticType:[qlco] PreferredName:Cancer Death Rate SemanticType:[qnco] PreferredName:Magnitude SemanticType:[qnco] PreferredName:Greater SemanticType:[qnco] PreferredName:Observed SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Comparison SemanticType:[acty] PreferredName:Randomization SemanticType:[resa] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] POS:JJ POS:NNS POS:IN POS:NNP POS:VBP POS:RB POS:VBN POS:IN POS:NN POS:TO POS:NN POS:IN POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:VBZ POS:VBN POS:IN POS:NN POS:IN POS:NN POS:NN POS:NN POS:, POS:IN POS:DT POS:JJR POS:NN POS:IN POS:NNS POS:VBN POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:IN POS:NN POS:VBN POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:. 
[sentNum: 208]<Annotation Id="24335" Type="Sentence" StartNode="36446" EndNode="36712">30,32,35 The evidence synthesis for the 2009 US Preventive Services Task Force (USPSTF) recommendations by Nelson et al35 compared women in 10-year age groups and observed RRs of 0.85, 0.86, and 0.68 for women aged 40 to 49 years, 50 to 59 years, and 60 to 69 years.PreferredName:Synthesis SemanticType:[acty] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Comparison SemanticType:[acty] PreferredName:Recommendation SemanticType:[idcn] PreferredName:per year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Observed SemanticType:[ftcn] PreferredName:Human Age Group SemanticType:[aggp] PreferredName:Arabic numeral 68 SemanticType:[inpr] PreferredName:Robinow syndrome, autosomal recessive SemanticType:[dsyn] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:year SemanticType:[tmco] PreferredName:year SemanticType:[tmco] POS:CD POS:, POS:CD POS:, POS:CD POS:DT POS:NN POS:NN POS:IN POS:DT POS:CD POS:NNP POS:NNP POS:NNPS POS:NNP POS:NNP POS:( POS:NNP POS:) POS:NNS POS:IN POS:NNP POS:NNP POS:NNP POS:CD POS:VBN POS:NNS POS:IN POS:CD POS:: POS:NN POS:NN POS:NNS POS:CC POS:NNP POS:NNP POS:IN POS:CD POS:. POS:CD POS:, POS:CD POS:. POS:CD POS:, POS:CC POS:CD POS:. POS:CD POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:, POS:CD POS:TO POS:CD POS:NNS POS:, POS:CC POS:CD POS:TO POS:CD POS:NNS POS:. 
[sentNum: 209]<Annotation Id="24336" Type="Sentence" StartNode="36714" EndNode="36901">In contrast, incidence-based mortality studies and case-control studies tended to show greater and more similar mortality reductions between age-specific groups based on age at diagnosis. PreferredName:Contrast SemanticType:[qlco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Incidence Studies SemanticType:[qnco] PreferredName:Case-Control Studies SemanticType:[resa] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Show SemanticType:[inpr] PreferredName:To SemanticType:[qlco] PreferredName:More SemanticType:[ftcn] PreferredName:Greater SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Similarity SemanticType:[qlco] PreferredName:Groups SemanticType:[idcn] PreferredName:Age-Specific Death Rate SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Diagnosis Study SemanticType:[resa] POS:IN POS:NN POS:, POS:JJ POS:NN POS:NNS POS:CC POS:JJ POS:NNS POS:VBD POS:TO POS:VB POS:JJR POS:CC POS:JJR POS:JJ POS:NN POS:NNS POS:IN POS:JJ POS:NNS POS:VBN POS:IN POS:NN POS:IN POS:NN POS:. 
[sentNum: 210]<Annotation Id="24337" Type="Sentence" StartNode="36902" EndNode="37075">Evaluation of screening by age at diagnosis more directly addresses the question of age-specific benefits and overcomes the issue of age migration in the evaluation of RCTs.66PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Belarus SemanticType:[geoa] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Direct (qualifier) SemanticType:[qlco] PreferredName:Age at diagnosis SemanticType:[clna] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Address SemanticType:[spco] PreferredName:Specific qualifier value SemanticType:[qlco] PreferredName:Age SemanticType:[orga] PreferredName:Overcome SemanticType:[acty] PreferredName:Benefits SemanticType:[qnco] PreferredName:population migration SemanticType:[socb] PreferredName:Problem of aging SemanticType:[patf] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Within SemanticType:[spco] POS:NNP POS:IN POS:NN POS:IN POS:NN POS:IN POS:NN POS:RBR POS:RB POS:VBZ POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:CC POS:VBZ POS:DT POS:NN POS:IN POS:NN POS:NN POS:IN POS:DT POS:NN POS:IN POS:NNP POS:. 
[sentNum: 211]<Annotation Id="24338" Type="Sentence" StartNode="37075" EndNode="37411">66,67 For the age group that tends to be most controversial (ie, 40-49 years), Hellquist et al68 compared breast cancer mortality rates for Swedish women living in counties that invited women in their 40s to screening with breast cancer mortality rates among women living in counties that did not invite women in their 40s to screening. PreferredName:To SemanticType:[qlco] PreferredName:Human Age Group SemanticType:[aggp] PreferredName:/40 SemanticType:[tmco] PreferredName:controversy SemanticType:[socb] PreferredName:Comparison SemanticType:[acty] PreferredName:year SemanticType:[tmco] PreferredName:Swedish SemanticType:[popg] PreferredName:Death Rate SemanticType:[qnco] PreferredName:Life SemanticType:[idcn] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Woman SemanticType:[popg] PreferredName:County SemanticType:[geoa] PreferredName:To SemanticType:[qlco] PreferredName:/40 SemanticType:[tmco] PreferredName:Death Rate SemanticType:[qnco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Life SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Negation SemanticType:[ftcn] PreferredName:County SemanticType:[geoa] PreferredName:/40 SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:CD POS:, POS:CD POS:IN POS:DT POS:NN POS:NN POS:WDT POS:VBZ POS:TO POS:VB POS:RBS POS:JJ POS:( POS:NNP POS:, POS:CD POS:, POS:CD POS:NNS POS:) POS:, POS:NNP POS:CC POS:NNP POS:CD POS:VBN POS:NN POS:NN POS:NN POS:NNS POS:IN POS:JJ POS:NNS POS:VBG POS:IN POS:NNS POS:WDT POS:VBD POS:NNS POS:IN POS:PRP$ POS:CD POS:NNS POS:TO POS:NN POS:IN POS:NN POS:NN POS:NN POS:NNS POS:IN POS:NNS POS:VBG POS:IN POS:NNS POS:WDT POS:VBD POS:RB POS:VB POS:NNS POS:IN POS:PRP$ POS:CD POS:NNS POS:TO POS:NN POS:. 
[sentNum: 212]<Annotation Id="24339" Type="Sentence" StartNode="37412" EndNode="37618">After an average 16 years of follow-up, the investigators observed an overall 29% mortality reduction (RR, 0.71; 95% CI, 0.62-0.80) associated with exposure to screening, after adjustment for nonattendance. PreferredName:Status post SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Average SemanticType:[qnco] PreferredName:Research Personnel SemanticType:[prog] PreferredName:Follow-Up Report SemanticType:[inpr] PreferredName:Overall Publication Type SemanticType:[inpr] PreferredName:Observed SemanticType:[ftcn] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Arabic numeral 71 SemanticType:[inpr] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Exposure to SemanticType:[clna] PreferredName:Individual Adjustment SemanticType:[inbe] POS:IN POS:DT POS:JJ POS:CD POS:NNS POS:IN POS:NN POS:, POS:DT POS:NNS POS:VBD POS:DT POS:JJ POS:CD POS:NN POS:NN POS:NN POS:( POS:RB POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:NN POS:NNP POS:, POS:SYM POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:) POS:VBN POS:IN POS:NN POS:TO POS:NN POS:, POS:IN POS:NN POS:IN POS:NN POS:. 
[sentNum: 213]<Annotation Id="24340" Type="Sentence" StartNode="37619" EndNode="37773">Among women aged 40 to 44 years, an 18% mortality reduction was observed, whereas among women aged 45 to 49 years, a 32% mortality reduction was observed.PreferredName:Woman SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:Observed SemanticType:[ftcn] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Age SemanticType:[orga] PreferredName:Woman SemanticType:[popg] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:Observed SemanticType:[ftcn] PreferredName:Reduction - action SemanticType:[topp] POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:, POS:DT POS:CD POS:NN POS:NN POS:NN POS:VBD POS:VBN POS:, POS:IN POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:, POS:DT POS:CD POS:NN POS:NN POS:NN POS:VBD POS:VBN POS:. 
[sentNum: 214]<Annotation Id="24341" Type="Sentence" StartNode="37775" EndNode="38170">As noted earlier, based on published findings from the BCSC that mostly are based on outcomes of population screening with both screen-film and digital mammography, the cumulative 10-year rates for at least 1 false-positive finding (both those resulting in additional imaging examinations and those resulting in biopsies) were similar whether screening begins at age 40 years or at age 50 years.37PreferredName:Early SemanticType:[tmco] PreferredName:Note (document) SemanticType:[inpr] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Breast Cancer Surveillance Consortium SemanticType:[prog] PreferredName:findings aspects SemanticType:[ftcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:mostly SemanticType:[idcn] PreferredName:Growth Inhibition Screening Result SemanticType:[cnce] PreferredName:geographic population SemanticType:[qnco] PreferredName:film (photographic) SemanticType:[mnob] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Cumulative SemanticType:[qlco] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Rating (action) SemanticType:[acty] PreferredName:per year SemanticType:[tmco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Less Than SemanticType:[inpr] PreferredName:Resulting in SemanticType:[ftcn] PreferredName:Bilateral SemanticType:[spco] PreferredName:Diagnostic Imaging SemanticType:[diap] PreferredName:Additional SemanticType:[ftcn] PreferredName:Resulting in SemanticType:[ftcn] PreferredName:Physical Examination SemanticType:[hlca] PreferredName:Similarity SemanticType:[qlco] PreferredName:Biopsy SemanticType:[diap] PreferredName:Beginning SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:/40 SemanticType:[tmco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Age-Years SemanticType:[tmco] POS:IN POS:VBD POS:RBR POS:, POS:VBN POS:IN POS:VBN POS:NNS POS:IN POS:DT POS:NN POS:WDT POS:RB POS:VBP POS:VBN POS:IN POS:NNS POS:IN POS:NN POS:NN POS:IN POS:DT POS:JJ POS:CC POS:JJ POS:NN POS:, POS:DT POS:JJ POS:CD POS:: POS:NN POS:NNS POS:IN POS:IN POS:JJS POS:CD POS:JJ POS:NN POS:( POS:CC POS:DT POS:VBG POS:IN POS:JJ POS:NN POS:NNS POS:CC POS:DT POS:VBG POS:IN POS:NNS POS:) POS:VBD POS:JJ POS:IN POS:NN POS:VBZ POS:IN POS:NN POS:CD POS:NNS POS:CC POS:IN POS:NN POS:CD POS:NNS POS:. 
[sentNum: 215]<Annotation Id="24342" Type="Sentence" StartNode="38170" EndNode="38523">37 Although the false-positive rates were similar when women began screening at age 50 years compared with age 40 years, estimates of the lifetime cumulative risk of at least 1 of either type of false-positive outcome were consistently higher when screening began at younger ages because of an increased number of screening examinations over a lifetime. PreferredName:False Discovery Rate SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Similarity SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Beginning SemanticType:[tmco] PreferredName:Comparison SemanticType:[acty] PreferredName:Age-Years SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Risk Estimate SemanticType:[qnco] PreferredName:Cumulative SemanticType:[qlco] PreferredName:Type - attribute SemanticType:[qlco] PreferredName:SLC33A1 gene SemanticType:[gngm] PreferredName:High SemanticType:[qlco] PreferredName:False Positive Result Medical Device Problem SemanticType:[fndg] PreferredName:Beginning SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Age SemanticType:[orga] PreferredName:Young SemanticType:[tmco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Screening Examination SemanticType:[diap] POS:CD POS:IN POS:DT POS:JJ POS:NNS POS:VBD POS:JJ POS:WRB POS:NNS POS:VBD POS:NN POS:IN POS:NN POS:CD POS:NNS POS:VBN POS:IN POS:NN POS:CD POS:NNS POS:, POS:NNS POS:IN POS:DT POS:NN POS:JJ POS:NN POS:IN POS:IN POS:JJS POS:CD POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:VBD POS:RB POS:JJR POS:WRB POS:NN POS:VBD POS:IN POS:JJR POS:NNS POS:RB POS:IN POS:DT POS:VBN POS:NN POS:IN POS:NN POS:NNS POS:IN POS:DT POS:NN POS:. 
[sentNum: 216]<Annotation Id="24343" Type="Sentence" StartNode="38524" EndNode="38855">Because digital mammography has nearly entirely replaced screen-film mammography in the United States, evidence on the frequency of false-positive findings from the BCSC was sought by the Pacific Northwest Evidence-based Practice Center for their systematic review to update the USPSTF 2009 breast cancer screening recommendations. PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Replacement SemanticType:[ftcn] PreferredName:United States SemanticType:[geoa] PreferredName:Film Mammography SemanticType:[diap] PreferredName:Frequencies (time pattern) SemanticType:[tmco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Breast Cancer Surveillance Consortium SemanticType:[prog] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Evidence-Based Practice SemanticType:[ftcn] PreferredName:Pacific Northwest SemanticType:[geoa] PreferredName:Review, Systematic SemanticType:[inpr] PreferredName:Central SemanticType:[spco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Update SemanticType:[tmco] PreferredName:Recommendation SemanticType:[idcn] POS:IN POS:JJ POS:NN POS:VBZ POS:RB POS:RB POS:VBN POS:JJ POS:NN POS:IN POS:DT POS:NNP POS:NNPS POS:, POS:NN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:DT POS:NNP POS:VBD POS:VBN POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:IN POS:PRP$ POS:JJ POS:NN POS:TO POS:VB POS:DT POS:NNP POS:CD POS:NN POS:NN POS:VBG POS:NNS POS:. 
[sentNum: 217]<Annotation Id="24344" Type="Sentence" StartNode="38856" EndNode="39156">Based on all-digital, nonprevalent (first screening examination excluded) screening mammography, there was an inverse relationship between age and false-positive findings per 1000 screening examinations among women aged 40 to 89 years, although the differences between 10-year age groups were modest.65PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:First (number) SemanticType:[qnco] PreferredName:Digital X-ray SemanticType:[inpr] PreferredName:Exclusion SemanticType:[acty] PreferredName:Screening Examination SemanticType:[diap] PreferredName:Inverse Association SemanticType:[cnce] PreferredName:Screening mammography SemanticType:[topp] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Age SemanticType:[orga] PreferredName:Woman SemanticType:[popg] PreferredName:Screening Examination SemanticType:[diap] PreferredName:/40 SemanticType:[tmco] PreferredName:Old age SemanticType:[popg] PreferredName:Menopause SemanticType:[phsf] PreferredName:year SemanticType:[tmco] PreferredName:Human Age Group SemanticType:[aggp] PreferredName:per year SemanticType:[tmco] POS:VBN POS:IN POS:JJ POS:, POS:NN POS:( POS:JJ POS:NN POS:NN POS:VBN POS:) POS:JJ POS:NN POS:, POS:EX POS:VBD POS:DT POS:JJ POS:NN POS:IN POS:NN POS:CC POS:NN POS:NNS POS:IN POS:CD POS:NN POS:NNS POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:, POS:IN POS:DT POS:NNS POS:IN POS:CD POS:: POS:NN POS:NN POS:NNS POS:VBD POS:JJ POS:. 
[sentNum: 218]<Annotation Id="24345" Type="Sentence" StartNode="39156" EndNode="39438">65 For example, false-positive findings per 1000 examinations for women aged 40 to 49 years (121.2) vs 50 to 59 years (93.2) differed by only 28 examinations per 1000 women, and recommendations for biopsy per 1000 women differed by less than 1 per 1000 (16.4 vs 15.9, respectively).PreferredName:Example SemanticType:[cnce] PreferredName:Arabic numeral 65 SemanticType:[inpr] PreferredName:Physical Examination SemanticType:[hlca] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Old age SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Singular SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Physical Examination SemanticType:[hlca] PreferredName:Biopsy SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] POS:CD POS:IN POS:NN POS:, POS:JJ POS:NNS POS:IN POS:CD POS:NNS POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:( POS:NNP POS:. POS:CD POS:) POS:VBP POS:CD POS:TO POS:CD POS:NNS POS:( POS:NNP POS:. POS:CD POS:) POS:VBN POS:IN POS:RB POS:CD POS:NNS POS:IN POS:CD POS:NNS POS:, POS:CC POS:NNS POS:IN POS:NN POS:IN POS:CD POS:NNS POS:VBD POS:IN POS:JJR POS:IN POS:CD POS:IN POS:CD POS:( POS:CD POS:. POS:CD POS:NNP POS:CD POS:. POS:CD POS:, POS:RB POS:) POS:. 
[sentNum: 219]<Annotation Id="24346" Type="Sentence" StartNode="39440" EndNode="39664">The evidence review noted that some overdiagnosis was associated with screening across all age groups25; however, the quality of evidence for estimating the magnitude of the risk of overdiagnosis by age was judged to be low. PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Note (document) SemanticType:[inpr] PreferredName:Review [Publication Type] SemanticType:[inpr] PreferredName:Associated with SemanticType:[qlco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Age SemanticType:[orga] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Quality SemanticType:[qlco] PreferredName:Magnitude SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Risk SemanticType:[qlco] PreferredName:Judge SemanticType:[prog] PreferredName:Age SemanticType:[orga] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:To SemanticType:[qlco] POS:DT POS:NN POS:NN POS:VBD POS:IN POS:DT POS:NNS POS:VBD POS:VBN POS:IN POS:VBG POS:IN POS:DT POS:NN POS:NNS POS:CD POS:: POS:RB POS:, POS:DT POS:NN POS:IN POS:NN POS:IN POS:VBG POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:IN POS:NN POS:VBD POS:VBN POS:TO POS:VB POS:JJ POS:. 
[sentNum: 220]<Annotation Id="24347" Type="Sentence" StartNode="39665" EndNode="39786">Thus, it is not possible to determine if the lifetime risk of overdiagnosis was increased by beginning screening earlier.PreferredName:Possibly Related to Intervention SemanticType:[qlco] PreferredName:Negation SemanticType:[ftcn] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Early SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] POS:RB POS:, POS:PRP POS:VBZ POS:RB POS:JJ POS:TO POS:VB POS:IN POS:DT POS:NN POS:NN POS:IN POS:NNS POS:VBD POS:VBN POS:IN POS:VBG POS:VBG POS:JJR POS:. 
[sentNum: 221]<Annotation Id="24348" Type="Sentence" StartNode="39788" EndNode="40055">Of the 20 screening strategies considered in the 2009 report from the Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network (CISNET), only 2 strategies started at age 45 years: annual and biennial screening from ages 45 to 69 years.69PreferredName:strategy SemanticType:[menp] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Reporting SemanticType:[hlca] PreferredName:consider SemanticType:[idcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:From SemanticType:[qlco] PreferredName:Intervention regimes SemanticType:[hlca] PreferredName:Working Group SemanticType:[popg] PreferredName:Consortium or Network SemanticType:[prog] PreferredName:Surveillance Modeling SemanticType:[resa] PreferredName:Singular SemanticType:[qnco] PreferredName:Cancer Intervention and Surveillance Modeling Network SemanticType:[hcro] PreferredName:Age Started SemanticType:[tmco] PreferredName:strategy SemanticType:[menp] PreferredName:Annual SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:year SemanticType:[tmco] PreferredName:Arabic numeral 69 SemanticType:[inpr] POS:IN POS:DT POS:CD POS:NN POS:NNS POS:VBN POS:IN POS:DT POS:CD POS:NN POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:IN POS:DT POS:NNP POS:NN POS:CC POS:NNP POS:NNP POS:NNP POS:( POS:NNP POS:) POS:, POS:RB POS:CD POS:NNS POS:VBD POS:IN POS:NN POS:CD POS:NNS POS:: POS:JJ POS:CC POS:JJ POS:NN POS:IN POS:NNS POS:CD POS:TO POS:CD POS:NNS POS:. 
[sentNum: 222]<Annotation Id="24349" Type="Sentence" StartNode="40055" EndNode="40492">69 The incremental differences in breast cancer deaths averted and the number of false-positive biopsies per 1000 women resulting from extending biennial screening from ages 50-69 years to ages 45-69 years were similar (0.8 additional deaths prevented and 19 additional biopsies per 1000 women screened) to those of extending screening from ages 55-69 years to ages 50-69 years (0.5 additional deaths averted and 15 additional biopsies).69PreferredName:Delta (difference) SemanticType:[qnco] PreferredName:Increment SemanticType:[qnco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Number of biopsies SemanticType:[qnco] PreferredName:Extent SemanticType:[spco] PreferredName:Woman SemanticType:[popg] PreferredName:From SemanticType:[qlco] PreferredName:Growth Inhibition Screening Result SemanticType:[cnce] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Similarity SemanticType:[qlco] PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Biopsy SemanticType:[diap] PreferredName:Additional SemanticType:[ftcn] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Extent SemanticType:[spco] PreferredName:To SemanticType:[qlco] PreferredName:From SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Arabic numeral 55 SemanticType:[inpr] PreferredName:Age-Years SemanticType:[tmco] PreferredName:0/5 SemanticType:[qnco] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Additional SemanticType:[ftcn] PreferredName:Biopsy SemanticType:[diap] PreferredName:Additional SemanticType:[ftcn] POS:CD POS:NNP POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:NNS POS:VBN POS:CC POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:CD POS:NNS POS:VBG POS:IN POS:VBG POS:JJ POS:NN POS:IN POS:NNS POS:CD POS:: POS:CD POS:NNS POS:TO POS:CD POS:CD POS:: POS:CD POS:NNS POS:VBD POS:JJ POS:( POS:NNP POS:. POS:CD POS:JJ POS:NNS POS:VBD POS:CC POS:CD POS:JJ POS:NNS POS:IN POS:CD POS:NNS POS:VBD POS:) POS:TO POS:DT POS:IN POS:VBG POS:NN POS:IN POS:NNS POS:CD POS:: POS:CD POS:NNS POS:TO POS:CD POS:CD POS:: POS:CD POS:NNS POS:( POS:NNP POS:. POS:CD POS:JJ POS:NNS POS:VBN POS:CC POS:CD POS:JJ POS:NNS POS:) POS:. 
[sentNum: 223]<Annotation Id="24350" Type="Sentence" StartNode="40492" EndNode="40881">69 Similarities also were evident when extending annual screening from ages 50-69 years to 45-69 years (with an estimated 0.7 additional deaths averted and 31 additional biopsies per 1000 women screened), compared with extending annual screening from ages 55-69 years to ages 50-69 years (with an estimated 1.2 additional deaths averted and 28 additional biopsies per 1000 women screened).69PreferredName:Similarity SemanticType:[qlco] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Extent SemanticType:[spco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Age-Years SemanticType:[tmco] PreferredName:annual screening SemanticType:[diap] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Estimated SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Additional SemanticType:[ftcn] PreferredName:Additional SemanticType:[ftcn] PreferredName:Arabic numeral 31 SemanticType:[inpr] PreferredName:Woman SemanticType:[popg] PreferredName:Biopsy SemanticType:[diap] PreferredName:Comparison SemanticType:[acty] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:annual screening SemanticType:[diap] PreferredName:Extent SemanticType:[spco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:From SemanticType:[qlco] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Arabic numeral 55 SemanticType:[inpr] PreferredName:Additional SemanticType:[ftcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Woman SemanticType:[popg] PreferredName:Biopsy SemanticType:[diap] PreferredName:Screening - procedure intent SemanticType:[ftcn] POS:CD POS:NNS POS:RB POS:VBD POS:JJ POS:WRB POS:VBG POS:JJ POS:NN POS:IN POS:NNS POS:CD POS:: POS:CD POS:NNS POS:TO POS:CD POS:: POS:CD POS:NNS POS:( POS:IN POS:DT POS:VBN POS:CD POS:. POS:CD POS:JJ POS:NNS POS:VBN POS:CC POS:CD POS:JJ POS:NNS POS:IN POS:CD POS:NNS POS:VBD POS:) POS:, POS:VBN POS:IN POS:VBG POS:JJ POS:NN POS:IN POS:NNS POS:CD POS:: POS:CD POS:NNS POS:TO POS:CD POS:CD POS:: POS:CD POS:NNS POS:( POS:IN POS:DT POS:VBN POS:CD POS:. POS:CD POS:JJ POS:NNS POS:VBN POS:CC POS:CD POS:JJ POS:NNS POS:IN POS:CD POS:NNS POS:VBD POS:) POS:. 
[sentNum: 224]<Annotation Id="24351" Type="Sentence" StartNode="40881" EndNode="40883">69PreferredName:Arabic numeral 69 SemanticType:[inpr] POS:NNP 
[sentNum: 225]<Annotation Id="24352" Type="Sentence" StartNode="40885" EndNode="41172">In the absence of direct evidence comparing breast cancer mortality by screening intervals, the GDG relied on indirect evidence, including meta-analyses, mathematical models, observational studies, and microsimulation models, to form recommendations regarding the interval for screening.PreferredName:Absence (morphologic abnormality) SemanticType:[anab] PreferredName:Within SemanticType:[spco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Direct type of relationship SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Comparison SemanticType:[acty] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Indirect SemanticType:[qlco] PreferredName:Interval SemanticType:[tmco] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Mathematical Model SemanticType:[inpr] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:Model SemanticType:[inpr] PreferredName:Observational Study SemanticType:[resa] PreferredName:Formation SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:VBG POS:NN POS:NN POS:NN POS:IN POS:NN POS:NNS POS:, POS:DT POS:NNP POS:VBD POS:IN POS:JJ POS:NN POS:, POS:VBG POS:NNS POS:, POS:JJ POS:NNS POS:, POS:JJ POS:NNS POS:, POS:CC POS:NN POS:NNS POS:, POS:TO POS:VB POS:NNS POS:VBG POS:DT POS:NN POS:IN POS:NN POS:. 
[sentNum: 226]<Annotation Id="24353" Type="Sentence" StartNode="41174" EndNode="41441">A meta-analysis of screening trials comparing broad age groups (&lt;50 vs 50-69 years) and screening intervals (&lt;24 vs ≥24 months) found that the benefit of an invitation to screening was not related to screening intervals for women aged 50 to 69 years at randomization.32PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:Comparison SemanticType:[acty] PreferredName:Screening Study SemanticType:[resa] PreferredName:Human Age Group SemanticType:[aggp] PreferredName:Widening SemanticType:[spco] PreferredName:year SemanticType:[tmco] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Interval SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Present SemanticType:[qnco] PreferredName:month SemanticType:[tmco] PreferredName:Invitation SemanticType:[inpr] PreferredName:Benefits SemanticType:[qnco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Relationships SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Interval SemanticType:[tmco] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Randomization SemanticType:[resa] PreferredName:year SemanticType:[tmco] POS:DT POS:NNS POS:IN POS:NN POS:NNS POS:VBG POS:JJ POS:NN POS:NNS POS:( POS:CD POS:CD POS:NN POS:CD POS:: POS:CD POS:NNS POS:) POS:CC POS:VBG POS:NNS POS:( POS:CD POS:CD POS:JJ POS:NNS POS:CD POS:NNS POS:) POS:VBD POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:TO POS:NN POS:VBD POS:RB POS:VBN POS:TO POS:NN POS:NNS POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:IN POS:NN POS:. 
[sentNum: 227]<Annotation Id="24354" Type="Sentence" StartNode="41441" EndNode="41729">32 However, among women randomized before age 50 years, a significant reduction in mortality was observed only for invitation at intervals less than 24 months (RR, 0.82; 95% CI, 0.72-0.94), whereas for intervals of 24 or more months, no benefit was observed (RR, 1.04; 95% CI, 0.72-1.50). PreferredName:Randomization SemanticType:[resa] PreferredName:Woman SemanticType:[popg] PreferredName:Significant SemanticType:[idcn] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Singular SemanticType:[qnco] PreferredName:Observed SemanticType:[ftcn] PreferredName:At SemanticType:[spco] PreferredName:Invitation SemanticType:[inpr] PreferredName:month SemanticType:[tmco] PreferredName:Interval SemanticType:[tmco] PreferredName:More SemanticType:[ftcn] PreferredName:Interval SemanticType:[tmco] PreferredName:Benefits SemanticType:[qnco] PreferredName:month SemanticType:[tmco] PreferredName:1+ Score, WHO SemanticType:[clas] PreferredName:Observed SemanticType:[ftcn] POS:CD POS:RB POS:, POS:IN POS:NNS POS:VBN POS:IN POS:NN POS:CD POS:NNS POS:, POS:DT POS:JJ POS:NN POS:IN POS:NN POS:VBD POS:VBN POS:RB POS:IN POS:NN POS:IN POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:( POS:RB POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:NN POS:NNP POS:, POS:SYM POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:) POS:, POS:IN POS:IN POS:NNS POS:IN POS:CD POS:CC POS:JJR POS:NNS POS:, POS:DT POS:NN POS:VBD POS:VBN POS:( POS:RB POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:NN POS:NNP POS:, POS:SYM POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:) POS:. 
[sentNum: 228]<Annotation Id="24355" Type="Sentence" StartNode="41730" EndNode="41934">In the Swedish Two County Trial, women were screened at intervals of 24 months or longer, and investigators sought to identify the point at which breast cancers began to reemerge after a normal mammogram. PreferredName:Two SemanticType:[qnco] PreferredName:Swedish SemanticType:[popg] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:County SemanticType:[geoa] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:month SemanticType:[tmco] PreferredName:Interval SemanticType:[tmco] PreferredName:Research Personnel SemanticType:[prog] PreferredName:Long SemanticType:[qlco] PreferredName:point - UnitsOfMeasure SemanticType:[qnco] PreferredName:To SemanticType:[qlco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Normal SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] POS:IN POS:DT POS:JJ POS:CD POS:NNP POS:NN POS:, POS:NNS POS:VBD POS:VBN POS:IN POS:NNS POS:IN POS:CD POS:NNS POS:CC POS:RB POS:, POS:CC POS:NNS POS:VBD POS:TO POS:VB POS:DT POS:NN POS:IN POS:WDT POS:NN POS:NNS POS:VBD POS:TO POS:VB POS:IN POS:DT POS:JJ POS:NN POS:. 
[sentNum: 229]<Annotation Id="24356" Type="Sentence" StartNode="41935" EndNode="42240">Among women older than 50 years at entry to the study, few interval cancers were observed in the first 2 years, whereas among women aged 40 to 49 years at randomization, the rate of interval cancers was 40% of the control group incidence rate within the first 12 months after a normal screening mammogram.70PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Entry (data) SemanticType:[inpr] PreferredName:At SemanticType:[spco] PreferredName:Few SemanticType:[qnco] PreferredName:Study SemanticType:[resa] PreferredName:Observed SemanticType:[ftcn] PreferredName:Malignant neoplasm detection during interval between recommended screening examinations SemanticType:[fndg] PreferredName:year SemanticType:[tmco] PreferredName:First (number) SemanticType:[qnco] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Rate SemanticType:[qnco] PreferredName:Randomization SemanticType:[resa] PreferredName:/40 SemanticType:[tmco] PreferredName:Malignant neoplasm detection during interval between recommended screening examinations SemanticType:[fndg] PreferredName:Incidence Rate SemanticType:[qnco] PreferredName:Control Groups SemanticType:[grup] PreferredName:Normal first month SemanticType:[fndg] PreferredName:Within SemanticType:[spco] PreferredName:Screening mammography SemanticType:[topp] POS:IN POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:IN POS:NN POS:TO POS:DT POS:NN POS:, POS:JJ POS:JJ POS:NNS POS:VBD POS:VBN POS:IN POS:DT POS:JJ POS:CD POS:NNS POS:, POS:IN POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:IN POS:NN POS:, POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:VBD POS:CD POS:NN POS:IN POS:DT POS:NN POS:NN POS:NN POS:NN POS:IN POS:DT POS:JJ POS:CD POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:NN POS:. 
[sentNum: 230]<Annotation Id="24357" Type="Sentence" StartNode="42240" EndNode="42242">70POS:NN 
[sentNum: 231]<Annotation Id="24358" Type="Sentence" StartNode="42244" EndNode="42511">Mathematical models capture the benefit of screening by modeling its estimated ability to detect cancers at smaller sizes; several of these models suggested that annual screening intervals are associated with detection of fewer tumors at larger and more lethal sizes.71PreferredName:Mathematical Model SemanticType:[inpr] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Detected (finding) SemanticType:[fndg] PreferredName:Ability SemanticType:[orga] PreferredName:small size SemanticType:[fndg] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Model SemanticType:[inpr] PreferredName:Numerous SemanticType:[qnco] PreferredName:annual screening SemanticType:[diap] PreferredName:suggestion SemanticType:[idcn] PreferredName:Associated with SemanticType:[qlco] PreferredName:Interval SemanticType:[tmco] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Detection SemanticType:[topp] PreferredName:More SemanticType:[ftcn] PreferredName:Greater SemanticType:[qnco] PreferredName:Lethal SemanticType:[fndg] PreferredName:effect size SemanticType:[qnco] POS:JJ POS:NNS POS:VB POS:DT POS:NN POS:IN POS:VBG POS:IN POS:NN POS:PRP$ POS:JJ POS:NN POS:TO POS:VB POS:NNS POS:IN POS:JJR POS:NNS POS:: POS:JJ POS:IN POS:DT POS:NNS POS:VBD POS:IN POS:JJ POS:NN POS:NNS POS:VBP POS:VBN POS:IN POS:NN POS:IN POS:JJR POS:NNS POS:IN POS:JJR POS:CC POS:RBR POS:JJ POS:NNS POS:. 
[sentNum: 232]<Annotation Id="24359" Type="Sentence" StartNode="42511" EndNode="42975">71- 73 In the 2009 CISNET analysis of the effects of mammography screening under different screening schedules, results from an exemplar model (from model S, Stanford University, chosen by the investigators as an exemplar model to summarize the balance of benefits and harms) estimated more cancer deaths averted with annual compared with biennial screening for all age groups and a greater number of cancer deaths averted when screening began before age 50 years.69PreferredName:Arabic numeral 71 SemanticType:[inpr] PreferredName:Analysis of substances SemanticType:[lbpr] PreferredName:Cancer Intervention and Surveillance Modeling Network SemanticType:[hcro] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Different SemanticType:[qlco] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Act Relationship Type - schedules SemanticType:[idcn] PreferredName:Model SemanticType:[inpr] PreferredName:Model SemanticType:[inpr] PreferredName:Choose (action) SemanticType:[acty] PreferredName:Universities SemanticType:[mnob, orgt] PreferredName:Model SemanticType:[inpr] PreferredName:Research Personnel SemanticType:[prog] PreferredName:Benefits SemanticType:[qnco] PreferredName:Equilibrium SemanticType:[orgf] PreferredName:More SemanticType:[ftcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Comparison SemanticType:[acty] PreferredName:Annual SemanticType:[tmco] PreferredName:Human Age Group SemanticType:[aggp] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Numbers SemanticType:[qnco] PreferredName:Greater SemanticType:[qnco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Malignant Neoplasms SemanticType:[neop] PreferredName:Beginning SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Age-Years SemanticType:[tmco] POS:CD POS:: POS:CD POS:IN POS:DT POS:CD POS:NN POS:NN POS:IN POS:DT POS:NNS POS:IN POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:NNS POS:, POS:NNS POS:IN POS:DT POS:NN POS:NN POS:( POS:IN POS:NN POS:NNP POS:, POS:NNP POS:NNP POS:, POS:VBN POS:IN POS:DT POS:NNS POS:IN POS:DT POS:NN POS:NN POS:TO POS:VB POS:DT POS:NN POS:IN POS:NNS POS:CC POS:NNS POS:) POS:VBD POS:JJR POS:NN POS:NNS POS:VBN POS:IN POS:JJ POS:VBN POS:IN POS:JJ POS:NN POS:IN POS:PDT POS:NN POS:NNS POS:CC POS:DT POS:JJR POS:NN POS:IN POS:NN POS:NNS POS:VBN POS:WRB POS:NN POS:VBD POS:IN POS:NN POS:CD POS:NNS POS:. 
[sentNum: 233]<Annotation Id="24360" Type="Sentence" StartNode="42975" EndNode="43138">69 However, the additional benefit of annual screening and beginning screening earlier incurred higher rates of false-positive screening examinations and biopsies. PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Benefits SemanticType:[qnco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Beginning SemanticType:[tmco] PreferredName:annual screening SemanticType:[diap] PreferredName:Early SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:False Discovery Rate SemanticType:[qnco] PreferredName:High SemanticType:[qlco] PreferredName:Biopsy SemanticType:[diap] PreferredName:Screening Examination SemanticType:[diap] POS:CD POS:RB POS:, POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:CC POS:NN POS:NN POS:RB POS:VBD POS:JJR POS:NNS POS:IN POS:JJ POS:NN POS:NNS POS:CC POS:NNS POS:. 
[sentNum: 234]<Annotation Id="24361" Type="Sentence" StartNode="43139" EndNode="43325">The CISNET study estimated that screening every other year maintained an average of 81% of the mortality benefit of annual screening with about half the number of false-positive results.69PreferredName:Study SemanticType:[resa] PreferredName:Cancer Intervention and Surveillance Modeling Network SemanticType:[hcro] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Maintaining (action) SemanticType:[ftcn] PreferredName:per year SemanticType:[tmco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Average SemanticType:[qnco] PreferredName:annual screening SemanticType:[diap] PreferredName:Benefits SemanticType:[qnco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Half SemanticType:[qnco] PreferredName:False Positive SemanticType:[lbtr] POS:DT POS:NNP POS:NN POS:VBD POS:IN POS:VBG POS:DT POS:JJ POS:NN POS:VBD POS:DT POS:NN POS:IN POS:CD POS:NN POS:IN POS:DT POS:NN POS:NN POS:IN POS:JJ POS:NN POS:IN POS:RB POS:PDT POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 235]<Annotation Id="24362" Type="Sentence" StartNode="43325" EndNode="43423">69 The exemplar model did not explore a hybrid strategy that varied the screening interval by age.PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Negation SemanticType:[ftcn] PreferredName:Model SemanticType:[inpr] PreferredName:strategy SemanticType:[menp] PreferredName:Hybrids SemanticType:[orgm] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Age SemanticType:[orga] POS:CD POS:NNP POS:NN POS:NN POS:VBD POS:RB POS:VB POS:DT POS:JJ POS:NN POS:WDT POS:VBD POS:DT POS:JJ POS:NN POS:IN POS:NN POS:. 
[sentNum: 236]<Annotation Id="24363" Type="Sentence" StartNode="43425" EndNode="43660">The ACS commissioned the BCSC to examine the association between annual vs biennial screening and outcomes using definitions of these intervals that more closely approximated 12 vs 24 months than were used in earlier BCSC publications. PreferredName:Breast Cancer Surveillance Consortium SemanticType:[prog] PreferredName:Annual SemanticType:[tmco] PreferredName:Relationships SemanticType:[qlco] PreferredName:Result SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:definition - ActMoodCompletionTrack SemanticType:[idcn] PreferredName:Use of SemanticType:[ftcn] PreferredName:More SemanticType:[ftcn] PreferredName:Interval SemanticType:[tmco] PreferredName:month SemanticType:[tmco] PreferredName:Approximate SemanticType:[qlco] PreferredName:Early SemanticType:[tmco] PreferredName:Used by SemanticType:[fndg] PreferredName:Publications SemanticType:[inpr, mnob] PreferredName:Breast Cancer Surveillance Consortium SemanticType:[prog] POS:DT POS:NNP POS:VBD POS:DT POS:NN POS:TO POS:VB POS:DT POS:NN POS:IN POS:JJ POS:JJ POS:JJ POS:NN POS:CC POS:NNS POS:VBG POS:NNS POS:IN POS:DT POS:NNS POS:WDT POS:RBR POS:RB POS:VBD POS:CD POS:NN POS:CD POS:NNS POS:IN POS:VBD POS:VBN POS:IN POS:JJR POS:NN POS:NNS POS:. 
[sentNum: 237]<Annotation Id="24364" Type="Sentence" StartNode="43661" EndNode="43908">Miglioretti et al74 examined the association between screening intervals and tumor characteristics (stage [IIB, III, IV], larger size [&gt;15 mm], positive nodes, and any 1 or more of these characteristics) as indicators for less favorable prognosis. PreferredName:Relationships SemanticType:[qlco] PreferredName:Examined SemanticType:[fndg] PreferredName:Interval SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Characteristics SemanticType:[qlco] PreferredName:Neoplasm SemanticType:[neop] PreferredName:III (suffix) SemanticType:[qlco] PreferredName:Stage 2 lower case b SemanticType:[clas] PreferredName:size SemanticType:[spco] PreferredName:Greater SemanticType:[qnco] PreferredName:Anatomic Node SemanticType:[bpoc] PreferredName:Positive Finding SemanticType:[fndg] PreferredName:More SemanticType:[ftcn] PreferredName:1+ Score, WHO SemanticType:[clas] PreferredName:Indicators SemanticType:[irda] PreferredName:Characteristics SemanticType:[qlco] PreferredName:Forecast of outcome SemanticType:[hlca] PreferredName:Favorable SemanticType:[qlco] POS:NNP POS:CC POS:NNP POS:NNP POS:VBD POS:DT POS:NN POS:IN POS:NN POS:NNS POS:CC POS:NN POS:NNS POS:( POS:NN POS:NNP POS:NNP POS:, POS:NNP POS:, POS:NNP POS:NNP POS:, POS:JJR POS:NN POS:NNS POS:VBG POS:CD POS:NN POS:NNS POS:, POS:JJ POS:NNS POS:, POS:CC POS:DT POS:CD POS:CC POS:JJR POS:IN POS:DT POS:NNS POS:) POS:IN POS:NNS POS:IN POS:RBR POS:JJ POS:NN POS:. 
[sentNum: 238]<Annotation Id="24365" Type="Sentence" StartNode="43909" EndNode="44157">Multivariable analyses suggested that somewhat more favorable characteristics were associated with a shorter interval among women aged 40 to 49 years, but not among older women (&gt;50 years), although the difference was not statistically significant. PreferredName:suggestion SemanticType:[idcn] PreferredName:Analysis of substances SemanticType:[lbpr] PreferredName:Favorable SemanticType:[qlco] PreferredName:Somewhat SemanticType:[inpr] PreferredName:Associated with SemanticType:[qlco] PreferredName:Characteristics SemanticType:[qlco] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Short SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Negation SemanticType:[ftcn] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Not significant SemanticType:[fndg] PreferredName:Delta (difference) SemanticType:[qnco] POS:JJ POS:NNS POS:VBD POS:IN POS:RB POS:RBR POS:JJ POS:NNS POS:VBD POS:VBN POS:IN POS:DT POS:JJR POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:, POS:CC POS:RB POS:IN POS:JJR POS:NNS POS:( POS:CD POS:CD POS:NNS POS:) POS:, POS:IN POS:DT POS:NN POS:VBD POS:RB POS:RB POS:JJ POS:. 
[sentNum: 239]<Annotation Id="24366" Type="Sentence" StartNode="44158" EndNode="44251">Additional analyses indicated that these results likely were influenced by menopausal status. PreferredName:Analysis of substances SemanticType:[lbpr] PreferredName:Additional SemanticType:[ftcn] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Indicated SemanticType:[fndg] PreferredName:Menopausal Status SemanticType:[clna] PreferredName:Probably SemanticType:[idcn] POS:JJ POS:NNS POS:VBD POS:IN POS:DT POS:NNS POS:RB POS:VBD POS:VBN POS:IN POS:JJ POS:NN POS:. 
[sentNum: 240]<Annotation Id="24367" Type="Sentence" StartNode="44252" EndNode="44571">Premenopausal women were more likely to have advanced stage (RR, 1.28; 95% CI, 1.01-1.63), larger tumor size (RR, 1.21; 95% CI, 1.07-1.37), and poor prognosis tumors at diagnosis (RR, 1.11; 95% CI, 1.00-1.22) associated with a screening interval of 23 to 26 months compared with a screening interval of 11 to 14 months. PreferredName:Woman SemanticType:[popg] PreferredName:Premenopausal - menopausal status SemanticType:[tmco] PreferredName:Probably SemanticType:[idcn] PreferredName:More SemanticType:[ftcn] PreferredName:1+ Score, WHO SemanticType:[clas] PreferredName:Advanced phase SemanticType:[qlco] PreferredName:Greater SemanticType:[qnco] PreferredName:1+ Score, WHO SemanticType:[clas] PreferredName:1+ Score, WHO SemanticType:[clas] PreferredName:Tumor size SemanticType:[spco] PreferredName:Prognosis bad SemanticType:[fndg] PreferredName:1+ Score, WHO SemanticType:[clas] PreferredName:1+ Score, WHO SemanticType:[clas] PreferredName:neoplasm diagnosis SemanticType:[diap] PreferredName:Associated with SemanticType:[qlco] PreferredName:1+ Score, WHO SemanticType:[clas] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:month SemanticType:[tmco] PreferredName:Arabic numeral 23 SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Comparison SemanticType:[acty] PreferredName:month SemanticType:[tmco] PreferredName:Data Type Interval SemanticType:[inpr] POS:JJ POS:NNS POS:VBD POS:RBR POS:JJ POS:TO POS:VB POS:JJ POS:NN POS:( POS:NNP POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:NN POS:RB POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:) POS:, POS:JJR POS:NN POS:NN POS:( POS:NNP POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:NN POS:RB POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:) POS:, POS:CC POS:JJ POS:NN POS:NNS POS:IN POS:NN POS:( POS:RB POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:NN POS:RB POS:, POS:CD POS:. POS:CD POS:: POS:CD POS:. POS:CD POS:) POS:VBN POS:IN POS:DT POS:NN POS:NN POS:IN POS:CD POS:TO POS:CD POS:NNS POS:VBN POS:IN POS:DT POS:NN POS:NN POS:IN POS:CD POS:TO POS:CD POS:NNS POS:. 
[sentNum: 241]<Annotation Id="24368" Type="Sentence" StartNode="44572" EndNode="44746">The degree to which this observation is due to age, premenopausal status, or reduced sensitivity of screening in young women (or a combination of these factors) is uncertain. PreferredName:Observation in research SemanticType:[resa] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:Due to SemanticType:[ftcn] PreferredName:Status SemanticType:[qlco] PreferredName:Premenopausal - menopausal status SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Decreased Device Sensitivity SemanticType:[phpr] PreferredName:Woman SemanticType:[popg] PreferredName:Young SemanticType:[tmco] PreferredName:combination of objects SemanticType:[phob] PreferredName:A-factor (Streptomyces) SemanticType:[bacs, orch] PreferredName:Uncertainty SemanticType:[idcn] POS:DT POS:NN POS:TO POS:WDT POS:DT POS:NN POS:VBZ POS:JJ POS:TO POS:NN POS:, POS:JJ POS:NN POS:, POS:CC POS:JJ POS:NN POS:IN POS:NN POS:IN POS:JJ POS:NNS POS:( POS:CC POS:DT POS:NN POS:IN POS:DT POS:NNS POS:) POS:VBZ POS:JJ POS:. 
[sentNum: 242]<Annotation Id="24369" Type="Sentence" StartNode="44747" EndNode="45101">The authors highlighted several potential limitations in their analysis, including whether women at higher risk may be motivated to seek more frequent screening (although the analysis adjusted for family history), and whether the decision to maximize sample sizes by inclusion of women exposed to screen-film and digital mammography affected the results. PreferredName:Journalist SemanticType:[prog] PreferredName:Potential SemanticType:[qlco] PreferredName:Numerous SemanticType:[qnco] PreferredName:Analysis of substances SemanticType:[lbpr] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:High risk of SemanticType:[qlco] PreferredName:Frequent SemanticType:[tmco] PreferredName:More SemanticType:[ftcn] PreferredName:Analysis of substances SemanticType:[lbpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Family history SemanticType:[fndg] PreferredName:Adjustment Action SemanticType:[ftcn] PreferredName:Sample Size SemanticType:[qnco] PreferredName:Decision SemanticType:[menp] PreferredName:Woman SemanticType:[popg] PreferredName:Inclusion SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Exposure to SemanticType:[clna] PreferredName:film (photographic) SemanticType:[mnob] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Involvement with SemanticType:[ftcn] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Experimental Result SemanticType:[fndg] POS:DT POS:NNS POS:VBD POS:JJ POS:JJ POS:NNS POS:IN POS:PRP$ POS:NN POS:, POS:VBG POS:IN POS:NNS POS:IN POS:JJR POS:NN POS:MD POS:VB POS:VBN POS:TO POS:VB POS:RBR POS:JJ POS:NN POS:( POS:IN POS:DT POS:NN POS:VBN POS:IN POS:NN POS:NN POS:) POS:, POS:CC POS:IN POS:DT POS:NN POS:TO POS:VB POS:NN POS:NNS POS:IN POS:NN POS:IN POS:NNS POS:VBN POS:TO POS:JJ POS:CC POS:JJ POS:NN POS:VBD POS:DT POS:NNS POS:. 
[sentNum: 243]<Annotation Id="24370" Type="Sentence" StartNode="45102" EndNode="45287">Although overall the sensitivity of digital and screen-film mammography is similar, digital mammography is more sensitive in younger women and women with mammographically dense breasts.75PreferredName:Overall Publication Type SemanticType:[inpr] PreferredName:Digital SemanticType:[qlco] PreferredName:Statistical sensitivity SemanticType:[qnco] PreferredName:Film Mammography SemanticType:[diap] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Similarity SemanticType:[qlco] PreferredName:Confidentiality - sensitive SemanticType:[idcn] PreferredName:More SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Young SemanticType:[tmco] PreferredName:Dense breasts NOS SemanticType:[fndg] PreferredName:Woman SemanticType:[popg] POS:IN POS:JJ POS:DT POS:NN POS:IN POS:JJ POS:CC POS:JJ POS:NN POS:VBZ POS:JJ POS:, POS:JJ POS:NN POS:VBZ POS:RBR POS:JJ POS:IN POS:JJR POS:NNS POS:CC POS:NNS POS:IN POS:JJ POS:JJ POS:NNS POS:. 
[sentNum: 244]<Annotation Id="24371" Type="Sentence" StartNode="45287" EndNode="45289">75POS:NNP 
[sentNum: 245]<Annotation Id="24372" Type="Sentence" StartNode="45291" EndNode="45392">When making decisions on screening intervals, it is important to consider the harm-benefit trade-off. PreferredName:Disease Screening SemanticType:[diap] PreferredName:Decision Making SemanticType:[menp] PreferredName:consider SemanticType:[idcn] PreferredName:Interval SemanticType:[tmco] PreferredName:Benefits SemanticType:[qnco] POS:WRB POS:VBG POS:NNS POS:IN POS:VBG POS:NNS POS:, POS:PRP POS:VBZ POS:JJ POS:TO POS:VB POS:DT POS:NN POS:NN POS:. 
[sentNum: 246]<Annotation Id="24373" Type="Sentence" StartNode="45393" EndNode="45590">While annual screening yielded a larger reduction in breast cancer mortality than biennial screening,69 a more frequent screening schedule also resulted in a higher rate of false-positive findings. PreferredName:annual screening SemanticType:[diap] PreferredName:Reduced SemanticType:[qlco] PreferredName:Large SemanticType:[qnco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:More SemanticType:[ftcn] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Frequent SemanticType:[tmco] PreferredName:High SemanticType:[qlco] PreferredName:Schedule (document type) SemanticType:[inpr] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Rating (action) SemanticType:[acty] PreferredName:findings aspects SemanticType:[ftcn] POS:IN POS:JJ POS:NN POS:VBD POS:DT POS:JJR POS:NN POS:IN POS:NN POS:NN POS:NN POS:IN POS:JJ POS:NN POS:, POS:CD POS:DT POS:RBR POS:JJ POS:NN POS:NN POS:RB POS:VBD POS:IN POS:DT POS:JJR POS:NN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 247]<Annotation Id="24374" Type="Sentence" StartNode="45591" EndNode="45942">Given that screening annually appears to provide additional benefit over biennial screening particularly in younger women, the GDG concludes that women aged 45 to 54 years should be screened annually (Qualified Recommendation), and women aged 40 to 44 years who choose to initiate screening also should be screened annually (Qualified Recommendation). PreferredName:GIVEN SemanticType:[cnce] PreferredName:Annual SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:To SemanticType:[qlco] PreferredName:Appearance SemanticType:[qlco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Benefits SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Young SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:year SemanticType:[tmco] PreferredName:Old age SemanticType:[popg] PreferredName:Annual SemanticType:[tmco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Recommendation SemanticType:[idcn] PreferredName:/40 SemanticType:[tmco] PreferredName:Old age SemanticType:[popg] PreferredName:Choose (action) SemanticType:[acty] PreferredName:year SemanticType:[tmco] PreferredName:Initiation SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Annual SemanticType:[tmco] POS:VBN POS:IN POS:NN POS:RB POS:VBZ POS:TO POS:VB POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:RB POS:IN POS:JJR POS:NNS POS:, POS:DT POS:NNP POS:VBZ POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:MD POS:VB POS:VBN POS:RB POS:( POS:NNP POS:NNP POS:) POS:, POS:CC POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:WP POS:VBP POS:TO POS:VB POS:NN POS:RB POS:MD POS:VB POS:VBN POS:RB POS:( POS:NNP POS:NNP POS:) POS:. 
[sentNum: 248]<Annotation Id="24375" Type="Sentence" StartNode="45943" EndNode="46388">Because relative benefits of annual vs biennial screening are less after menopause and as women get older,69 and more frequent screening over a lifetime horizon carries with it an increased chance of additional false-positive results, women aged 55 years, the age at which the large majority of women are postmenopausal,76 should transition to biennial screening or have the opportunity to continue screening annually (Qualified Recommendation).PreferredName:Benefits SemanticType:[qnco] PreferredName:Relative SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Annual SemanticType:[tmco] PreferredName:Menopause SemanticType:[phsf] PreferredName:Less Than SemanticType:[inpr] PreferredName:Woman SemanticType:[popg] PreferredName:And SemanticType:[idcn] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Old SemanticType:[tmco] PreferredName:Frequent SemanticType:[tmco] PreferredName:More SemanticType:[ftcn] PreferredName:Carrying SemanticType:[acty] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Chance SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Additional SemanticType:[ftcn] PreferredName:Old age SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Arabic numeral 55 SemanticType:[inpr] PreferredName:Large SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:Woman SemanticType:[popg] PreferredName:majority SemanticType:[socb] PreferredName:Transition Mutation SemanticType:[comd] PreferredName:Postmenopausal state SemanticType:[tmco] PreferredName:Continuous SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Annual SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] POS:IN POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:JJ POS:NN POS:VBP POS:CC POS:IN POS:NN POS:CC POS:IN POS:NNS POS:VB POS:JJR POS:, POS:CD POS:CC POS:JJR POS:JJ POS:NN POS:IN POS:DT POS:NN POS:NN POS:VBZ POS:IN POS:PRP POS:DT POS:VBN POS:NN POS:IN POS:JJ POS:JJ POS:NNS POS:, POS:NNS POS:VBN POS:CD POS:NNS POS:, POS:DT POS:NN POS:IN POS:WDT POS:DT POS:JJ POS:NN POS:IN POS:NNS POS:VBP POS:JJ POS:, POS:CD POS:MD POS:VB POS:TO POS:JJ POS:NN POS:CC POS:VB POS:DT POS:NN POS:TO POS:VB POS:NN POS:RB POS:( POS:NNP POS:NNP POS:) POS:. 
[sentNum: 249]<Annotation Id="24376" Type="Sentence" StartNode="46390" EndNode="46528">Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer. PreferredName:Woman SemanticType:[popg] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Continuous SemanticType:[idcn] PreferredName:Long SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] PreferredName:Health SemanticType:[idcn] PreferredName:Overall SemanticType:[qlco] PreferredName:antineoplaston A10 SemanticType:[orch, phsu] PreferredName:Good SemanticType:[qlco] PreferredName:year SemanticType:[tmco] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Long SemanticType:[qlco] POS:NNS POS:MD POS:VB POS:VBG POS:NN POS:RB POS:RB POS:IN POS:PRP$ POS:JJ POS:NN POS:VBZ POS:JJ POS:CC POS:PRP POS:VBP POS:DT POS:NN POS:NN POS:IN POS:CD POS:NNS POS:CC POS:RBR POS:. 
[sentNum: 250]<Annotation Id="24377" Type="Sentence" StartNode="46529" EndNode="46555">(Qualified Recommendation)PreferredName:Recommendation SemanticType:[idcn] POS:( POS:NN POS:NN POS:) 
[sentNum: 251]<Annotation Id="24378" Type="Sentence" StartNode="46557" EndNode="46735">Breast cancer incidence continues to increase until ages 75 to 79 years, and 26% of breast cancer deaths each year are attributable to a diagnosis after age 74 years (Figure 1B).3PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:To SemanticType:[qlco] PreferredName:Continuous SemanticType:[idcn] PreferredName:Age SemanticType:[orga] PreferredName:Increase SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:year SemanticType:[tmco] PreferredName:per year SemanticType:[tmco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Diagnosis Study SemanticType:[resa] PreferredName:Attribution SemanticType:[menp] PreferredName:1B SemanticType:[inpr] PreferredName:Age-Years SemanticType:[tmco] POS:JJ POS:NN POS:NN POS:VBZ POS:TO POS:VB POS:IN POS:NNS POS:CD POS:TO POS:CD POS:NNS POS:, POS:CC POS:CD POS:NN POS:IN POS:NN POS:NN POS:NNS POS:DT POS:NN POS:VBP POS:JJ POS:TO POS:DT POS:NN POS:IN POS:NN POS:CD POS:NNS POS:( POS:NN POS:CD POS:NNP POS:) POS:. 
[sentNum: 252]<Annotation Id="24379" Type="Sentence" StartNode="46735" EndNode="46919">3 Because the sensitivity and specificity of mammography improve with increasing age,77 this suggests considerable opportunity to further reduce breast cancer deaths among older women. PreferredName:Sensitivity and Specificity SemanticType:[qnco] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] PreferredName:Increasing SemanticType:[ftcn] PreferredName:Mammography SemanticType:[diap] PreferredName:suggestion SemanticType:[idcn] PreferredName:Age SemanticType:[orga] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Further SemanticType:[spco] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Old SemanticType:[tmco] POS:LS POS:IN POS:DT POS:NN POS:CC POS:NN POS:IN POS:NN POS:VBP POS:IN POS:VBG POS:NN POS:, POS:CD POS:DT POS:VBZ POS:JJ POS:NN POS:TO POS:RB POS:VB POS:NN POS:NN POS:NNS POS:IN POS:JJR POS:NNS POS:. 
[sentNum: 253]<Annotation Id="24380" Type="Sentence" StartNode="46920" EndNode="47258">While none of the RCTs included women 75 years and older, observational78,79 and modeling studies69 have observed a reduction in breast cancer mortality associated with mammographic detection of breast cancer in women 75 years and older, although these findings must be interpreted with caution given the limitations of the study designs.PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:None SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Old SemanticType:[tmco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Observed SemanticType:[ftcn] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Mammography SemanticType:[diap] PreferredName:Associated with SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Detection SemanticType:[topp] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:findings aspects SemanticType:[ftcn] PreferredName:Old SemanticType:[tmco] PreferredName:GIVEN SemanticType:[cnce] PreferredName:Interprets SemanticType:[ftcn] PreferredName:Research Design SemanticType:[resa] PreferredName:Limitation SemanticType:[ftcn] POS:IN POS:NN POS:IN POS:DT POS:NNPS POS:VBD POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:, POS:JJ POS:CD POS:, POS:CD POS:CC POS:CD POS:NNS POS:CD POS:VBP POS:VBN POS:DT POS:NN POS:IN POS:NN POS:NN POS:NN POS:VBN POS:IN POS:JJ POS:NN POS:IN POS:NN POS:NN POS:IN POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:, POS:IN POS:DT POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:NN POS:VBN POS:DT POS:NNS POS:IN POS:DT POS:NN POS:NNS POS:. 
[sentNum: 254]<Annotation Id="24381" Type="Sentence" StartNode="47260" EndNode="47387">Quiz Ref IDThe reduced life expectancy associated with being older decreases the likelihood of screening benefit in some women. PreferredName:Reduced SemanticType:[qlco] PreferredName:ALYREF gene SemanticType:[gngm] PreferredName:Associated with SemanticType:[qlco] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Reduced SemanticType:[qlco] PreferredName:Old SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Probability SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Benefits SemanticType:[qnco] POS:NNP POS:NNP POS:NNP POS:JJ POS:NN POS:NN POS:VBN POS:IN POS:VBG POS:JJR POS:VBZ POS:DT POS:NN POS:IN POS:VBG POS:NN POS:IN POS:DT POS:NNS POS:. 
[sentNum: 255]<Annotation Id="24382" Type="Sentence" StartNode="47388" EndNode="47717">Observational studies have shown that older women in poor health, for example, those with Charlson Comorbidity Index scores of 2 or higher, do not experience a reduction in breast cancer mortality associated with screening mammography due to competing causes of mortality80 and therefore may not be good candidates for screening. PreferredName:Show SemanticType:[inpr] PreferredName:Observational Study SemanticType:[resa] PreferredName:Women's Health SemanticType:[bmod] PreferredName:Old SemanticType:[tmco] PreferredName:Example SemanticType:[cnce] PreferredName:Poor - qualifier SemanticType:[qlco] PreferredName:Score SemanticType:[qnco] PreferredName:Comorbidity Index SemanticType:[qnco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Associated with SemanticType:[qlco] PreferredName:Etiology SemanticType:[ftcn] PreferredName:Due to SemanticType:[ftcn] PreferredName:Good SemanticType:[qlco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] POS:JJ POS:NNS POS:VBP POS:VBN POS:IN POS:JJR POS:NNS POS:IN POS:JJ POS:NN POS:, POS:IN POS:NN POS:, POS:DT POS:IN POS:NNP POS:NNP POS:NNP POS:NNS POS:IN POS:CD POS:CC POS:JJR POS:, POS:VBP POS:RB POS:VB POS:DT POS:NN POS:IN POS:NN POS:NN POS:NN POS:VBN POS:IN POS:VBG POS:RB POS:JJ POS:TO POS:VBG POS:NNS POS:IN POS:NN POS:CD POS:CC POS:RB POS:MD POS:RB POS:VB POS:JJ POS:NNS POS:IN POS:NN POS:. 
[sentNum: 256]<Annotation Id="24383" Type="Sentence" StartNode="47718" EndNode="47972">This is an issue of concern because recent studies suggest that many women who have serious or terminal health conditions are still receiving screening mammograms,81,82 despite its low likelihood of increasing life expectancy or improving other outcomes. PreferredName:Problem SemanticType:[fndg] PreferredName:Recent SemanticType:[tmco] PreferredName:Concern SemanticType:[idcn] PreferredName:suggestion SemanticType:[idcn] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Serious SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Health conditions SemanticType:[fndg] PreferredName:End-stage SemanticType:[tmco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Receive SemanticType:[qlco] PreferredName:Probability SemanticType:[qnco] PreferredName:low SemanticType:[qlco] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Increasing SemanticType:[ftcn] PreferredName:Result SemanticType:[ftcn] PreferredName:Improving (qualifier value) SemanticType:[qlco] POS:DT POS:VBZ POS:DT POS:NN POS:IN POS:NN POS:IN POS:JJ POS:NNS POS:VBP POS:IN POS:JJ POS:NNS POS:WP POS:VBP POS:JJ POS:CC POS:JJ POS:NN POS:NNS POS:VBP POS:RB POS:VBG POS:NN POS:NNS POS:, POS:CD POS:, POS:CD POS:IN POS:PRP$ POS:JJ POS:NN POS:IN POS:VBG POS:NN POS:NN POS:CC POS:VBG POS:JJ POS:NNS POS:. 
[sentNum: 257]<Annotation Id="24384" Type="Sentence" StartNode="47973" EndNode="48328">Women in poor health or with severe comorbid conditions and limited life expectancy may also be more vulnerable to harms of screening, including anxiety and discomfort associated with additional testing83- 85 and risk of overdiagnosis (due to increased risk of dying from non–breast cancer–related causes) as well as to harms from breast cancer treatment.86PreferredName:Poor - qualifier SemanticType:[qlco] PreferredName:Women's Health SemanticType:[bmod] PreferredName:Co-morbid conditions SemanticType:[fndg] PreferredName:Severe (severity modifier) SemanticType:[qlco] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:More SemanticType:[ftcn] PreferredName:Anxiety SemanticType:[menp] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Associated with SemanticType:[qlco] PreferredName:Sensory Discomfort SemanticType:[sosy] PreferredName:Risk SemanticType:[qlco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Due to SemanticType:[ftcn] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Risk SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Dying Process SemanticType:[orgf] PreferredName:Relationships SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Good SemanticType:[qlco] PreferredName:Etiology SemanticType:[ftcn] PreferredName:Breast Cancer Therapeutic Procedure SemanticType:[topp] POS:NNS POS:IN POS:JJ POS:NN POS:CC POS:IN POS:JJ POS:JJ POS:NNS POS:CC POS:JJ POS:NN POS:NN POS:MD POS:RB POS:VB POS:RBR POS:JJ POS:TO POS:NNS POS:IN POS:NN POS:, POS:VBG POS:NN POS:CC POS:NN POS:VBN POS:IN POS:JJ POS:NN POS:CD POS:: POS:CD POS:CC POS:NN POS:IN POS:NNS POS:( POS:JJ POS:TO POS:VBN POS:NN POS:IN POS:VBG POS:IN POS:JJ POS:JJ POS:NNS POS:) POS:RB POS:RB POS:IN POS:TO POS:NNS POS:IN POS:NN POS:NN POS:NN POS:. 
[sentNum: 258]<Annotation Id="24385" Type="Sentence" StartNode="48328" EndNode="48427">86- 88 Thus, health and life expectancy, not simply age, must be considered in screening decisions.PreferredName:Health SemanticType:[idcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:consider SemanticType:[idcn] PreferredName:Age SemanticType:[orga] PreferredName:Decision SemanticType:[menp] PreferredName:Disease Screening SemanticType:[diap] POS:CD POS:: POS:CD POS:RB POS:, POS:NN POS:CC POS:NN POS:NN POS:, POS:RB POS:RB POS:NN POS:, POS:MD POS:VB POS:VBN POS:IN POS:NN POS:NNS POS:. 
[sentNum: 259]<Annotation Id="24386" Type="Sentence" StartNode="48429" EndNode="48568">A significant proportion of women 75 years and older are in good health and can be expected to live considerably longer than 10 more years.89PreferredName:Proportion SemanticType:[qnco] PreferredName:Significant SemanticType:[idcn] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:are unit of measure SemanticType:[qnco] PreferredName:Old SemanticType:[tmco] PreferredName:Expected SemanticType:[idcn] PreferredName:Personal Satisfaction SemanticType:[fndg] PreferredName:% live SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:year SemanticType:[tmco] PreferredName:Long SemanticType:[qlco] POS:DT POS:JJ POS:NN POS:IN POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:VBP POS:IN POS:JJ POS:NN POS:CC POS:MD POS:VB POS:VBN POS:TO POS:VB POS:RB POS:RB POS:IN POS:CD POS:JJR POS:NNS POS:. 
[sentNum: 260]<Annotation Id="24387" Type="Sentence" StartNode="48568" EndNode="48708">89 Based on 2010 US Life Tables, approximately 50% of 80-year-old women and 25% of 85-year-old women will live at least 10 years (Figure 2).90PreferredName:2010s SemanticType:[tmco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Approximate SemanticType:[qlco] PreferredName:Life Tables SemanticType:[inpr, qnco] PreferredName:Old SemanticType:[tmco] PreferredName:per year SemanticType:[tmco] PreferredName:per year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:Old SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:% live SemanticType:[qlco] POS:CD POS:VBN POS:IN POS:CD POS:NNP POS:NNP POS:NNP POS:, POS:RB POS:CD POS:NN POS:IN POS:CD POS:: POS:JJ POS:NNS POS:CC POS:CD POS:NN POS:IN POS:CD POS:: POS:JJ POS:NNS POS:MD POS:VB POS:IN POS:JJS POS:CD POS:NNS POS:( POS:NN POS:CD POS:) POS:. 
[sentNum: 261]<Annotation Id="24388" Type="Sentence" StartNode="48708" EndNode="49057">90 Mortality indices that use age, comorbidities, and functional status to predict long-term mortality among community-dwelling older women can be useful for corroborating clinical judgment about the likelihood that an older woman’s life expectancy exceeds 10 years (generally defined as having greater than a 50% probability of surviving 10 years).91PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:&lt;90 SemanticType:[qnco] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:% index SemanticType:[qnco] PreferredName:Comorbidity SemanticType:[idcn] PreferredName:Age SemanticType:[orga] PreferredName:Long-term SemanticType:[tmco] PreferredName:Functional Status SemanticType:[fndg] PreferredName:Community SemanticType:[geoa] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Old SemanticType:[tmco] PreferredName:Home environment SemanticType:[cnce] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Judgment SemanticType:[menp] PreferredName:Clinical SemanticType:[qlco] PreferredName:Old SemanticType:[tmco] PreferredName:Probability SemanticType:[qnco] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Woman SemanticType:[popg] PreferredName:Definition SemanticType:[cnce] PreferredName:year SemanticType:[tmco] PreferredName:Probability SemanticType:[qnco] PreferredName:Greater Than SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:SURVIVE SemanticType:[phsu] POS:CD POS:NNP POS:NNS POS:WDT POS:VBP POS:NN POS:, POS:JJ POS:, POS:CC POS:JJ POS:NN POS:TO POS:VB POS:JJ POS:NN POS:IN POS:JJ POS:JJR POS:NNS POS:MD POS:VB POS:JJ POS:IN POS:VBG POS:JJ POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:JJR POS:NN POS:NN POS:VBZ POS:NN POS:NN POS:VBZ POS:CD POS:NNS POS:( POS:RB POS:VBN POS:IN POS:VBG POS:JJR POS:IN POS:DT POS:CD POS:NN POS:NN POS:IN POS:VBG POS:CD POS:NNS POS:) POS:. 
[sentNum: 262]<Annotation Id="24389" Type="Sentence" StartNode="49057" EndNode="49208">91,92 For women who are healthy and have at least a 10-year life expectancy, individualized decisions about screening mammography should be considered.89PreferredName:Health SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:per year SemanticType:[tmco] PreferredName:Possess SemanticType:[idcn] PreferredName:Individualized SemanticType:[qlco] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Decision SemanticType:[menp] PreferredName:consider SemanticType:[idcn] POS:CD POS:, POS:CD POS:IN POS:NNS POS:WP POS:VBP POS:JJ POS:CC POS:VBP POS:IN POS:JJS POS:DT POS:CD POS:: POS:NN POS:NN POS:NN POS:, POS:JJ POS:NNS POS:IN POS:VBG POS:NN POS:MD POS:VB POS:VBN POS:. 
[sentNum: 263]<Annotation Id="24390" Type="Sentence" StartNode="49208" EndNode="49360">89 Decision aids may help older women make decisions that are informed by an understanding of the potential benefits and harms of screening mammography.89PreferredName:Decision Aids SemanticType:[inpr] PreferredName:Old SemanticType:[tmco] PreferredName:Helping Behavior SemanticType:[socb] PreferredName:Make - Instruction Imperative SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Informed SemanticType:[qlco] PreferredName:Decision SemanticType:[menp] PreferredName:Potential SemanticType:[qlco] PreferredName:Comprehension SemanticType:[menp] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Benefits SemanticType:[qnco] POS:CD POS:JJ POS:NNS POS:MD POS:VB POS:JJR POS:NNS POS:VB POS:NNS POS:WDT POS:VBP POS:VBN POS:IN POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NNS POS:CC POS:NNS POS:IN POS:VBG POS:NN POS:. 
[sentNum: 264]<Annotation Id="24391" Type="Sentence" StartNode="49360" EndNode="49554">89 Given the uncertainty surrounding the harm-benefit trade-off in older women and likely changes in health priorities over time, patient preferences should be weighed in the screening decision. PreferredName:Surrounding (qualifier value) SemanticType:[spco] PreferredName:Uncertainty SemanticType:[idcn] PreferredName:Old SemanticType:[tmco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Probably SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Health Priorities SemanticType:[qlco] PreferredName:Changing SemanticType:[ftcn] PreferredName:Patient Preference SemanticType:[qlco] PreferredName:Time SemanticType:[tmco] PreferredName:Decision SemanticType:[menp] PreferredName:Screening procedure SemanticType:[hlca] POS:CD POS:VBN POS:DT POS:NN POS:VBG POS:DT POS:JJ POS:NN POS:IN POS:JJR POS:NNS POS:CC POS:JJ POS:NNS POS:IN POS:NN POS:NNS POS:IN POS:NN POS:, POS:JJ POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:DT POS:NN POS:NN POS:. 
[sentNum: 265]<Annotation Id="24392" Type="Sentence" StartNode="49555" EndNode="49705">The GDG recommends that women should continue screening as long as their overall health is good and they have a life expectancy of 10 years or longer.PreferredName:Woman SemanticType:[popg] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:Continuous SemanticType:[idcn] PreferredName:Overall SemanticType:[qlco] PreferredName:Long SemanticType:[qlco] PreferredName:Good SemanticType:[qlco] PreferredName:Health SemanticType:[idcn] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:antineoplaston A10 SemanticType:[orch, phsu] PreferredName:Long SemanticType:[qlco] PreferredName:year SemanticType:[tmco] POS:DT POS:NNP POS:VBZ POS:IN POS:NNS POS:MD POS:VB POS:VBG POS:RB POS:RB POS:IN POS:PRP$ POS:JJ POS:NN POS:VBZ POS:JJ POS:CC POS:PRP POS:VBP POS:DT POS:NN POS:NN POS:IN POS:CD POS:NNS POS:CC POS:RBR POS:. 
[sentNum: 266]<Annotation Id="24393" Type="Sentence" StartNode="49707" EndNode="49832">The ACS does not recommend clinical breast examination (CBE) for breast cancer screening among average-risk women at any age. PreferredName:Recommendation SemanticType:[idcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:Woman SemanticType:[popg] POS:DT POS:NNP POS:VBZ POS:RB POS:VB POS:JJ POS:NN POS:NN POS:( POS:NNP POS:) POS:IN POS:NN POS:NN POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:DT POS:NN POS:. 
[sentNum: 267]<Annotation Id="24394" Type="Sentence" StartNode="49833" EndNode="49859">(Qualified Recommendation)PreferredName:Recommendation SemanticType:[idcn] POS:( POS:NN POS:NN POS:) 
[sentNum: 268]<Annotation Id="24395" Type="Sentence" StartNode="49861" EndNode="49958">Previous guideline recommendations for routine CBE have acknowledged the limitations in evidence. PreferredName:Previous SemanticType:[tmco] PreferredName:Routine SemanticType:[qlco] PreferredName:recommendations or guidelines SemanticType:[inpr] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Evidence of SemanticType:[ftcn] POS:JJ POS:JJ POS:NNS POS:IN POS:JJ POS:NNP POS:VBP POS:VBN POS:DT POS:NNS POS:IN POS:NN POS:. 
[sentNum: 269]<Annotation Id="24396" Type="Sentence" StartNode="49959" EndNode="50104">For Key Question 3, the evidence review found a lack of evidence showing any benefit of a CBE alone or in conjunction with screening mammography. PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Review [Publication Type] SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Lacking SemanticType:[qlco] PreferredName:Present SemanticType:[qnco] PreferredName:Show SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Any SemanticType:[qlco] PreferredName:alone - group size SemanticType:[grpa] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Conjunction SemanticType:[idcn] POS:IN POS:NNP POS:NNP POS:CD POS:, POS:DT POS:NN POS:NN POS:VBD POS:DT POS:NN POS:IN POS:NN POS:VBG POS:DT POS:NN POS:IN POS:DT POS:NNP POS:RB POS:CC POS:IN POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 270]<Annotation Id="24397" Type="Sentence" StartNode="50105" EndNode="50215">There is moderate-quality evidence that adding CBE to mammography screening increased the false-positive rate. PreferredName:Quality SemanticType:[qlco] PreferredName:Moderation SemanticType:[qlco] PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:False Discovery Rate SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] POS:EX POS:VBZ POS:JJ POS:NN POS:IN POS:VBG POS:NNP POS:TO POS:NN POS:NN POS:VBD POS:DT POS:JJ POS:NN POS:. 
[sentNum: 271]<Annotation Id="24398" Type="Sentence" StartNode="50216" EndNode="50277">No studies were identified assessing other critical outcomes. PreferredName:Identified SemanticType:[qlco] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Critical SemanticType:[qlco] PreferredName:Assessed SemanticType:[acty] PreferredName:Result SemanticType:[ftcn] POS:DT POS:NNS POS:VBD POS:VBN POS:VBG POS:JJ POS:JJ POS:NNS POS:. 
[sentNum: 272]<Annotation Id="24399" Type="Sentence" StartNode="50278" EndNode="50499">A supplemental search identified studies on CBE performance characteristics, most of which show that the addition of CBE will detect a small number of additional breast cancers (ie, 2%-6%) compared with mammography alone.93PreferredName:Supplement SemanticType:[ftcn] PreferredName:Identified SemanticType:[qlco] PreferredName:Search - action SemanticType:[acty] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Study Characteristics SemanticType:[inpr] PreferredName:Most SemanticType:[qnco] PreferredName:Performance SemanticType:[inbe] PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Show SemanticType:[inpr] PreferredName:Detected (finding) SemanticType:[fndg] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Numbers SemanticType:[qnco] PreferredName:A little bit SemanticType:[inpr] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Additional SemanticType:[ftcn] PreferredName:Comparison SemanticType:[acty] PreferredName:Integer +2 SemanticType:[qnco] PreferredName:alone - group size SemanticType:[grpa] PreferredName:Mammography SemanticType:[diap] POS:DT POS:JJ POS:NN POS:VBD POS:NNS POS:IN POS:NNP POS:NN POS:NNS POS:, POS:JJS POS:IN POS:WDT POS:VBP POS:IN POS:DT POS:NN POS:IN POS:NNP POS:MD POS:VB POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:NNS POS:( POS:NNP POS:, POS:CD POS:NN POS:, POS:CD POS:NN POS:) POS:VBN POS:IN POS:NN POS:RB POS:. 
[sentNum: 273]<Annotation Id="24400" Type="Sentence" StartNode="50499" EndNode="50574">93- 95 There are no data on whether patient outcomes are improved with CBE. PreferredName:Patient Outcome SemanticType:[idcn] PreferredName:No Information Available SemanticType:[qlco] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Better SemanticType:[qlco] POS:CD POS:: POS:CD POS:RB POS:VBP POS:DT POS:NN POS:IN POS:IN POS:JJ POS:NNS POS:VBP POS:VBN POS:IN POS:NNP POS:. 
[sentNum: 274]<Annotation Id="24401" Type="Sentence" StartNode="50575" EndNode="50756">Given the lack of benefit concurrent with the increase in false-positive rates, CBE is not recommended for breast cancer screening among average-risk, asymptomatic women at any age. PreferredName:Lacking SemanticType:[qlco] PreferredName:GIVEN SemanticType:[cnce] PreferredName:Concurrent SemanticType:[tmco] PreferredName:Benefits SemanticType:[qnco] PreferredName:False Discovery Rate SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Asymptomatic SemanticType:[fndg] PreferredName:Age SemanticType:[orga] POS:VBN POS:DT POS:NN POS:IN POS:NN POS:JJ POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:, POS:NNP POS:VBZ POS:RB POS:VBN POS:IN POS:NN POS:NN POS:NN POS:IN POS:JJ POS:, POS:JJ POS:NNS POS:IN POS:DT POS:NN POS:. 
[sentNum: 275]<Annotation Id="24402" Type="Sentence" StartNode="50757" EndNode="51044">Recognizing the time constraints in a typical clinic visit, clinicians should use this time instead for ascertaining family history and counseling women regarding the importance of being alert to breast changes and the potential benefits, limitations, and harms of screening mammography.PreferredName:Time SemanticType:[tmco] PreferredName:Usual SemanticType:[qlco] PreferredName:Restricted SemanticType:[ftcn] PreferredName:Clinician SemanticType:[prog] PreferredName:Clinic Visits SemanticType:[hlca] PreferredName:This SemanticType:[euka] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:Family History Domain SemanticType:[idcn] PreferredName:Time SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Counseling SemanticType:[hlca] PreferredName:Breast changes SemanticType:[fndg] PreferredName:Consciousness clear SemanticType:[fndg] PreferredName:Benefits SemanticType:[qnco] PreferredName:Potential SemanticType:[qlco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Limitation SemanticType:[ftcn] POS:VBG POS:DT POS:NN POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:NN POS:, POS:NNS POS:MD POS:VB POS:DT POS:NN POS:RB POS:IN POS:VBG POS:NN POS:NN POS:CC POS:NN POS:NNS POS:VBG POS:DT POS:NN POS:IN POS:VBG POS:JJ POS:TO POS:NN POS:NNS POS:CC POS:DT POS:JJ POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:IN POS:NN POS:NN POS:. 
[sentNum: 276]<Annotation Id="24403" Type="Sentence" StartNode="51046" EndNode="51216">Even though a substantial proportion of breast cancers are self-detected, the relative contributions of a systematic self-examination vs incidental discovery are unknown. PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Proportion SemanticType:[qnco] PreferredName:Detection SemanticType:[topp] PreferredName:subscriber - self SemanticType:[inpr] PreferredName:Contribution SemanticType:[acty] PreferredName:Relative SemanticType:[qlco] PreferredName:Self-Examination SemanticType:[diap] PreferredName:systematic SemanticType:[ftcn] PreferredName:Unknown SemanticType:[qlco] PreferredName:Incidental Discovery SemanticType:[fndg] POS:RB POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NNS POS:VBP POS:VBN POS:, POS:DT POS:JJ POS:NNS POS:IN POS:DT POS:JJ POS:JJ POS:JJ POS:JJ POS:NN POS:VBP POS:JJ POS:. 
[sentNum: 277]<Annotation Id="24404" Type="Sentence" StartNode="51217" EndNode="51427">Given the absence of evidence of improved outcomes associated with self-examination, the 2003 ACS guideline did not include a recommendation for routine performance of or instruction in breast self-examination. PreferredName:Absent SemanticType:[qnco] PreferredName:Given name SemanticType:[inpr] PreferredName:Better SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Associated with SemanticType:[qlco] PreferredName:Result SemanticType:[ftcn] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Self-Examination SemanticType:[diap] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Routine SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Educational process of instructing SemanticType:[edac] PreferredName:Performance SemanticType:[inbe] PreferredName:Breast Self-Examination SemanticType:[diap] POS:VBN POS:DT POS:NN POS:IN POS:NN POS:IN POS:VBN POS:NNS POS:VBN POS:IN POS:NN POS:, POS:DT POS:CD POS:NN POS:NN POS:VBD POS:RB POS:VB POS:DT POS:NN POS:IN POS:JJ POS:NN POS:IN POS:CC POS:CD POS:IN POS:NN POS:NN POS:. 
[sentNum: 278]<Annotation Id="24405" Type="Sentence" StartNode="51428" EndNode="51528">No new studies have been reported in recent years that warranted reconsideration of that conclusion.PreferredName:New SemanticType:[tmco] PreferredName:Report (document) SemanticType:[inpr] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:year SemanticType:[tmco] PreferredName:Recent SemanticType:[tmco] PreferredName:Conclusion SemanticType:[idcn] POS:DT POS:JJ POS:NNS POS:VBP POS:VBN POS:VBN POS:IN POS:JJ POS:NNS POS:IN POS:VBN POS:NN POS:IN POS:DT POS:NN POS:. 
[sentNum: 279]<Annotation Id="24406" Type="Sentence" StartNode="51530" EndNode="51745">There are invariably gaps between the available evidence and the evidence needed for the development of guidelines that precisely quantify and weigh the benefits vs the harms associated with breast cancer screening.96PreferredName:Availability of SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Development SemanticType:[ftcn] PreferredName:Needs SemanticType:[qlco] PreferredName:Quantitation SemanticType:[qnco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Associated with SemanticType:[qlco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] POS:EX POS:VBP POS:RB POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:CC POS:DT POS:NN POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:WDT POS:RB POS:VB POS:CC POS:VB POS:DT POS:NNS POS:VBP POS:DT POS:NNS POS:VBN POS:IN POS:NN POS:NN POS:NN POS:. 
[sentNum: 280]<Annotation Id="24407" Type="Sentence" StartNode="51745" EndNode="51896">96 The GDG synthesized evidence from a variety of sources, including the RCTs, observational studies of modern service screening, and modeling studies. PreferredName:Synthesis SemanticType:[acty] PreferredName:Assortment SemanticType:[cnce] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Source SemanticType:[fndg] PreferredName:Services SemanticType:[ocac] PreferredName:Observational Study SemanticType:[resa] PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Scientific Study SemanticType:[lbpr] POS:NNP POS:DT POS:NNP POS:VBD POS:NN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:, POS:VBG POS:DT POS:NNP POS:, POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:, POS:CC POS:NN POS:NNS POS:. 
[sentNum: 281]<Annotation Id="24408" Type="Sentence" StartNode="51897" EndNode="51957">Still, even after broadening the evidence base, gaps remain. PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Base SemanticType:[chvf] POS:RB POS:, POS:RB POS:IN POS:VBG POS:DT POS:JJ POS:NN POS:, POS:NNS POS:VBP POS:. 
[sentNum: 282]<Annotation Id="24409" Type="Sentence" StartNode="51958" EndNode="52144">Empirical comparisons of screening programs that differ in terms of their ages to start and stop screening, and in their intervals between screening examinations, generally were lacking. PreferredName:Empiric SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Comparison SemanticType:[acty] PreferredName:Term (temporal) SemanticType:[tmco] PreferredName:Programs - Publication Format SemanticType:[inpr] PreferredName:Beginning SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Stop (qualifier value) SemanticType:[tmco] PreferredName:Interval SemanticType:[tmco] PreferredName:And SemanticType:[idcn] PreferredName:Lacking SemanticType:[qlco] PreferredName:Screening Examination SemanticType:[diap] POS:JJ POS:NNS POS:IN POS:NN POS:NNS POS:WDT POS:VBP POS:IN POS:NNS POS:IN POS:PRP$ POS:NNS POS:TO POS:VB POS:CC POS:VB POS:NN POS:, POS:CC POS:IN POS:PRP$ POS:NNS POS:IN POS:NN POS:NNS POS:, POS:RB POS:VBD POS:VBG POS:. 
[sentNum: 283]<Annotation Id="24410" Type="Sentence" StartNode="52145" EndNode="52369">Further, most breast screening studies did not provide estimates of benefits and harms over a lifetime horizon, which is important when considering policies that will span several decades or more of an individual’s lifetime. PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Further SemanticType:[spco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Screening Study SemanticType:[resa] PreferredName:Estimated SemanticType:[qnco] PreferredName:Providing (action) SemanticType:[acty] PreferredName:consider SemanticType:[idcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Span - parameter SemanticType:[cnce] PreferredName:Policy SemanticType:[inpr] PreferredName:Decade SemanticType:[qnco] PreferredName:Numerous SemanticType:[qnco] PreferredName:Persons SemanticType:[popg] PreferredName:More SemanticType:[ftcn] POS:RB POS:, POS:JJS POS:NN POS:NN POS:NNS POS:VBD POS:RB POS:VB POS:NNS POS:IN POS:NNS POS:CC POS:NNS POS:IN POS:DT POS:NN POS:NN POS:, POS:WDT POS:VBZ POS:JJ POS:WRB POS:VBG POS:NNS POS:WDT POS:MD POS:VB POS:JJ POS:NNS POS:CC POS:JJR POS:IN POS:DT POS:JJ POS:NN POS:VBZ POS:NN POS:. 
[sentNum: 284]<Annotation Id="24411" Type="Sentence" StartNode="52370" EndNode="52511">The value and applicability of meta-analysis of mammography screening RCTs to guide current health policy also should be kept in perspective. PreferredName:Not Applicable SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Professional guide SemanticType:[prog] PreferredName:Retained SemanticType:[ftcn] PreferredName:Health Policy SemanticType:[rnlw] POS:DT POS:NN POS:CC POS:NN POS:IN POS:NNS POS:IN POS:NN POS:NN POS:NNS POS:TO POS:VB POS:JJ POS:NN POS:NN POS:RB POS:MD POS:VB POS:VBN POS:IN POS:NN POS:. 
[sentNum: 285]<Annotation Id="24412" Type="Sentence" StartNode="52512" EndNode="52750">While the RCT evidence demonstrated the efficacy of mammography screening, these studies were conducted from the 1960s through the 1990s with varying protocols, most using older screen-film systems and often using single-view mammography. PreferredName:Efficacy Study SemanticType:[resa] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Screening mammography SemanticType:[topp] PreferredName:1960s SemanticType:[tmco] PreferredName:Behavior SemanticType:[inbe] PreferredName:1990s SemanticType:[tmco] PreferredName:Through SemanticType:[ftcn] PreferredName:Most SemanticType:[qnco] PreferredName:Protocols documentation SemanticType:[inpr] PreferredName:Old SemanticType:[tmco] PreferredName:Use of SemanticType:[ftcn] PreferredName:film - layer SemanticType:[sbst] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Frequent SemanticType:[tmco] PreferredName:System SemanticType:[ftcn] PreferredName:Singular SemanticType:[qnco] PreferredName:Use of SemanticType:[ftcn] PreferredName:Mammography SemanticType:[diap] PreferredName:View SemanticType:[spco] POS:IN POS:DT POS:NNP POS:NN POS:VBD POS:DT POS:NN POS:IN POS:NN POS:NN POS:, POS:DT POS:NNS POS:VBD POS:VBN POS:IN POS:DT POS:CD POS:NNS POS:IN POS:DT POS:CD POS:NNS POS:IN POS:VBG POS:NNS POS:, POS:RBS POS:VBG POS:JJR POS:NN POS:NNS POS:CC POS:RB POS:VBG POS:NN POS:NN POS:. 
[sentNum: 286]<Annotation Id="24413" Type="Sentence" StartNode="52751" EndNode="53055">The RCTs demonstrated a range of outcomes in terms of mortality reductions and, importantly, in terms of the degree to which an invitation to screening was associated with a reduced risk of being diagnosed with an advanced breast cancer, which is strongly associated with reduced breast cancer mortality.97PreferredName:Result SemanticType:[ftcn] PreferredName:Sample Range SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Term (temporal) SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Invitation SemanticType:[inpr] PreferredName:Reduced SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Risk SemanticType:[qlco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Advanced Malignant Neoplasm SemanticType:[neop] PreferredName:Reduced SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:DT POS:NNPS POS:VBD POS:DT POS:NN POS:IN POS:NNS POS:IN POS:NNS POS:IN POS:NN POS:NNS POS:CC POS:, POS:UH POS:, POS:IN POS:NNS POS:IN POS:DT POS:NN POS:TO POS:WDT POS:DT POS:NN POS:TO POS:NN POS:VBD POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:VBN POS:IN POS:DT POS:VBN POS:NN POS:NN POS:, POS:WDT POS:VBZ POS:RB POS:VBN POS:IN POS:JJ POS:NN POS:NN POS:NN POS:. 
[sentNum: 287]<Annotation Id="24414" Type="Sentence" StartNode="53055" EndNode="53235">97 Overall and age-specific mortality reduction estimates derived from meta-analysis of intention-to-treat results do not reveal these differences in the performance of the trials. PreferredName:Overall SemanticType:[qlco] PreferredName:Arabic numeral 97 SemanticType:[inpr] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Age-Specific Death Rate SemanticType:[qnco] PreferredName:Derivation SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:intent SemanticType:[qlco] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Treatment intent SemanticType:[ftcn] PreferredName:Revealed SemanticType:[qlco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Delta (difference) SemanticType:[qnco] PreferredName:Theses SemanticType:[inpr] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Performance SemanticType:[inbe] POS:CD POS:RB POS:CC POS:JJ POS:NN POS:NN POS:NNS POS:VBN POS:IN POS:NNS POS:IN POS:NN POS:NNS POS:VBP POS:RB POS:VB POS:DT POS:NNS POS:IN POS:DT POS:NN POS:IN POS:DT POS:NNS POS:. 
[sentNum: 288]<Annotation Id="24415" Type="Sentence" StartNode="53236" EndNode="53385">In addition, RCT estimates based on intention-to-treat analyses are influenced by nonadherence to the protocol by both the invited and control group. PreferredName:Estimated SemanticType:[qnco] PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:intent SemanticType:[qlco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Analysis of substances SemanticType:[lbpr] PreferredName:Treatment intent SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Non Adherence SemanticType:[fndg] PreferredName:Control Groups SemanticType:[grup] PreferredName:Library Protocol SemanticType:[inpr] POS:IN POS:NN POS:, POS:NNP POS:NNS POS:VBN POS:IN POS:NN POS:NNS POS:VBP POS:VBN POS:IN POS:NN POS:TO POS:DT POS:NN POS:IN POS:PDT POS:DT POS:JJ POS:CC POS:NN POS:NN POS:. 
[sentNum: 289]<Annotation Id="24416" Type="Sentence" StartNode="53386" EndNode="53637">In these respects, meta-analysis results are a sound basis for judging the efficacy of mammography screening, but a poor basis for estimating the effectiveness of modern, high-quality screening, especially when calculating absolute benefits and harms.PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:respect SemanticType:[socb] PreferredName:Sound - physical agent SemanticType:[npop] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Judge SemanticType:[prog] PreferredName:Basis SemanticType:[phsu] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Efficacy Study SemanticType:[resa] PreferredName:Basis SemanticType:[phsu] PreferredName:Poor - qualifier SemanticType:[qlco] PreferredName:Effectiveness SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Quality SemanticType:[qlco] PreferredName:Value Above Reference Range SemanticType:[inpr] PreferredName:Calculation SemanticType:[acty] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Benefits SemanticType:[qnco] PreferredName:Absolute SemanticType:[qlco] POS:IN POS:DT POS:NNS POS:, POS:JJ POS:NNS POS:VBP POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:DT POS:NN POS:IN POS:JJ POS:NN POS:, POS:CC POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:DT POS:NN POS:IN POS:JJ POS:, POS:JJ POS:NN POS:, POS:RB POS:WRB POS:VBG POS:JJ POS:NNS POS:CC POS:NNS POS:. 
[sentNum: 290]<Annotation Id="24417" Type="Sentence" StartNode="53639" EndNode="53782">In evidence reviews, RCTs are favored over other study designs for their theoretical ability to provide the least biased estimates of efficacy.98PreferredName:Review [Publication Type] SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Research Design SemanticType:[resa] PreferredName:FAVOR SemanticType:[orch, phsu, vita] PreferredName:Ability SemanticType:[orga] PreferredName:Theory SemanticType:[idcn] PreferredName:Biases SemanticType:[idcn] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Efficacy Study SemanticType:[resa] PreferredName:Estimated SemanticType:[qnco] POS:IN POS:NN POS:NNS POS:, POS:NNP POS:VBP POS:VBN POS:IN POS:JJ POS:NN POS:NNS POS:IN POS:PRP$ POS:JJ POS:NN POS:TO POS:VB POS:DT POS:JJS POS:JJ POS:NNS POS:IN POS:NN POS:. 
[sentNum: 291]<Annotation Id="24418" Type="Sentence" StartNode="53782" EndNode="54046">98 However, deriving estimates of absolute benefit from the RCTs means these estimates are based on invitation to screening (NNI) rather than exposure to screening and therefore are contaminated by deaths from women in the study group who did not attend screening. PreferredName:Estimated SemanticType:[qnco] PreferredName:Deriving SemanticType:[qlco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Absolute SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Means SemanticType:[cnce] PreferredName:Invitation SemanticType:[inpr] PreferredName:Basis - conceptual entity SemanticType:[ftcn] PreferredName:Exposure to SemanticType:[clna] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Contamination SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:From SemanticType:[qlco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Study SemanticType:[resa] PreferredName:Women's Groups SemanticType:[popg] PreferredName:Attending (action) SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] POS:CD POS:RB POS:, POS:VBG POS:NNS POS:IN POS:JJ POS:NN POS:IN POS:DT POS:NNPS POS:VBZ POS:DT POS:NNS POS:VBP POS:VBN POS:IN POS:NN POS:TO POS:NN POS:( POS:NNP POS:) POS:RB POS:IN POS:NN POS:TO POS:NN POS:CC POS:RB POS:VBP POS:VBN POS:IN POS:NNS POS:IN POS:NNS POS:IN POS:DT POS:NN POS:NN POS:WP POS:VBD POS:RB POS:VB POS:NN POS:. 
[sentNum: 292]<Annotation Id="24419" Type="Sentence" StartNode="54047" EndNode="54305">Thus, it is preferable to regard the RCTs as providing the foundation on which mortality outcomes based on exposure to screening (NNS) from well-designed observational studies and evaluations of modern service screening can be viewed with greater confidence.PreferredName:Providing (action) SemanticType:[acty] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Foundations SemanticType:[orgt] PreferredName:Basis - conceptual entity SemanticType:[ftcn] PreferredName:Result SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Exposure to SemanticType:[clna] PreferredName:Design SemanticType:[acty] PreferredName:Good SemanticType:[qlco] PreferredName:Assessment service SemanticType:[hcro] PreferredName:Observational Study SemanticType:[resa] PreferredName:View SemanticType:[spco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Statistical Confidence SemanticType:[qlco] PreferredName:Largest SemanticType:[qnco] POS:RB POS:, POS:PRP POS:VBZ POS:JJ POS:TO POS:VB POS:DT POS:NNPS POS:IN POS:VBG POS:DT POS:NN POS:IN POS:WDT POS:NN POS:NNS POS:VBN POS:IN POS:NN POS:TO POS:NN POS:( POS:NNP POS:) POS:IN POS:JJ POS:JJ POS:NNS POS:CC POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:MD POS:VB POS:VBN POS:IN POS:JJR POS:NN POS:. 
[sentNum: 293]<Annotation Id="24420" Type="Sentence" StartNode="54307" EndNode="54438">However, observational studies require methodological scrutiny, because they are subject to known and unknown bias and confounding. PreferredName:Methodology aspects SemanticType:[inpr] PreferredName:Observational Study SemanticType:[resa] PreferredName:Study Subject SemanticType:[grup] PreferredName:are unit of measure SemanticType:[qnco] PreferredName:Unknown SemanticType:[qlco] PreferredName:Known SemanticType:[qlco] PreferredName:Biases SemanticType:[idcn] POS:RB POS:, POS:JJ POS:NNS POS:VBP POS:JJ POS:NN POS:, POS:IN POS:PRP POS:VBP POS:JJ POS:TO POS:VBN POS:CC POS:JJ POS:NN POS:CC POS:NN POS:. 
[sentNum: 294]<Annotation Id="24421" Type="Sentence" StartNode="54439" EndNode="54757">For example, comparison groups may be dissimilar in important ways that are not apparent, and there may be differential ascertainment of screening histories, quality of treatment, differences in selection bias, and other differences in the characteristics of exposed and unexposed persons that could influence results. PreferredName:Example SemanticType:[cnce] PreferredName:Population Group SemanticType:[popg] PreferredName:Comparison SemanticType:[acty] PreferredName:Negation SemanticType:[ftcn] PreferredName:Dissimilar SemanticType:[qlco] PreferredName:Differential quality SemanticType:[qlco] PreferredName:apparent SemanticType:[idcn] PreferredName:History SemanticType:[ocdi] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Quality SemanticType:[qlco] PreferredName:Selection Bias SemanticType:[qnco] PreferredName:Different SemanticType:[qlco] PreferredName:Different SemanticType:[qlco] PreferredName:Other SemanticType:[qlco] PreferredName:Exposure to SemanticType:[clna] PreferredName:Characteristics SemanticType:[qlco] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Persons SemanticType:[popg] POS:IN POS:NN POS:, POS:NN POS:NNS POS:MD POS:VB POS:JJ POS:IN POS:JJ POS:NNS POS:WDT POS:VBP POS:RB POS:JJ POS:, POS:CC POS:EX POS:MD POS:VB POS:NN POS:NN POS:IN POS:NN POS:NNS POS:, POS:NN POS:IN POS:NN POS:, POS:NNS POS:IN POS:NN POS:NN POS:, POS:CC POS:JJ POS:NNS POS:IN POS:DT POS:NNS POS:IN POS:JJ POS:CC POS:JJ POS:NNS POS:WDT POS:MD POS:VB POS:NNS POS:. 
[sentNum: 295]<Annotation Id="24422" Type="Sentence" StartNode="54758" EndNode="54960">With careful attention to possible threats to validity,29,99,100 observational studies can provide evidence about the association between screening and outcomes among women who are exposed to screening. PreferredName:care activity SemanticType:[acty] PreferredName:In addition to SemanticType:[qlco] PreferredName:Possibly Related to Intervention SemanticType:[qlco] PreferredName:Attention SemanticType:[menp] PreferredName:Validity (characteristic) SemanticType:[qnco] PreferredName:threat SemanticType:[idcn] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Observational Study SemanticType:[resa] PreferredName:Relationships SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Result SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Exposure to SemanticType:[clna] PreferredName:Woman SemanticType:[popg] PreferredName:Disease Screening SemanticType:[diap] POS:IN POS:JJ POS:NN POS:TO POS:JJ POS:NNS POS:TO POS:NNP POS:, POS:CD POS:, POS:CD POS:, POS:CD POS:JJ POS:NNS POS:MD POS:VB POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:CC POS:NNS POS:IN POS:NNS POS:WP POS:VBP POS:VBN POS:TO POS:NN POS:. 
[sentNum: 296]<Annotation Id="24423" Type="Sentence" StartNode="54961" EndNode="55321">For this reason, the GDG considered observational studies of modern service screening (ie, organized, population-based screening) because these studies tend to demonstrate results that are consistent with the RCTs, while better reflecting contemporary screening protocols and providing evidence on both benefits and harms associated with exposure to screening.PreferredName:Indication of (contextual qualifier) SemanticType:[idcn] PreferredName:Observation - diagnostic procedure SemanticType:[diap] PreferredName:consider SemanticType:[idcn] PreferredName:Screening Study SemanticType:[resa] PreferredName:Services SemanticType:[ocac] PreferredName:Population Group SemanticType:[popg] PreferredName:Organized SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Consistent with SemanticType:[idcn] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Reflecting SemanticType:[menp] PreferredName:Better SemanticType:[qlco] PreferredName:Protocols documentation SemanticType:[inpr] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Associated with SemanticType:[qlco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Exposure to SemanticType:[clna] POS:IN POS:DT POS:NN POS:, POS:DT POS:NNP POS:VBD POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:( POS:NN POS:, POS:JJ POS:, POS:JJ POS:NN POS:) POS:IN POS:DT POS:NNS POS:VBP POS:TO POS:VB POS:NNS POS:WDT POS:VBP POS:JJ POS:IN POS:DT POS:NNPS POS:, POS:IN POS:RBR POS:VBG POS:JJ POS:NN POS:NNS POS:CC POS:VBG POS:NN POS:IN POS:DT POS:NNS POS:CC POS:NNS POS:VBN POS:IN POS:NN POS:TO POS:NN POS:. 
[sentNum: 297]<Annotation Id="24424" Type="Sentence" StartNode="55323" EndNode="55470">Breast cancer treatment has improved over time, leading some to question whether or not advances in therapy have rendered screening less important.101PreferredName:Better SemanticType:[qlco] PreferredName:Breast Cancer Therapeutic Procedure SemanticType:[topp] PreferredName:Leading SemanticType:[ftcn] PreferredName:Time SemanticType:[tmco] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:To SemanticType:[qlco] PreferredName:Advance SemanticType:[medd] PreferredName:Negation SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Less Than SemanticType:[inpr] POS:JJ POS:NN POS:NN POS:VBZ POS:VBN POS:IN POS:NN POS:, POS:VBG POS:DT POS:TO POS:VB POS:IN POS:CC POS:RB POS:NNS POS:IN POS:NN POS:VBP POS:VBN POS:VBG POS:RBR POS:JJ POS:. 
[sentNum: 298]<Annotation Id="24425" Type="Sentence" StartNode="55470" EndNode="55549">101 There is little evidence from any study design to support this speculation. PreferredName:Small SemanticType:[qnco] PreferredName:Research Design SemanticType:[resa] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Support, device SemanticType:[medd] POS:CD POS:RB POS:VBZ POS:JJ POS:NN POS:IN POS:DT POS:NN POS:NN POS:TO POS:VB POS:DT POS:NN POS:. 
[sentNum: 299]<Annotation Id="24426" Type="Sentence" StartNode="55550" EndNode="55801">Berry et al4 modeled the relative contributions of screening vs treatment and estimated that approximately half of the reduction in US breast cancer mortality was associated with screening and half was associated with improvements in adjuvant therapy. PreferredName:Berries SemanticType:[food] PreferredName:Model SemanticType:[inpr] PreferredName:GAGE7 wt Allele SemanticType:[gngm] PreferredName:Contribution SemanticType:[acty] PreferredName:Relative SemanticType:[qlco] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Approximate SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Half SemanticType:[qnco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Associated with SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Half SemanticType:[qnco] PreferredName:adjuvant therapy SemanticType:[topp] PreferredName:Improvement SemanticType:[cnce] POS:NNP POS:NNP POS:NNP POS:CD POS:VBD POS:DT POS:JJ POS:NNS POS:IN POS:VBG POS:NN POS:NN POS:CC POS:VBD POS:IN POS:RB POS:NN POS:IN POS:DT POS:NN POS:IN POS:NNP POS:NN POS:NN POS:NN POS:VBD POS:VBN POS:IN POS:NN POS:CC POS:NN POS:VBD POS:VBN POS:IN POS:NNS POS:IN POS:NN POS:NN POS:. 
[sentNum: 300]<Annotation Id="24427" Type="Sentence" StartNode="55802" EndNode="55936">Higher fractions of the mortality reductions associated with screening have been estimated by other evaluations of screening programs.64PreferredName:Fraction of SemanticType:[qnco] PreferredName:Decrease in height SemanticType:[fndg] PreferredName:Associated with SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Program Evaluation SemanticType:[ocac] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:JJ POS:NNS POS:IN POS:DT POS:NN POS:NNS POS:VBN POS:IN POS:NN POS:VBP POS:VBN POS:VBN POS:IN POS:JJ POS:NNS POS:IN POS:NN POS:NNS POS:. 
[sentNum: 301]<Annotation Id="24428" Type="Sentence" StartNode="55936" EndNode="56213">64,102,103 While emphasis on the question of the relative contributions of therapy vs screening typically focuses on advances in treatment, it also is the case that substantial improvements in imaging technology and quality assurance have occurred over the past 30 to 40 years. PreferredName:Relative SemanticType:[qlco] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Contribution SemanticType:[acty] PreferredName:Focal SemanticType:[spco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Within SemanticType:[spco] PreferredName:Advance SemanticType:[medd] PreferredName:Clinical Study Case SemanticType:[cnce] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Imaging Technology SemanticType:[bmod] PreferredName:Improvement SemanticType:[cnce] PreferredName:Occur (action) SemanticType:[acty] PreferredName:quality assurance SemanticType:[ocac] PreferredName:/40 SemanticType:[tmco] PreferredName:Past SemanticType:[tmco] PreferredName:year SemanticType:[tmco] POS:CD POS:, POS:CD POS:, POS:CD POS:IN POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:NN POS:RB POS:VBZ POS:IN POS:NNS POS:IN POS:NN POS:, POS:PRP POS:RB POS:VBZ POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:CC POS:NN POS:NN POS:VBP POS:VBN POS:IN POS:DT POS:JJ POS:CD POS:TO POS:CD POS:NNS POS:. 
[sentNum: 302]<Annotation Id="24429" Type="Sentence" StartNode="56214" EndNode="56466">Screen-film systems improved over time, and these mostly have been replaced by full-field digital mammography units, resulting in further improvements in imaging performance, particularly for younger women and women with mammographically dense breasts.75PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:System SemanticType:[ftcn] PreferredName:film (photographic) SemanticType:[mnob] PreferredName:Time SemanticType:[tmco] PreferredName:Better SemanticType:[qlco] PreferredName:Replaced by SemanticType:[ftcn] PreferredName:mostly SemanticType:[idcn] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Full field SemanticType:[spco] PreferredName:Resulting in SemanticType:[ftcn] PreferredName:Unit of Measure SemanticType:[qnco] PreferredName:Improvement SemanticType:[cnce] PreferredName:Further SemanticType:[spco] PreferredName:Performance SemanticType:[inbe] PreferredName:Imaging Techniques SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Young SemanticType:[tmco] PreferredName:Dense SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Digital breast tomosynthesis SemanticType:[diap] POS:JJ POS:NNS POS:VBD POS:IN POS:NN POS:, POS:CC POS:DT POS:RB POS:VBP POS:VBN POS:VBN POS:IN POS:JJ POS:JJ POS:NN POS:NNS POS:, POS:VBG POS:IN POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:, POS:RB POS:IN POS:JJR POS:NNS POS:CC POS:NNS POS:IN POS:JJ POS:JJ POS:NNS POS:. 
[sentNum: 303]<Annotation Id="24430" Type="Sentence" StartNode="56466" EndNode="56690">75 Accumulating data on digital breast tomosynthesis (DBT) appear to demonstrate further improvements in accuracy (both sensitivity and specificity),104 and DBT is steadily increasing in prevalence in mammography facilities. PreferredName:Data SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Appearance SemanticType:[qlco] PreferredName:Improvement SemanticType:[cnce] PreferredName:Further SemanticType:[spco] PreferredName:Sensitivity and Specificity SemanticType:[qnco] PreferredName:Accurate (qualifier) SemanticType:[qlco] PreferredName:Digital breast tomosynthesis SemanticType:[diap] PreferredName:Data SemanticType:[idcn] PreferredName:Prevalence aspects SemanticType:[qnco] PreferredName:Increasing SemanticType:[ftcn] PreferredName:Facility SemanticType:[idcn] PreferredName:Mammography SemanticType:[diap] POS:CD POS:NNP POS:NNS POS:IN POS:JJ POS:NN POS:NNS POS:( POS:NNP POS:) POS:VBP POS:TO POS:VB POS:JJ POS:NNS POS:IN POS:NN POS:( POS:DT POS:NN POS:CC POS:NN POS:) POS:, POS:NNP POS:CC POS:NNP POS:VBZ POS:RB POS:VBG POS:IN POS:NN POS:IN POS:NN POS:NNS POS:. 
[sentNum: 304]<Annotation Id="24431" Type="Sentence" StartNode="56691" EndNode="56798">At this time, both early detection and modern therapy have important roles in the control of breast cancer. PreferredName:Early Diagnosis SemanticType:[diap] PreferredName:Time SemanticType:[tmco] PreferredName:Social Role SemanticType:[socb] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Scientific Control SemanticType:[cnce] POS:IN POS:DT POS:NN POS:, POS:CC POS:JJ POS:NN POS:CC POS:JJ POS:NN POS:VBP POS:JJ POS:NNS POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 305]<Annotation Id="24432" Type="Sentence" StartNode="56799" EndNode="56921">The GDG did not attempt to disentangle the relative contribution of screening vs therapy in reducing breast cancer deaths.PreferredName:Attempt SemanticType:[evnt] PreferredName:Negation SemanticType:[ftcn] PreferredName:Relative SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Contribution SemanticType:[acty] PreferredName:Breast Cancer Therapeutic Procedure SemanticType:[topp] PreferredName:Reduced SemanticType:[qlco] PreferredName:Cessation of life SemanticType:[orgf] POS:DT POS:NNP POS:VBD POS:RB POS:VB POS:TO POS:VB POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:JJ POS:NN POS:IN POS:VBG POS:NN POS:NN POS:NNS POS:. 
[sentNum: 306]<Annotation Id="24433" Type="Sentence" StartNode="56923" EndNode="57263">The GDG did not formally compare the performance of screen-film mammography with full-field digital mammography, apart from noting that digital systems have been shown to have improved sensitivity in younger women and women with mammographically dense breasts75,105 and new data showing slightly worse specificity in younger vs older women.65PreferredName:Negation SemanticType:[ftcn] PreferredName:performance - action SemanticType:[acty] PreferredName:Comparison SemanticType:[acty] PreferredName:Film Mammography SemanticType:[diap] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Full field SemanticType:[spco] PreferredName:Digital SemanticType:[qlco] PreferredName:Note (document) SemanticType:[inpr] PreferredName:Show SemanticType:[inpr] PreferredName:System SemanticType:[ftcn] PreferredName:Better SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Young SemanticType:[tmco] PreferredName:Statistical sensitivity SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:New SemanticType:[tmco] PreferredName:Dense SemanticType:[qlco] PreferredName:Show SemanticType:[inpr] PreferredName:Data SemanticType:[idcn] PreferredName:Deterioration of status SemanticType:[fndg] PreferredName:Slightly SemanticType:[idcn] PreferredName:Young SemanticType:[tmco] PreferredName:Specificity SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Old SemanticType:[tmco] POS:DT POS:NNP POS:VBD POS:RB POS:RB POS:VB POS:DT POS:NN POS:IN POS:JJ POS:NN POS:IN POS:JJ POS:JJ POS:NN POS:, POS:RB POS:IN POS:VBG POS:IN POS:JJ POS:NNS POS:VBP POS:VBN POS:VBN POS:TO POS:VB POS:JJ POS:NN POS:IN POS:JJR POS:NNS POS:CC POS:NNS POS:IN POS:JJ POS:JJ POS:NNS POS:CD POS:, POS:CD POS:CC POS:JJ POS:NNS POS:VBG POS:RB POS:JJR POS:NN POS:IN POS:JJR POS:RB POS:JJR POS:NNS POS:. 
[sentNum: 307]<Annotation Id="24434" Type="Sentence" StartNode="57263" EndNode="57456">65 Because only a small fraction of mammography facilities are still using screen-film units, these comparisons would have had little practical purpose for policy or individual decision making. PreferredName:Singular SemanticType:[qnco] PreferredName:Arabic numeral 65 SemanticType:[inpr] PreferredName:Fraction of SemanticType:[qnco] PreferredName:A little bit SemanticType:[inpr] PreferredName:Facility SemanticType:[idcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Use of SemanticType:[ftcn] PreferredName:Unit of Measure SemanticType:[qnco] PreferredName:film (photographic) SemanticType:[mnob] PreferredName:Small SemanticType:[qnco] PreferredName:Comparison SemanticType:[acty] PreferredName:Policy SemanticType:[inpr] PreferredName:Purpose SemanticType:[ftcn] PreferredName:Decision Making SemanticType:[menp] PreferredName:Persons SemanticType:[popg] POS:CD POS:IN POS:RB POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NNS POS:VBP POS:RB POS:VBG POS:JJ POS:NNS POS:, POS:DT POS:NNS POS:MD POS:VB POS:VBN POS:JJ POS:JJ POS:NN POS:IN POS:NN POS:CC POS:JJ POS:NN POS:NN POS:. 
[sentNum: 308]<Annotation Id="24435" Type="Sentence" StartNode="57457" EndNode="57674">Although DBT units are steadily being introduced in mammography facilities, at the time the protocol for the evidence review was developed there were too few data on DBT to include comparisons of 2D vs 3D mammography.PreferredName:Unit of Measure SemanticType:[qnco] PreferredName:DBT gene SemanticType:[gngm] PreferredName:Mammography SemanticType:[diap] PreferredName:Introduces SemanticType:[ftcn] PreferredName:Time SemanticType:[tmco] PreferredName:Facility SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Library Protocol SemanticType:[inpr] PreferredName:Data SemanticType:[idcn] PreferredName:Review [Publication Type] SemanticType:[inpr] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:DBT gene SemanticType:[gngm] PreferredName:2-Dimensional SemanticType:[spco] PreferredName:Comparison SemanticType:[acty] PreferredName:Mammography SemanticType:[diap] PreferredName:Three-dimensional SemanticType:[spco] POS:IN POS:NNP POS:NNS POS:VBP POS:RB POS:VBG POS:VBN POS:IN POS:JJ POS:NNS POS:, POS:IN POS:DT POS:NN POS:DT POS:NN POS:IN POS:DT POS:NN POS:NN POS:VBD POS:VBN POS:EX POS:VBD POS:RB POS:JJ POS:NNS POS:IN POS:NNP POS:TO POS:VB POS:NNS POS:IN POS:CD POS:NNP POS:JJ POS:CD POS:NNP POS:NN POS:. 
[sentNum: 309]<Annotation Id="24436" Type="Sentence" StartNode="57676" EndNode="57828">The GDG recognizes that current knowledge suggests a continuum of risk; the categories of “average” and “high” or “higher” risk are not always distinct. PreferredName:Knowledge SemanticType:[inpr] PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Risk SemanticType:[qlco] PreferredName:suggestion SemanticType:[idcn] PreferredName:Average SemanticType:[qnco] PreferredName:Categories SemanticType:[inpr] PreferredName:High risk of SemanticType:[qlco] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:Always (frequency) SemanticType:[tmco] PreferredName:Negation SemanticType:[ftcn] POS:DT POS:NNP POS:VBZ POS:IN POS:JJ POS:NN POS:VBZ POS:DT POS:NN POS:IN POS:NN POS:: POS:DT POS:NNS POS:IN POS:VBG POS:JJ POS:NNS POS:CC POS:CD POS:JJ POS:NNS POS:CC POS:VBG POS:JJR POS:NN POS:NN POS:VBP POS:RB POS:RB POS:JJ POS:. 
[sentNum: 310]<Annotation Id="24437" Type="Sentence" StartNode="57829" EndNode="58086">Because an update of recommendations for women at high risk will follow this one, this guideline leaves unaddressed some important questions about mammography screening for women at increased risk for breast cancer or for diagnosis at a more advanced stage. PreferredName:Recommendation SemanticType:[idcn] PreferredName:Update SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Followed by SemanticType:[tmco] PreferredName:High risk of SemanticType:[qlco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:One SemanticType:[qnco] PreferredName:Some (qualifier value) SemanticType:[qnco] PreferredName:Plant Leaves SemanticType:[plnt] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Woman SemanticType:[popg] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Risk SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Advanced phase SemanticType:[qlco] PreferredName:More SemanticType:[ftcn] POS:IN POS:DT POS:NN POS:IN POS:NNS POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:MD POS:VB POS:DT POS:NN POS:, POS:DT POS:NN POS:NNS POS:VBD POS:DT POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:IN POS:NNS POS:IN POS:VBN POS:NN POS:IN POS:NN POS:NN POS:CC POS:IN POS:NN POS:IN POS:DT POS:RBR POS:JJ POS:NN POS:. 
[sentNum: 311]<Annotation Id="24438" Type="Sentence" StartNode="58087" EndNode="58338">At this time, women who are known or suspected carriers of deleterious mutations on breast cancer susceptibility genes and women treated with radiation at a young age are recommended to begin screening with mammography and breast MRI at a younger age.22PreferredName:Woman SemanticType:[popg] PreferredName:Time SemanticType:[tmco] PreferredName:suspected carrier SemanticType:[fndg] PreferredName:Known SemanticType:[qlco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Deleterious Mutation SemanticType:[comd] PreferredName:Woman SemanticType:[popg] PreferredName:Cancer-Predisposing Gene SemanticType:[gngm] PreferredName:Therapeutic radiology procedure SemanticType:[topp] PreferredName:Treated with SemanticType:[topp] PreferredName:Age SemanticType:[orga] PreferredName:Young SemanticType:[tmco] PreferredName:To SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Beginning SemanticType:[tmco] PreferredName:Young SemanticType:[tmco] PreferredName:Multisection:Finding:Point in time:Breast:Narrative:MRI SemanticType:[clna] PreferredName:Age SemanticType:[orga] POS:IN POS:DT POS:NN POS:, POS:NNS POS:WP POS:VBP POS:VBN POS:CC POS:VBN POS:NNS POS:IN POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:NN POS:NNS POS:CC POS:NNS POS:VBN POS:IN POS:NN POS:IN POS:DT POS:JJ POS:NN POS:VBP POS:VBN POS:TO POS:VB POS:NN POS:IN POS:NN POS:CC POS:NN POS:NNS POS:IN POS:DT POS:JJR POS:NN POS:. 
[sentNum: 312]<Annotation Id="24439" Type="Sentence" StartNode="58338" EndNode="58616">22,106,107 There are other risk factors, such as family histories not linked to identified susceptibility genes, and history of invasive or in situ breast cancer or biopsy-confirmed proliferative lesions,20,108 for which screening recommendations and current practices may vary. PreferredName:risk factors SemanticType:[qnco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Family history SemanticType:[fndg] PreferredName:Predisposition SemanticType:[orga] PreferredName:Identified SemanticType:[qlco] PreferredName:History of previous events SemanticType:[fndg] PreferredName:Linked gene SemanticType:[genf] PreferredName:Stage 0 Breast Carcinoma SemanticType:[neop] PreferredName:Invasive SemanticType:[qlco] PreferredName:Confirmed by SemanticType:[qlco] PreferredName:Biopsied lesion SemanticType:[fndg] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Proliferation (morphologic abnormality) SemanticType:[patf] PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Practice Experience SemanticType:[menp] POS:CD POS:, POS:CD POS:, POS:CD POS:EX POS:VBP POS:JJ POS:NN POS:NNS POS:, POS:JJ POS:IN POS:NN POS:NNS POS:RB POS:VBN POS:TO POS:VBN POS:NN POS:NNS POS:, POS:CC POS:NN POS:IN POS:NN POS:CC POS:IN POS:JJ POS:NN POS:NN POS:CC POS:JJ POS:NN POS:NNS POS:, POS:CD POS:, POS:CD POS:IN POS:WDT POS:NN POS:NNS POS:CC POS:JJ POS:NNS POS:MD POS:VB POS:. 
[sentNum: 313]<Annotation Id="24440" Type="Sentence" StartNode="58617" EndNode="58905">The GDG also did not include in this review evidence on the effectiveness of supplemental breast imaging for women with mammographically dense breasts, which place some women at a higher risk of breast cancer and or a higher risk of having their breast cancer not detected by mammography.21PreferredName:Negation SemanticType:[ftcn] PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Upon - dosing instruction fragment SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Supplement SemanticType:[ftcn] PreferredName:Effectiveness SemanticType:[qlco] PreferredName:Imaging Techniques SemanticType:[diap] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Dense breasts NOS SemanticType:[fndg] PreferredName:Woman SemanticType:[popg] PreferredName:Some (qualifier value) SemanticType:[qnco] PreferredName:Place SemanticType:[spco] PreferredName:High risk of SemanticType:[qlco] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:High risk of SemanticType:[qlco] PreferredName:Detection SemanticType:[topp] PreferredName:Negation SemanticType:[ftcn] PreferredName:Mammography SemanticType:[diap] POS:DT POS:NNP POS:RB POS:VBD POS:RB POS:VB POS:IN POS:DT POS:NN POS:NN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:JJ POS:NNS POS:, POS:WDT POS:VBP POS:DT POS:NNS POS:IN POS:DT POS:JJR POS:NN POS:IN POS:NN POS:NN POS:CC POS:CC POS:DT POS:JJR POS:NN POS:IN POS:VBG POS:PRP$ POS:NN POS:NN POS:RB POS:VBN POS:IN POS:NN POS:. 
[sentNum: 314]<Annotation Id="24441" Type="Sentence" StartNode="58905" EndNode="59092">21,109,110 The GDG will consider the evidence for screening effectiveness in women in these risk groups subsequent to the completion of the update of the guideline for average-risk women.PreferredName:consider SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Present SemanticType:[qnco] PreferredName:Effectiveness SemanticType:[qlco] PreferredName:Risk SemanticType:[qlco] PreferredName:Women's Groups SemanticType:[popg] PreferredName:Complete SemanticType:[qlco] PreferredName:Following SemanticType:[tmco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Update SemanticType:[tmco] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] POS:CD POS:, POS:CD POS:, POS:VBD POS:DT POS:NNP POS:MD POS:VB POS:DT POS:NN POS:IN POS:NN POS:NN POS:IN POS:NNS POS:IN POS:DT POS:NN POS:NNS POS:JJ POS:TO POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 315]<Annotation Id="24442" Type="Sentence" StartNode="59094" EndNode="59378">The issue of overdiagnosis is controversial, ranging from estimates of the overall rate, the relative fraction of overdiagnosis attributable to ductal carcinoma in situ (DCIS) vs invasive disease, and what women should be told about the possibility of overdiagnosis and overtreatment. PreferredName:Problem SemanticType:[fndg] PreferredName:controversy SemanticType:[socb] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Estimated SemanticType:[qnco] PreferredName:Sample Range SemanticType:[qnco] PreferredName:Rating (action) SemanticType:[acty] PreferredName:Overall Publication Type SemanticType:[inpr] PreferredName:Fraction of SemanticType:[qnco] PreferredName:Relative SemanticType:[qlco] PreferredName:Attribution SemanticType:[menp] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Invasive SemanticType:[qlco] PreferredName:Noninfiltrating Intraductal Carcinoma SemanticType:[neop] PreferredName:Woman SemanticType:[popg] PreferredName:Disease SemanticType:[dsyn] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Possibly Related to Intervention SemanticType:[qlco] POS:DT POS:NN POS:IN POS:NNS POS:VBZ POS:JJ POS:, POS:VBG POS:IN POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:, POS:DT POS:JJ POS:NN POS:IN POS:NNS POS:JJ POS:TO POS:JJ POS:NN POS:IN POS:JJ POS:( POS:NNP POS:) POS:VBP POS:JJ POS:NN POS:, POS:CC POS:WP POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:CC POS:NN POS:. 
[sentNum: 316]<Annotation Id="24443" Type="Sentence" StartNode="59379" EndNode="59534">There is an estimate in the literature to support almost any position on overdiagnosis and, likewise, almost any percentage of DCIS that is nonprogressive. PreferredName:Publications SemanticType:[inpr, mnob] PreferredName:Estimated SemanticType:[qnco] PreferredName:Any SemanticType:[qlco] PreferredName:Support, device SemanticType:[medd] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Positioning Attribute SemanticType:[spco] PreferredName:Money or percentage indicator - Percentage SemanticType:[idcn] PreferredName:Any SemanticType:[qlco] PreferredName:Nonprogressive SemanticType:[fndg] PreferredName:Noninfiltrating Intraductal Carcinoma SemanticType:[neop] POS:EX POS:VBZ POS:DT POS:NN POS:IN POS:DT POS:NN POS:TO POS:VB POS:RB POS:DT POS:NN POS:IN POS:NNS POS:CC POS:, POS:RB POS:, POS:RB POS:DT POS:NN POS:IN POS:NNS POS:WDT POS:VBZ POS:JJ POS:. 
[sentNum: 317]<Annotation Id="24444" Type="Sentence" StartNode="59535" EndNode="59685">The evidence review judged the evidence for the existence of overdiagnosis as high, but evidence for estimating the magnitude of overdiagnosis as low.23PreferredName:Review [Publication Type] SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Judge SemanticType:[prog] PreferredName:Abnormally high SemanticType:[qlco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Estimated SemanticType:[qnco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] POS:DT POS:NN POS:NN POS:VBN POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:RB POS:JJ POS:, POS:CC POS:NN POS:IN POS:VBG POS:DT POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:. 
[sentNum: 318]<Annotation Id="24445" Type="Sentence" StartNode="59685" EndNode="59826">23 The UK Independent Panel also concluded that the uncertainties around the estimates reported result in a “spurious impression of accuracy.”PreferredName:Arabic numeral 23 SemanticType:[qnco] PreferredName:Laboratory Order Panels SemanticType:[inpr] PreferredName:Independence SemanticType:[idcn] PreferredName:Uncertainty SemanticType:[idcn] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Report (document) SemanticType:[inpr] PreferredName:Estimated SemanticType:[qnco] PreferredName:Artificial (qualifier value) SemanticType:[qlco] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Accurate (qualifier) SemanticType:[qlco] PreferredName:Impression SemanticType:[qlco] POS:CD POS:NNP POS:NNP POS:JJ POS:NN POS:RB POS:VBD POS:IN POS:DT POS:NNS POS:IN POS:DT POS:NNS POS:VBD POS:NN POS:IN POS:DT POS:JJ POS:JJ POS:NN POS:IN POS:NN POS:. 
[sentNum: 319]<Annotation Id="24446" Type="Sentence" StartNode="59826" EndNode="59830">”111POS:NN POS:CD 
[sentNum: 320]<Annotation Id="24447" Type="Sentence" StartNode="59832" EndNode="59985">Quiz Ref IDThe main goal of mammography screening programs is to reduce breast cancer mortality by reducing the incidence rate of advanced breast cancer. PreferredName:Main SemanticType:[qlco] PreferredName:ALYREF gene SemanticType:[gngm] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Act Mood - Goal SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Programs - Publication Format SemanticType:[inpr] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Incidence Rate SemanticType:[qnco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Advanced phase SemanticType:[qlco] POS:CD POS:NNP POS:NNP POS:JJ POS:NN POS:IN POS:NN POS:NN POS:NNS POS:VBZ POS:TO POS:VB POS:NN POS:NN POS:NN POS:IN POS:VBG POS:DT POS:NN POS:NN POS:IN POS:VBN POS:NN POS:NN POS:. 
[sentNum: 321]<Annotation Id="24448" Type="Sentence" StartNode="59986" EndNode="60081">Thus, the aim of screening mammography is to detect breast cancer early in its natural history. PreferredName:Screening mammography SemanticType:[topp] PreferredName:Aim (idea) SemanticType:[idcn] PreferredName:Detected (finding) SemanticType:[fndg] PreferredName:To SemanticType:[qlco] PreferredName:Early SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Natural History SemanticType:[ocdi] POS:RB POS:, POS:DT POS:NN POS:IN POS:VBG POS:NN POS:VBZ POS:TO POS:VB POS:NN POS:NN POS:RB POS:IN POS:PRP$ POS:JJ POS:NN POS:. 
[sentNum: 322]<Annotation Id="24449" Type="Sentence" StartNode="60082" EndNode="60194">A screening test that is successful in detecting small invasive cancers also will detect some precursor lesions. PreferredName:Screening Tests SemanticType:[hlca] PreferredName:Detected (finding) SemanticType:[fndg] PreferredName:Successful SemanticType:[qlco] PreferredName:Invasive Malignant Neoplasm SemanticType:[neop] PreferredName:Small SemanticType:[qnco] PreferredName:Precursor SemanticType:[idcn] PreferredName:Detected (finding) SemanticType:[fndg] PreferredName:Lesion SemanticType:[fndg] POS:DT POS:NN POS:NN POS:WDT POS:VBZ POS:JJ POS:IN POS:VBG POS:JJ POS:JJ POS:NNS POS:RB POS:MD POS:VB POS:DT POS:JJ POS:NNS POS:. 
[sentNum: 323]<Annotation Id="24450" Type="Sentence" StartNode="60195" EndNode="60324">This likely does result in some overdiagnosis, but in other instances, it advances the time of diagnosis of a progressive lesion. PreferredName:Probably SemanticType:[idcn] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Result SemanticType:[ftcn] PreferredName:Instance SemanticType:[idcn] PreferredName:Butting SemanticType:[mobd] PreferredName:Time SemanticType:[tmco] PreferredName:Advance SemanticType:[medd] PreferredName:Progressive SemanticType:[ftcn] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Lesion SemanticType:[fndg] POS:DT POS:RB POS:VBZ POS:VB POS:IN POS:DT POS:NNS POS:, POS:CC POS:IN POS:JJ POS:NNS POS:, POS:PRP POS:VBZ POS:DT POS:NN POS:IN POS:NN POS:IN POS:DT POS:JJ POS:NN POS:. 
[sentNum: 324]<Annotation Id="24451" Type="Sentence" StartNode="60325" EndNode="60614">Narod et al112 recently reviewed outcomes of 108 196 women diagnosed with and treated for DCIS from 1998-2011 and concluded that both DCIS and invasive disease are heterogeneous with respect to prognostic features and outcomes and that DCIS and small invasive cancers share much in common. PreferredName:Recent SemanticType:[tmco] PreferredName:Result SemanticType:[ftcn] PreferredName:Reviewed SemanticType:[qlco] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Woman SemanticType:[popg] PreferredName:Noninfiltrating Intraductal Carcinoma SemanticType:[neop] PreferredName:Treated with SemanticType:[topp] PreferredName:Noninfiltrating Intraductal Carcinoma SemanticType:[neop] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Disease SemanticType:[dsyn] PreferredName:Invasive SemanticType:[qlco] PreferredName:respect SemanticType:[socb] PreferredName:Heterogeneity SemanticType:[qlco] PreferredName:Characteristics SemanticType:[qlco] PreferredName:prognostic SemanticType:[inpr] PreferredName:Noninfiltrating Intraductal Carcinoma SemanticType:[neop] PreferredName:Result SemanticType:[ftcn] PreferredName:Invasive Malignant Neoplasm SemanticType:[neop] PreferredName:Small SemanticType:[qnco] PreferredName:shared attribute SemanticType:[ftcn] PreferredName:Sharing (Social Behavior) SemanticType:[socb] POS:NNP POS:CC POS:NNP POS:CD POS:RB POS:VBN POS:NNS POS:IN POS:CD POS:CD POS:NNS POS:VBN POS:IN POS:CC POS:VBN POS:IN POS:NNS POS:IN POS:CD POS:: POS:CD POS:CC POS:VBD POS:IN POS:DT POS:NNS POS:CC POS:NN POS:NN POS:VBP POS:VBG POS:IN POS:NN POS:TO POS:JJ POS:NNS POS:CC POS:NNS POS:CC POS:IN POS:NNPS POS:CC POS:JJ POS:NN POS:NNS POS:VBP POS:RB POS:IN POS:JJ POS:. 
[sentNum: 325]<Annotation Id="24452" Type="Sentence" StartNode="60615" EndNode="60902">In the future, biological markers may be identified that will aid in treatment decision making and overcome the current inability to distinguish a nonprogressive tumor from one that is progressive and, among progressive tumors, less aggressive tumors from those that are more aggressive. PreferredName:Biological Markers SemanticType:[clna] PreferredName:Future SemanticType:[tmco] PreferredName:Helping Behavior SemanticType:[socb] PreferredName:Identified SemanticType:[qlco] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Present SemanticType:[qnco] PreferredName:Overcome SemanticType:[acty] PreferredName:Decision Making SemanticType:[menp] PreferredName:Nonprogressive SemanticType:[fndg] PreferredName:Current (present time) SemanticType:[tmco] PreferredName:One SemanticType:[qnco] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Progressive SemanticType:[ftcn] PreferredName:Progressive SemanticType:[ftcn] PreferredName:Less Than SemanticType:[inpr] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Aggressive course SemanticType:[tmco] PreferredName:Aggressive course SemanticType:[tmco] PreferredName:More SemanticType:[ftcn] POS:IN POS:DT POS:NN POS:, POS:JJ POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:MD POS:VB POS:IN POS:NN POS:NN POS:NN POS:CC POS:VB POS:DT POS:JJ POS:NN POS:TO POS:VB POS:DT POS:JJ POS:NN POS:IN POS:CD POS:WDT POS:VBZ POS:JJ POS:CC POS:, POS:IN POS:JJ POS:NNS POS:, POS:RBR POS:JJ POS:NNS POS:IN POS:DT POS:WDT POS:VBP POS:RBR POS:JJ POS:. 
[sentNum: 326]<Annotation Id="24453" Type="Sentence" StartNode="60903" EndNode="61047">New markers may also contribute to progress in personalized medicine, providing opportunities for women to be counseled about treatment choices.113PreferredName:Biological Markers SemanticType:[clna] PreferredName:New SemanticType:[tmco] PreferredName:To SemanticType:[qlco] PreferredName:Contribution SemanticType:[acty] PreferredName:Individualized Medicine SemanticType:[topp] PreferredName:Progress SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Counsel - legal SemanticType:[prog] PreferredName:Choice Behavior SemanticType:[inbe] POS:NNP POS:NNS POS:MD POS:RB POS:VB POS:TO POS:VB POS:IN POS:JJ POS:NN POS:, POS:VBG POS:NNS POS:IN POS:NNS POS:TO POS:VB POS:VBN POS:IN POS:NN POS:NNS POS:. 
[sentNum: 327]<Annotation Id="24454" Type="Sentence" StartNode="61047" EndNode="61050">113POS:NN 
[sentNum: 328]<Annotation Id="24455" Type="Sentence" StartNode="61052" EndNode="61290">Given the common agreement that women should know what to expect when undergoing breast cancer screening, there is a need for more research on communicating information about the benefits, limitations, and risks associated with screening. PreferredName:GIVEN SemanticType:[cnce] PreferredName:Agreement SemanticType:[socb] PreferredName:shared attribute SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Needs SemanticType:[qlco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Communicating SemanticType:[ftcn] PreferredName:Research Activities SemanticType:[resa] PreferredName:Benefits SemanticType:[qnco] PreferredName:Information SemanticType:[idcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Associated with SemanticType:[qlco] POS:VBN POS:DT POS:JJ POS:NN POS:IN POS:NNS POS:MD POS:VB POS:WP POS:TO POS:VB POS:WRB POS:VBG POS:NN POS:NN POS:NN POS:, POS:EX POS:VBZ POS:DT POS:NN POS:IN POS:JJR POS:NN POS:IN POS:VBG POS:NN POS:IN POS:DT POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:NN POS:. 
[sentNum: 329]<Annotation Id="24456" Type="Sentence" StartNode="61291" EndNode="61616">The current state of QALY literature related to mammography screening points to the need in future research for better utility assessment studies to address health states that accurately capture women’s experience throughout the process of mammography screening and the associated health utilities, as well as time durations. PreferredName:Quality-Adjusted Life Years SemanticType:[tmco] PreferredName:Current state SemanticType:[inpr] PreferredName:Relationships SemanticType:[qlco] PreferredName:Publications SemanticType:[inpr, mnob] PreferredName:Point Name SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Needs SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Research Activities SemanticType:[resa] PreferredName:Future SemanticType:[tmco] PreferredName:Utilities (organization) SemanticType:[orgt] PreferredName:Better SemanticType:[qlco] PreferredName:Study SemanticType:[resa] PreferredName:Evaluation procedure SemanticType:[hlca] PreferredName:Address SemanticType:[spco] PreferredName:To SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:state of health SemanticType:[fndg] PreferredName:Processed SemanticType:[phpr] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Associated with SemanticType:[qlco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Utilities (organization) SemanticType:[orgt] PreferredName:Health SemanticType:[idcn] PreferredName:Duration (temporal concept) SemanticType:[tmco] PreferredName:Time SemanticType:[tmco] POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:VBN POS:TO POS:VB POS:NN POS:NNS POS:TO POS:DT POS:NN POS:IN POS:JJ POS:NN POS:IN POS:JJR POS:NN POS:NN POS:NNS POS:TO POS:VB POS:NN POS:NNS POS:WDT POS:RB POS:VB POS:NNS POS:NNS POS:VBZ POS:NN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:CC POS:DT POS:JJ POS:NN POS:NNS POS:, POS:RB POS:RB POS:IN POS:NN POS:NNS POS:. 
[sentNum: 330]<Annotation Id="24457" Type="Sentence" StartNode="61617" EndNode="61998">Recognizing the high frequency of false-positive findings from screening mammography in the United States, more study is needed on understanding which women are at greater risk for near- and long-term psychological harm associated with false-positive results, and it also is a high priority to identify strategies that can reduce the stress associated with false-positive findings.60PreferredName:False Positive SemanticType:[lbtr] PreferredName:High frequency SemanticType:[tmco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:From SemanticType:[qlco] PreferredName:More SemanticType:[ftcn] PreferredName:United States SemanticType:[geoa] PreferredName:Needs SemanticType:[qlco] PreferredName:Study SemanticType:[resa] PreferredName:Woman SemanticType:[popg] PreferredName:Comprehension SemanticType:[menp] PreferredName:Greater SemanticType:[qnco] PreferredName:are unit of measure SemanticType:[qnco] PreferredName:Near SemanticType:[qlco] PreferredName:Risk SemanticType:[qlco] PreferredName:Psychiatric problem SemanticType:[mobd] PreferredName:Long-term SemanticType:[tmco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Associated with SemanticType:[qlco] PreferredName:strategy SemanticType:[menp] PreferredName:High priority SemanticType:[tmco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Stress SemanticType:[fndg] PreferredName:False Positive SemanticType:[lbtr] POS:VBG POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:VBG POS:RB POS:IN POS:DT POS:NNP POS:NNPS POS:, POS:JJR POS:NN POS:VBZ POS:VBN POS:IN POS:NN POS:WDT POS:NNS POS:VBP POS:IN POS:JJR POS:NN POS:IN POS:JJ POS:CC POS:JJ POS:JJ POS:NN POS:VBN POS:IN POS:JJ POS:NNS POS:, POS:CC POS:PRP POS:RB POS:VBZ POS:DT POS:JJ POS:NN POS:TO POS:VB POS:NNS POS:WDT POS:MD POS:VB POS:DT POS:NN POS:VBN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 331]<Annotation Id="24458" Type="Sentence" StartNode="61998" EndNode="62004">60,114POS:CD POS:, POS:JJ 
[sentNum: 332]<Annotation Id="24459" Type="Sentence" StartNode="62006" EndNode="62334">The 2015 updated recommendations from the ACS are intended to balance the goal of reducing the burden of breast cancer against the understanding that breast cancer screening is a preventive health intervention applied to the entire eligible population of women, most of whom will not develop breast cancer during their lifetime. PreferredName:Update SemanticType:[tmco] PreferredName:intent SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:objective (goal) SemanticType:[inpr] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Burden SemanticType:[idcn] PreferredName:Reduced SemanticType:[qlco] PreferredName:Comprehension SemanticType:[menp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Prophylactic treatment SemanticType:[topp] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Application procedure SemanticType:[hlca] PreferredName:Health SemanticType:[idcn] PreferredName:eligible SemanticType:[idcn] PreferredName:Entire SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Population Group SemanticType:[popg] PreferredName:Negation SemanticType:[ftcn] PreferredName:Most SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:DT POS:CD POS:VBN POS:NNS POS:IN POS:DT POS:NNP POS:VBP POS:VBN POS:TO POS:VB POS:DT POS:NN POS:IN POS:VBG POS:DT POS:NN POS:IN POS:NN POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:NN POS:VBZ POS:DT POS:JJ POS:NN POS:NN POS:VBN POS:TO POS:DT POS:JJ POS:JJ POS:NN POS:IN POS:NNS POS:, POS:JJS POS:IN POS:WP POS:MD POS:RB POS:VB POS:NN POS:NN POS:IN POS:PRP$ POS:NN POS:. 
[sentNum: 333]<Annotation Id="24460" Type="Sentence" StartNode="62335" EndNode="62445">In developing a guideline, some measure of judgment is required when weighing the balance of benefit and harm. PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Measurement SemanticType:[ftcn] PreferredName:Some (qualifier value) SemanticType:[qnco] PreferredName:Requirement SemanticType:[ftcn] PreferredName:Judgment SemanticType:[menp] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Weighing patient SemanticType:[diap] PreferredName:Benefits SemanticType:[qnco] POS:IN POS:VBG POS:DT POS:NN POS:, POS:DT POS:NN POS:IN POS:NN POS:VBZ POS:VBN POS:WRB POS:VBG POS:DT POS:NN POS:IN POS:NN POS:CC POS:NN POS:. 
[sentNum: 334]<Annotation Id="24461" Type="Sentence" StartNode="62446" EndNode="62860">The GDG carefully evaluated the burden of disease, the available evidence on the relative and absolute benefit of screening by age, the estimated frequency and relative importance of known and uncertain adverse events, and the importance of allowing for differences in women’s values and preferences about the relative importance of potential benefits and harms in decisions about undergoing mammography screening.60PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Disease SemanticType:[dsyn] PreferredName:Burden SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Availability of SemanticType:[ftcn] PreferredName:Absolute SemanticType:[qlco] PreferredName:Relative SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:Relative SemanticType:[qlco] PreferredName:Frequencies (time pattern) SemanticType:[tmco] PreferredName:Uncertainty SemanticType:[idcn] PreferredName:Known SemanticType:[qlco] PreferredName:allowing SemanticType:[socb] PreferredName:Adverse event SemanticType:[patf] PreferredName:Change values SemanticType:[inpr] PreferredName:Preposition For SemanticType:[qlco] PreferredName:preference SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Potential SemanticType:[qlco] PreferredName:Relative SemanticType:[qlco] PreferredName:Decision SemanticType:[menp] PreferredName:Benefits SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] POS:DT POS:NNP POS:RB POS:VBN POS:DT POS:NN POS:IN POS:NN POS:, POS:DT POS:JJ POS:NN POS:IN POS:DT POS:JJ POS:CC POS:JJ POS:NN POS:IN POS:VBG POS:IN POS:NN POS:, POS:DT POS:VBN POS:NN POS:CC POS:JJ POS:NN POS:IN POS:VBN POS:CC POS:JJ POS:JJ POS:NNS POS:, POS:CC POS:DT POS:NN POS:IN POS:VBG POS:IN POS:NNS POS:IN POS:NNS POS:NNS POS:VBZ POS:NNS POS:CC POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:CC POS:NNS POS:IN POS:NNS POS:IN POS:VBG POS:JJ POS:NN POS:. 
[sentNum: 335]<Annotation Id="24462" Type="Sentence" StartNode="62860" EndNode="63081">60,114- 117 There remain important differences of opinion about the trade-offs between benefits and harms of breast cancer screening in screening recommendations, and these differences were reflected in GDG deliberations. PreferredName:ATTITUDE CHANGED SemanticType:[qlco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Benefits SemanticType:[qnco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Reflecting SemanticType:[menp] PreferredName:Delta (difference) SemanticType:[qnco] POS:CD POS:, POS:CD POS:: POS:CD POS:RB POS:VBP POS:JJ POS:NNS POS:IN POS:NN POS:IN POS:DT POS:NNS POS:IN POS:NNS POS:CC POS:NNS POS:IN POS:NN POS:NN POS:NN POS:IN POS:NN POS:NNS POS:, POS:CC POS:DT POS:NNS POS:VBD POS:VBN POS:IN POS:NNP POS:NNS POS:. 
[sentNum: 336]<Annotation Id="24463" Type="Sentence" StartNode="63082" EndNode="63275">These new recommendations represent the collective judgment of the GDG and are intended to provide guidance to women and health care professionals about breast cancer screening over a lifetime.PreferredName:Recommendation SemanticType:[idcn] PreferredName:New SemanticType:[tmco] PreferredName:collective SemanticType:[orgt] PreferredName:Representation (action) SemanticType:[acty] PreferredName:intent SemanticType:[qlco] PreferredName:Judgment SemanticType:[menp] PreferredName:Providing (action) SemanticType:[acty] PreferredName:To SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Spatial guidance for medical procedure SemanticType:[clna] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Health Personnel SemanticType:[prog] POS:DT POS:JJ POS:NNS POS:VBP POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NNP POS:CC POS:VBP POS:VBN POS:TO POS:VB POS:NN POS:TO POS:NNS POS:CC POS:NN POS:NN POS:NNS POS:IN POS:NN POS:NN POS:NN POS:IN POS:DT POS:NN POS:. 
[sentNum: 337]<Annotation Id="24464" Type="Sentence" StartNode="63277" EndNode="63401">This updated guideline departs in some respects from the previous ACS recommendations for breast cancer screening (Table 5). PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Update SemanticType:[tmco] PreferredName:respect SemanticType:[socb] PreferredName:Departure - action SemanticType:[acty] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Previous SemanticType:[tmco] PreferredName:Table - furniture SemanticType:[mnob] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] POS:DT POS:VBN POS:NN POS:VBZ POS:IN POS:DT POS:NNS POS:IN POS:DT POS:JJ POS:NNP POS:NNS POS:IN POS:NN POS:NN POS:NN POS:( POS:NNP POS:CD POS:) POS:. 
[sentNum: 338]<Annotation Id="24465" Type="Sentence" StartNode="63402" EndNode="63809">Rather than view new evidence in the context of affirming existing guidelines, the GDG chose to more carefully examine the evidence on disease burden and the efficacy and effectiveness of screening in narrower age groups, with particular emphasis on the age range (40-55 years) for which disagreements about the age to begin screening and the screening interval have persisted over the past several decades. PreferredName:New SemanticType:[tmco] PreferredName:View SemanticType:[spco] PreferredName:Context SemanticType:[fndg] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Choose (action) SemanticType:[acty] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Burden SemanticType:[idcn] PreferredName:Disease SemanticType:[dsyn] PreferredName:Effectiveness SemanticType:[qlco] PreferredName:Effectiveness SemanticType:[qlco] PreferredName:Human Age Group SemanticType:[aggp] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Age SemanticType:[orga] PreferredName:In addition to SemanticType:[qlco] PreferredName:/40 SemanticType:[tmco] PreferredName:Range SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:Arabic numeral 55 SemanticType:[inpr] PreferredName:Discord SemanticType:[socb] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Past SemanticType:[tmco] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Decade SemanticType:[qnco] POS:RB POS:IN POS:NN POS:JJ POS:NN POS:IN POS:DT POS:NN POS:IN POS:VBG POS:VBG POS:NNS POS:, POS:DT POS:NNP POS:VBD POS:TO POS:RBR POS:RB POS:VB POS:DT POS:NN POS:IN POS:NN POS:NN POS:CC POS:DT POS:NN POS:CC POS:NN POS:IN POS:VBG POS:IN POS:JJR POS:NN POS:NNS POS:, POS:IN POS:JJ POS:NN POS:IN POS:DT POS:NN POS:NN POS:( POS:CD POS:, POS:CD POS:NNS POS:) POS:IN POS:WDT POS:NNS POS:IN POS:DT POS:NN POS:TO POS:VB POS:NN POS:CC POS:DT POS:NN POS:NN POS:VBP POS:VBD POS:IN POS:DT POS:JJ POS:JJ POS:NNS POS:. 
[sentNum: 339]<Annotation Id="24466" Type="Sentence" StartNode="63810" EndNode="64070">There also was greater scrutiny of the evidence on experiences collectively described as harms, but that more specifically differ quantitatively, from recall for additional imaging to biopsy to overtreatment, and differ qualitatively in terms of their effects. PreferredName:Largest SemanticType:[qnco] PreferredName:Experience SemanticType:[menp] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:More SemanticType:[ftcn] PreferredName:described SemanticType:[idcn] PreferredName:Recall:-:Point in time:^Patient:- SemanticType:[clna] PreferredName:From SemanticType:[qlco] PreferredName:Diagnostic Imaging SemanticType:[diap] PreferredName:Additional SemanticType:[ftcn] PreferredName:Term (lexical) SemanticType:[idcn] PreferredName:Biopsy SemanticType:[diap] PreferredName:Effect SemanticType:[qlco] POS:EX POS:RB POS:VBD POS:JJR POS:NN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:RB POS:VBN POS:IN POS:NNS POS:, POS:CC POS:DT POS:RBR POS:RB POS:VBP POS:RB POS:, POS:IN POS:VBP POS:IN POS:JJ POS:NN POS:TO POS:VB POS:TO POS:VB POS:, POS:CC POS:VBP POS:RB POS:IN POS:NNS POS:IN POS:PRP$ POS:NNS POS:. 
[sentNum: 340]<Annotation Id="24467" Type="Sentence" StartNode="64071" EndNode="64250">For some women, being recalled for additional imaging has little or no lasting adverse effects, while other women will experience greater and sometimes persistent adverse effects. PreferredName:Woman SemanticType:[popg] PreferredName:Additional SemanticType:[ftcn] PreferredName:Recall:-:Point in time:^Patient:- SemanticType:[clna] PreferredName:Small SemanticType:[qnco] PreferredName:Diagnostic Imaging SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Adverse effects SemanticType:[patf] PreferredName:Largest SemanticType:[qnco] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Persistent SemanticType:[tmco] PreferredName:Sometimes SemanticType:[tmco] PreferredName:Adverse effects SemanticType:[patf] POS:IN POS:DT POS:NNS POS:, POS:VBG POS:VBN POS:IN POS:JJ POS:NN POS:VBZ POS:JJ POS:CC POS:DT POS:JJ POS:JJ POS:NNS POS:, POS:IN POS:JJ POS:NNS POS:MD POS:VB POS:JJR POS:CC POS:RB POS:JJ POS:JJ POS:NNS POS:. 
[sentNum: 341]<Annotation Id="24468" Type="Sentence" StartNode="64251" EndNode="64412">The GDG also judged women’s values and preferences as having a more important role in decisions where the balance of absolute benefits and harms is less certain. PreferredName:Judge SemanticType:[prog] PreferredName:Values SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Social Role SemanticType:[socb] PreferredName:preference SemanticType:[idcn] PreferredName:Equilibrium SemanticType:[orgf] PreferredName:Decision SemanticType:[menp] PreferredName:Benefits SemanticType:[qnco] PreferredName:Absolute SemanticType:[qlco] PreferredName:Certain (qualifier value) SemanticType:[qlco] PreferredName:Less Than SemanticType:[inpr] POS:DT POS:NNP POS:RB POS:VBD POS:NNS POS:NNS POS:VBZ POS:NNS POS:CC POS:NNS POS:IN POS:VBG POS:DT POS:RBR POS:JJ POS:NN POS:IN POS:NNS POS:WRB POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:CC POS:NNS POS:VBZ POS:RBR POS:JJ POS:. 
[sentNum: 342]<Annotation Id="24469" Type="Sentence" StartNode="64413" EndNode="64540">Historically, the ACS had recommended periodic CBE for women younger than 40 years and annual CBE for women 40 years and older. PreferredName:Periodic SemanticType:[tmco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:/40 SemanticType:[tmco] PreferredName:Young SemanticType:[tmco] PreferredName:Annual SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] POS:RB POS:, POS:DT POS:NNP POS:VBD POS:VBN POS:JJ POS:NNP POS:IN POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:CC POS:JJ POS:NNP POS:IN POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:. 
[sentNum: 343]<Annotation Id="24470" Type="Sentence" StartNode="64541" EndNode="64777">In this update, the absence of clear evidence that CBE contributed significantly to breast cancer detection prior to or after age 40 years led the GDG to conclude that it could no longer be recommended for average-risk women at any age. PreferredName:Update SemanticType:[tmco] PreferredName:Clear SemanticType:[qlco] PreferredName:Absent SemanticType:[qnco] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Breast Cancer Detection Research SemanticType:[hlca] PreferredName:Contribution SemanticType:[acty] PreferredName:/40 SemanticType:[tmco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Light Emitting Diode Device Component SemanticType:[mnob] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Long SemanticType:[qlco] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:Woman SemanticType:[popg] POS:IN POS:DT POS:NN POS:, POS:DT POS:NN POS:IN POS:JJ POS:NN POS:IN POS:NNP POS:VBD POS:RB POS:TO POS:NN POS:NN POS:NN POS:RB POS:TO POS:CC POS:IN POS:NN POS:CD POS:NNS POS:VBD POS:DT POS:NNP POS:TO POS:VB POS:IN POS:PRP POS:MD POS:RB POS:RB POS:VB POS:VBN POS:IN POS:JJ POS:NNS POS:IN POS:DT POS:NN POS:. 
[sentNum: 344]<Annotation Id="24471" Type="Sentence" StartNode="64778" EndNode="64952">This new recommendation should not be interpreted to discount the potential value of CBE in low- and medium-resource settings where mammography screening may not be feasible. PreferredName:Recommendation SemanticType:[idcn] PreferredName:New SemanticType:[tmco] PreferredName:Interprets SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:discount - ActCode SemanticType:[inpr] PreferredName:To SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Potential SemanticType:[qlco] PreferredName:Abnormally low (qualifier value) SemanticType:[qlco] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Resources SemanticType:[idcn] PreferredName:Communications Media SemanticType:[inpr] PreferredName:Screening mammography SemanticType:[topp] PreferredName:contextual factors SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] POS:DT POS:JJ POS:NN POS:MD POS:RB POS:VB POS:VBN POS:TO POS:VB POS:DT POS:JJ POS:NN POS:IN POS:NNP POS:IN POS:JJ POS:CC POS:JJ POS:NNS POS:WRB POS:NN POS:NN POS:MD POS:RB POS:VB POS:JJ POS:. 
[sentNum: 345]<Annotation Id="24472" Type="Sentence" StartNode="64953" EndNode="65134">Clinical breast examination also may have a role in some groups of women at very high risk, but this question will be addressed in the update of recommendations for high-risk women. PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Women's Groups SemanticType:[popg] PreferredName:Social Role SemanticType:[socb] PreferredName:Risk SemanticType:[qlco] PreferredName:Very high SemanticType:[fndg] PreferredName:Address SemanticType:[spco] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Update SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:High risk of SemanticType:[qlco] POS:JJ POS:NN POS:NN POS:RB POS:MD POS:VB POS:DT POS:NN POS:IN POS:DT POS:NNS POS:IN POS:NNS POS:IN POS:RB POS:JJ POS:NN POS:, POS:CC POS:DT POS:NN POS:MD POS:VB POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 346]<Annotation Id="24473" Type="Sentence" StartNode="65135" EndNode="65270">The GDG did not address breast self-examination, which the ACS did not recommend, and thus there is no change from the 2003 guidelines.PreferredName:Address SemanticType:[spco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Breast Self-Examination SemanticType:[diap] PreferredName:No status change SemanticType:[fndg] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Guideline [Publication Type] SemanticType:[inpr] POS:DT POS:NNP POS:VBD POS:RB POS:VB POS:NN POS:NN POS:, POS:WDT POS:DT POS:NNP POS:VBD POS:RB POS:VB POS:, POS:CC POS:RB POS:EX POS:VBZ POS:DT POS:NN POS:IN POS:DT POS:CD POS:NNS POS:. 
[sentNum: 347]<Annotation Id="24474" Type="Sentence" StartNode="65272" EndNode="65542">The ACS endorses beginning annual screening mammography at age 45 years and transitioning to biennial screening at age 55 years, while retaining the option to continue annual screening, which some women may elect based on personal preference, clinical guidance, or both. PreferredName:Retained SemanticType:[ftcn] PreferredName:Arabic numeral 55 SemanticType:[inpr] PreferredName:Continuous SemanticType:[idcn] PreferredName:Options SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:annual screening SemanticType:[diap] PreferredName:Personal Attribute SemanticType:[orga] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Clinical SemanticType:[qlco] PreferredName:preference SemanticType:[idcn] PreferredName:Spatial guidance for medical procedure SemanticType:[clna] PreferredName:Beginning SemanticType:[tmco] PreferredName:Mammography SemanticType:[diap] PreferredName:annual screening SemanticType:[diap] PreferredName:Transition Mutation SemanticType:[comd] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] POS:DT POS:NNP POS:VBZ POS:VBG POS:JJ POS:NN POS:RB POS:IN POS:NN POS:CD POS:NNS POS:CC POS:VBG POS:TO POS:JJ POS:NN POS:IN POS:NN POS:CD POS:NNS POS:, POS:IN POS:VBG POS:DT POS:NN POS:TO POS:VB POS:JJ POS:NN POS:, POS:WDT POS:DT POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:JJ POS:NN POS:, POS:JJ POS:NN POS:, POS:CC POS:DT POS:. 
[sentNum: 348]<Annotation Id="24475" Type="Sentence" StartNode="65543" EndNode="65863">After careful examination of the burden of disease among women aged 40 to 54 years, the GDG concluded that the lesser, but not insignificant, burden of disease for women aged 40 to 44 years and the higher cumulative risk of adverse outcomes no longer warranted a direct recommendation to begin screening at age 40 years. PreferredName:Aftercare SemanticType:[hlca] PreferredName:Disease SemanticType:[dsyn] PreferredName:Burden SemanticType:[idcn] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Smaller SemanticType:[qlco] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Burden SemanticType:[idcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Disease SemanticType:[dsyn] PreferredName:/40 SemanticType:[tmco] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:High risk of SemanticType:[qlco] PreferredName:year SemanticType:[tmco] PreferredName:Result SemanticType:[ftcn] PreferredName:Cumulative SemanticType:[qlco] PreferredName:Direct (qualifier) SemanticType:[qlco] PreferredName:Long SemanticType:[qlco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Advice SemanticType:[hlca] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:/40 SemanticType:[tmco] POS:IN POS:JJ POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:, POS:DT POS:NNP POS:VBD POS:IN POS:DT POS:JJR POS:, POS:CC POS:RB POS:JJ POS:, POS:NN POS:IN POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:CC POS:DT POS:JJR POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:RB POS:RB POS:VBD POS:DT POS:JJ POS:NN POS:TO POS:VB POS:VBG POS:IN POS:NN POS:CD POS:NNS POS:. 
[sentNum: 349]<Annotation Id="24476" Type="Sentence" StartNode="65864" EndNode="66088">However, the GDG also concluded that women in this age group should have the choice to begin screening mammography at age 40 years or before age 45 years, based on their preferences and their consideration of the trade-offs. PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Age SemanticType:[orga] PreferredName:Women's Groups SemanticType:[popg] PreferredName:Beginning SemanticType:[tmco] PreferredName:Choose (action) SemanticType:[acty] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Age-Years SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:preference SemanticType:[idcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:consideration SemanticType:[fndg] POS:RB POS:, POS:DT POS:NNP POS:RB POS:VBD POS:IN POS:NNS POS:IN POS:DT POS:NN POS:NN POS:MD POS:VB POS:DT POS:NN POS:TO POS:VB POS:VBG POS:RB POS:IN POS:NN POS:CD POS:NNS POS:CC POS:IN POS:NN POS:CD POS:NNS POS:, POS:VBN POS:IN POS:PRP$ POS:NNS POS:CC POS:PRP$ POS:NN POS:IN POS:DT POS:NNS POS:. 
[sentNum: 350]<Annotation Id="24477" Type="Sentence" StartNode="66089" EndNode="66258">Some women will value the potential early detection benefit and will be willing to accept the risk of additional testing and will thus choose to begin screening earlier. PreferredName:Woman SemanticType:[popg] PreferredName:Potential SemanticType:[qlco] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Early Diagnosis SemanticType:[diap] PreferredName:To SemanticType:[qlco] PreferredName:Willing SemanticType:[fndg] PreferredName:Risk SemanticType:[qlco] PreferredName:Accept - Source type SemanticType:[idcn] PreferredName:Testing SemanticType:[ftcn] PreferredName:Additional SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Choose (action) SemanticType:[acty] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Beginning SemanticType:[tmco] PreferredName:Early SemanticType:[tmco] POS:DT POS:NNS POS:MD POS:VB POS:DT POS:JJ POS:JJ POS:NN POS:NN POS:CC POS:MD POS:VB POS:JJ POS:TO POS:VB POS:DT POS:NN POS:IN POS:JJ POS:NN POS:CC POS:MD POS:RB POS:VB POS:TO POS:VB POS:VBG POS:RBR POS:. 
[sentNum: 351]<Annotation Id="24478" Type="Sentence" StartNode="66259" EndNode="66365">Other women will choose to defer beginning screening, based on the relatively lower risk of breast cancer.PreferredName:Woman SemanticType:[popg] PreferredName:To SemanticType:[qlco] PreferredName:Choose (action) SemanticType:[acty] PreferredName:Beginning SemanticType:[tmco] PreferredName:Deferred SemanticType:[tmco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Low Risk SemanticType:[qnco] POS:JJ POS:NNS POS:MD POS:VB POS:TO POS:VB POS:VBG POS:NN POS:, POS:VBN POS:IN POS:DT POS:RB POS:JJR POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 352]<Annotation Id="24479" Type="Sentence" StartNode="66367" EndNode="66798">Given that annual screening mammography appears to provide additional benefit over biennial screening, particularly among younger women, the GDG recommends that women aged 45 to 54 years should be screened annually, that women aged 40 to 44 years who choose to be screened should do so annually, and that women 55 years and older should transition to biennial screening but also have the opportunity to continue screening annually. PreferredName:annual screening SemanticType:[diap] PreferredName:GIVEN SemanticType:[cnce] PreferredName:Appearance SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] PreferredName:Providing (action) SemanticType:[acty] PreferredName:To SemanticType:[qlco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Young SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Old age SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Annual SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Old age SemanticType:[popg] PreferredName:Choose (action) SemanticType:[acty] PreferredName:year SemanticType:[tmco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Annual SemanticType:[tmco] PreferredName:Somalia SemanticType:[geoa] PreferredName:Arabic numeral 55 SemanticType:[inpr] PreferredName:Woman SemanticType:[popg] PreferredName:Old SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Transition Mutation SemanticType:[comd] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Continuous SemanticType:[idcn] PreferredName:Annual SemanticType:[tmco] POS:VBN POS:IN POS:JJ POS:NN POS:NN POS:VBZ POS:TO POS:VB POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:, POS:RB POS:IN POS:JJR POS:NNS POS:, POS:DT POS:NNP POS:VBZ POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:MD POS:VB POS:VBN POS:RB POS:, POS:IN POS:NNS POS:VBN POS:CD POS:TO POS:CD POS:NNS POS:WP POS:VBP POS:TO POS:VB POS:JJ POS:MD POS:VB POS:RB POS:RB POS:, POS:CC POS:IN POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:MD POS:VB POS:TO POS:JJ POS:NN POS:CC POS:RB POS:VB POS:DT POS:NN POS:TO POS:VB POS:NN POS:RB POS:. 
[sentNum: 353]<Annotation Id="24480" Type="Sentence" StartNode="66799" EndNode="67061">The guideline recognizes the potential benefit of continuing screening mammography for women in good health who are older than 74 years, but also the importance of identifying those women with life-limiting comorbidity who are unlikely to benefit from screening.PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Benefits SemanticType:[qnco] PreferredName:Potential SemanticType:[qlco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Continuous SemanticType:[idcn] PreferredName:Women's Health SemanticType:[bmod] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Old SemanticType:[tmco] PreferredName:Good SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Life SemanticType:[idcn] PreferredName:Unlikely SemanticType:[cnce] PreferredName:Comorbidity SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Benefits SemanticType:[qnco] POS:DT POS:NN POS:VBZ POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:NN POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:WP POS:VBP POS:JJR POS:IN POS:CD POS:NNS POS:, POS:CC POS:RB POS:DT POS:NN POS:IN POS:VBG POS:DT POS:NNS POS:IN POS:JJ POS:NN POS:WP POS:VBP POS:JJ POS:TO POS:VB POS:IN POS:NN POS:. 
[sentNum: 354]<Annotation Id="24481" Type="Sentence" StartNode="67063" EndNode="67165">The GDG remains concerned about the contentious nature of debates surrounding breast cancer screening. PreferredName:Natures SemanticType:[ftcn] PreferredName:Concern SemanticType:[idcn] PreferredName:Surrounding (qualifier value) SemanticType:[spco] PreferredName:debate SemanticType:[acty] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] POS:DT POS:NNP POS:VBZ POS:JJ POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NNS POS:VBG POS:NN POS:NN POS:NN POS:. 
[sentNum: 355]<Annotation Id="24482" Type="Sentence" StartNode="67166" EndNode="67408">At the extreme, these debates challenge the value of screening altogether, whereas more generally the debate is characterized by disparate characterizations, in both the academic literature and the media, of the balance of benefits and harms. PreferredName:Extreme SemanticType:[qlco] PreferredName:Challenge SemanticType:[hlca] PreferredName:debate SemanticType:[acty] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Numerical value SemanticType:[qnco] PreferredName:debate SemanticType:[acty] PreferredName:More SemanticType:[ftcn] PreferredName:Characterization SemanticType:[acty] PreferredName:Characterization SemanticType:[acty] PreferredName:Publications SemanticType:[inpr, mnob] PreferredName:Academia (organization) SemanticType:[orgt] PreferredName:Within SemanticType:[spco] PreferredName:Communications Media SemanticType:[inpr] PreferredName:Benefits SemanticType:[qnco] PreferredName:Balanced - adjective SemanticType:[ftcn] POS:IN POS:DT POS:NN POS:, POS:DT POS:NNS POS:VBP POS:DT POS:NN POS:IN POS:NN POS:RB POS:, POS:IN POS:RBR POS:RB POS:DT POS:NN POS:VBZ POS:VBN POS:IN POS:JJ POS:NNS POS:, POS:IN POS:CC POS:DT POS:JJ POS:NN POS:CC POS:DT POS:NNS POS:, POS:IN POS:DT POS:NN POS:IN POS:NNS POS:CC POS:NNS POS:. 
[sentNum: 356]<Annotation Id="24483" Type="Sentence" StartNode="67409" EndNode="67677">Given the weight of the evidence that mammography screening is associated with a significant reduction in the risk of dying from breast cancer after age 40 years, a more productive discussion would be focused on how to improve the performance of mammography screening. PreferredName:Weighing patient SemanticType:[diap] PreferredName:GIVEN SemanticType:[cnce] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Significant SemanticType:[idcn] PreferredName:Associated with SemanticType:[qlco] PreferredName:Within SemanticType:[spco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Dying Process SemanticType:[orgf] PreferredName:Risk SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:From SemanticType:[qlco] PreferredName:/40 SemanticType:[tmco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Productivity SemanticType:[qnco] PreferredName:More SemanticType:[ftcn] PreferredName:Focal SemanticType:[spco] PreferredName:Discussion (communication) SemanticType:[socb] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Performance SemanticType:[inbe] POS:VBN POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:VBZ POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NN POS:IN POS:VBG POS:IN POS:NN POS:NN POS:IN POS:NN POS:CD POS:NNS POS:, POS:DT POS:RBR POS:JJ POS:NN POS:MD POS:VB POS:VBN POS:IN POS:WRB POS:TO POS:VB POS:DT POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 357]<Annotation Id="24484" Type="Sentence" StartNode="67678" EndNode="67816">The absence of organized screening in the United States contributes to many of the shortcomings commonly attributed to the screening test. PreferredName:Organized SemanticType:[ftcn] PreferredName:Absence (morphologic abnormality) SemanticType:[anab] PreferredName:United States SemanticType:[geoa] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Concept Attribute SemanticType:[idcn] PreferredName:Contribution SemanticType:[acty] PreferredName:Screening Tests SemanticType:[hlca] POS:DT POS:NN POS:IN POS:JJ POS:NN POS:IN POS:DT POS:NNP POS:NNP POS:VBZ POS:TO POS:JJ POS:IN POS:DT POS:NNS POS:RB POS:VBN POS:TO POS:DT POS:NN POS:NN POS:. 
[sentNum: 358]<Annotation Id="24485" Type="Sentence" StartNode="67817" EndNode="68005">For example, the lack of central registries for call/recall hampers the efficiency with which women are invited to screening, meaning adherence to recommended screening remains suboptimal. PreferredName:Example SemanticType:[cnce] PreferredName:Central SemanticType:[spco] PreferredName:Lacking SemanticType:[qlco] PreferredName:Decision SemanticType:[menp] PreferredName:Registries SemanticType:[inpr] PreferredName:Efficiency SemanticType:[qnco] PreferredName:Recall:-:Point in time:^Patient:- SemanticType:[clna] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Adherence (attribute) SemanticType:[ftcn] PreferredName:Meaning SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Suboptimal SemanticType:[qlco] POS:IN POS:NN POS:, POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:JJ POS:JJ POS:NN POS:VBZ POS:DT POS:NN POS:IN POS:WDT POS:NNS POS:VBP POS:VBN POS:TO POS:NN POS:, POS:VBG POS:NN POS:TO POS:VBN POS:NN POS:VBZ POS:JJ POS:. 
[sentNum: 359]<Annotation Id="24486" Type="Sentence" StartNode="68006" EndNode="68222">There is too much variability in the sensitivity and specificity of mammography, which could be improved with better training, stronger qualifying standards, continuing education, and regular feedback on performance.118PreferredName:Variability SemanticType:[cnce] PreferredName:Mammography SemanticType:[diap] PreferredName:Sensitivity and Specificity SemanticType:[qnco] PreferredName:Better SemanticType:[qlco] PreferredName:Better SemanticType:[qlco] PreferredName:Strong SemanticType:[qlco] PreferredName:Training Programs SemanticType:[edac] PreferredName:Standards of Weights and Measures SemanticType:[qlco] PreferredName:Qualifying SemanticType:[qlco] PreferredName:Regular SemanticType:[qlco] PreferredName:Education, Continuing SemanticType:[edac] PreferredName:Performance SemanticType:[inbe] PreferredName:Feedback - system communication SemanticType:[phpr] POS:EX POS:VBZ POS:RB POS:RB POS:JJ POS:IN POS:DT POS:NN POS:CC POS:NN POS:IN POS:NN POS:, POS:WDT POS:MD POS:VB POS:VBN POS:IN POS:JJR POS:NN POS:, POS:JJR POS:NN POS:NNS POS:, POS:VBG POS:NN POS:, POS:CC POS:JJ POS:NN POS:IN POS:NN POS:. 
[sentNum: 360]<Annotation Id="24487" Type="Sentence" StartNode="68222" EndNode="68340">118,119 Improved accuracy (both sensitivity and specificity) would contribute to increased benefits and reduced harms.PreferredName:Accurate (qualifier) SemanticType:[qlco] PreferredName:Better SemanticType:[qlco] PreferredName:Contribution SemanticType:[acty] PreferredName:Sensitivity and Specificity SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Reduced SemanticType:[qlco] POS:CD POS:, POS:CD POS:CD POS:NN POS:( POS:DT POS:NN POS:CC POS:NN POS:) POS:MD POS:VB POS:TO POS:VBN POS:NNS POS:CC POS:VBN POS:NNS POS:. 
[sentNum: 361]<Annotation Id="24488" Type="Sentence" StartNode="68342" EndNode="68409">Improving access to high-quality breast imaging remains a priority. PreferredName:Improving (qualifier value) SemanticType:[qlco] PreferredName:High SemanticType:[qlco] PreferredName:Role Class - access SemanticType:[idcn] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Quality SemanticType:[qlco] PreferredName:Priority SemanticType:[tmco] PreferredName:Imaging Techniques SemanticType:[diap] POS:VBG POS:NN POS:TO POS:JJ POS:NN POS:NN POS:VBZ POS:DT POS:NN POS:. 
[sentNum: 362]<Annotation Id="24489" Type="Sentence" StartNode="68410" EndNode="68580">In the United States, barriers to access continue to exist among low-income or uninsured women, those without a usual source of care, or those residing in rural counties.120PreferredName:BARRIER SemanticType:[medd] PreferredName:United States SemanticType:[geoa] PreferredName:Continuous SemanticType:[idcn] PreferredName:Role Class - access SemanticType:[idcn] PreferredName:Exist SemanticType:[cnce] PreferredName:To SemanticType:[qlco] PreferredName:Uninsured SemanticType:[popg] PreferredName:Low income SemanticType:[fndg] PreferredName:Usual SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:care activity SemanticType:[acty] PreferredName:Source SemanticType:[fndg] PreferredName:Rural SemanticType:[fndg] PreferredName:Reside SemanticType:[acty] PreferredName:County SemanticType:[geoa] POS:IN POS:DT POS:NNP POS:NNPS POS:, POS:NNS POS:TO POS:NN POS:VBP POS:TO POS:VB POS:IN POS:JJ POS:CC POS:JJ POS:NNS POS:, POS:DT POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:, POS:CC POS:DT POS:VBG POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 363]<Annotation Id="24490" Type="Sentence" StartNode="68580" EndNode="68751">120- 122 These and other barriers are a formidable challenge to the delivery of preventive services and likely will remain so for some time without further policy changes. PreferredName:BARRIER SemanticType:[medd] PreferredName:Obstetric Delivery SemanticType:[topp] PreferredName:Challenge:Type:Point in time:^Patient:Nominal SemanticType:[clna] PreferredName:Probably SemanticType:[idcn] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Time SemanticType:[tmco] PreferredName:Somalia SemanticType:[geoa] PreferredName:Policy SemanticType:[inpr] PreferredName:Further SemanticType:[spco] PreferredName:Changing SemanticType:[ftcn] POS:CD POS:: POS:CD POS:DT POS:CC POS:JJ POS:NNS POS:VBP POS:DT POS:JJ POS:NN POS:TO POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:CC POS:RB POS:MD POS:VB POS:RB POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:NNS POS:. 
[sentNum: 364]<Annotation Id="24491" Type="Sentence" StartNode="68752" EndNode="69066">While the intent of the Affordable Care Act (ACA) is to eliminate cost sharing for mammography screening, there is still a lack of clarity about coverage as it pertains to breast cancer screening at some ages and at some intervals that the ACS either recommends or endorses for informed and shared decision making. PreferredName:Act Mood - intent SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Patient Protection and Affordable Care Act SemanticType:[rnlw] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Cost Sharing SemanticType:[qnco] PreferredName:Clarity SemanticType:[clna] PreferredName:Lacking SemanticType:[qlco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Cover - action SemanticType:[ftcn] PreferredName:And SemanticType:[idcn] PreferredName:Age SemanticType:[orga] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Interval SemanticType:[tmco] PreferredName:Decision Making, Shared SemanticType:[menp] PreferredName:Informed SemanticType:[qlco] POS:IN POS:DT POS:NN POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:( POS:NNP POS:) POS:VBZ POS:TO POS:VB POS:NN POS:NN POS:IN POS:JJ POS:NN POS:, POS:EX POS:VBZ POS:RB POS:DT POS:NN POS:IN POS:NN POS:IN POS:NN POS:IN POS:PRP POS:VBZ POS:TO POS:NN POS:NN POS:NN POS:IN POS:DT POS:NNS POS:CC POS:IN POS:DT POS:NNS POS:IN POS:DT POS:NNP POS:RB POS:VBZ POS:CC POS:VBZ POS:IN POS:JJ POS:CC POS:JJ POS:NN POS:NN POS:. 
[sentNum: 365]<Annotation Id="24492" Type="Sentence" StartNode="69067" EndNode="69404">It is the ACS’ very strong position that average-risk women should not face financial disincentives when making decisions about mammography screening, either when adhering to these recommendations or when weighing the pros and cons of a different starting age or screening interval when informed or shared decision making is recommended.PreferredName:Strong SemanticType:[qlco] PreferredName:Very SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Positioning Attribute SemanticType:[spco] PreferredName:Woman SemanticType:[popg] PreferredName:Risk SemanticType:[qlco] PreferredName:Face SemanticType:[blor] PreferredName:Negation SemanticType:[ftcn] PreferredName:Disincentives SemanticType:[qlco] PreferredName:financial SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Decision Making SemanticType:[menp] PreferredName:Advice SemanticType:[hlca] PreferredName:Immobile SemanticType:[fndg] PreferredName:Proline SemanticType:[aapp, bacs] PreferredName:Weighing patient SemanticType:[diap] PreferredName:Beginning SemanticType:[tmco] PreferredName:Concanavalin A SemanticType:[aapp, bacs] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:age differences SemanticType:[aggp] PreferredName:Informed SemanticType:[qlco] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Decision Making, Shared SemanticType:[menp] POS:PRP POS:VBZ POS:DT POS:NNP POS:NNP POS:RB POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:MD POS:RB POS:VB POS:JJ POS:NNS POS:WRB POS:VBG POS:NNS POS:IN POS:JJ POS:NN POS:, POS:CC POS:WRB POS:VBG POS:TO POS:DT POS:NNS POS:CC POS:WRB POS:VBG POS:DT POS:NNS POS:CC POS:NNS POS:IN POS:DT POS:JJ POS:JJ POS:NN POS:CC POS:VBG POS:JJ POS:WRB POS:JJ POS:CC POS:VBN POS:NN POS:NN POS:VBZ POS:VBN POS:. 
[sentNum: 366]<Annotation Id="24493" Type="Sentence" StartNode="69406" EndNode="69560">This guideline is intended to provide guidance to the public and clinicians, and it is especially designed for use in the context of a clinical encounter. PreferredName:intended - ParticipationSignature SemanticType:[idcn] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Providing (action) SemanticType:[acty] PreferredName:To SemanticType:[qlco] PreferredName:Clinician SemanticType:[prog] PreferredName:Spatial guidance for medical procedure SemanticType:[clna] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:Design SemanticType:[acty] PreferredName:Clinical setting SemanticType:[spco] PreferredName:Present SemanticType:[qnco] PreferredName:Patient Visit SemanticType:[hlca] POS:DT POS:NN POS:VBZ POS:VBN POS:TO POS:VB POS:NN POS:TO POS:DT POS:NN POS:CC POS:NNS POS:, POS:CC POS:PRP POS:VBZ POS:RB POS:VBN POS:IN POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NN POS:. 
[sentNum: 367]<Annotation Id="24494" Type="Sentence" StartNode="69561" EndNode="69761">Women should be encouraged to be aware of and to discuss their family history and medical history with a clinician, who should periodically ascertain whether a woman’s risk factor profile has changed. PreferredName:Woman SemanticType:[popg] PreferredName:Awareness SemanticType:[menp] PreferredName:To SemanticType:[qlco] PreferredName:Family History Domain SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Clinician SemanticType:[prog] PreferredName:Medical History Domain SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Periodic SemanticType:[tmco] PreferredName:Profile (lab procedure) SemanticType:[lbpr] PreferredName:risk factors SemanticType:[qnco] PreferredName:Changing SemanticType:[ftcn] POS:NNS POS:MD POS:VB POS:VBN POS:TO POS:VB POS:JJ POS:IN POS:CC POS:TO POS:VB POS:PRP$ POS:NN POS:NN POS:CC POS:JJ POS:NN POS:IN POS:DT POS:NN POS:, POS:WP POS:MD POS:RB POS:VB POS:IN POS:DT POS:NN POS:NNS POS:NN POS:NN POS:NN POS:NN POS:VBZ POS:VBN POS:. 
[sentNum: 368]<Annotation Id="24495" Type="Sentence" StartNode="69762" EndNode="69896">If the woman has an average risk of developing breast cancer, the ACS encourages a discussion of screening around the age of 40 years. PreferredName:Woman SemanticType:[popg] PreferredName:Risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Discussion (procedure) SemanticType:[topp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:around SemanticType:[idcn] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:/40 SemanticType:[tmco] PreferredName:Age-Years SemanticType:[tmco] POS:IN POS:DT POS:NN POS:VBZ POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:NN POS:NN POS:, POS:DT POS:NNP POS:VBZ POS:DT POS:NN POS:IN POS:NN POS:IN POS:DT POS:NN POS:IN POS:CD POS:NNS POS:. 
[sentNum: 369]<Annotation Id="24496" Type="Sentence" StartNode="69897" EndNode="70076">The ACS also recommends that women be provided with information about risk factors, risk reduction, and the benefits, limitations, and harms associated with mammography screening.PreferredName:Woman SemanticType:[popg] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Information SemanticType:[idcn] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Risk Reduction SemanticType:[inbe] PreferredName:risk factors SemanticType:[qnco] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Associated with SemanticType:[qlco] POS:DT POS:NNP POS:RB POS:VBZ POS:IN POS:NNS POS:VB POS:VBN POS:IN POS:NN POS:IN POS:NN POS:NNS POS:, POS:NN POS:NN POS:, POS:CC POS:DT POS:NNS POS:, POS:NNS POS:, POS:CC POS:NNS POS:VBN POS:IN POS:NN POS:NN POS:. 
[sentNum: 370]<Annotation Id="24497" Type="Sentence" StartNode="70078" EndNode="70314">In conclusion, the ACS recommendations are made in the context of maximizing reductions in breast cancer mortality and reducing years of life lost while minimizing the associated harms among the population of women in the United States. PreferredName:Recommendation SemanticType:[idcn] PreferredName:Conclusion SemanticType:[idcn] PreferredName:Context SemanticType:[fndg] PreferredName:Make - Instruction Imperative SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Reduction (chemical) SemanticType:[npop] PreferredName:Reduced SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Life SemanticType:[idcn] PreferredName:year SemanticType:[tmco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Lost SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:geographic population SemanticType:[qnco] PreferredName:United States SemanticType:[geoa] POS:IN POS:NN POS:, POS:DT POS:NNP POS:NNS POS:VBP POS:VBN POS:IN POS:DT POS:NN POS:IN POS:VBG POS:NNS POS:IN POS:NN POS:NN POS:NN POS:CC POS:VBG POS:NNS POS:IN POS:NN POS:VBN POS:IN POS:VBG POS:DT POS:VBN POS:NNS POS:IN POS:DT POS:NN POS:IN POS:NNS POS:IN POS:DT POS:NNP POS:NNPS POS:. 
[sentNum: 371]<Annotation Id="24498" Type="Sentence" StartNode="70315" EndNode="70492">The ACS recognizes that the balance of benefits and harms will be close in some instances and that the spectrum of women’s values and preferences will lead to varying decisions. PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Closed SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Spectrum SemanticType:[cnce] PreferredName:Instance SemanticType:[idcn] PreferredName:Values SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Dietary Lead SemanticType:[elii] PreferredName:preference SemanticType:[idcn] PreferredName:Decision SemanticType:[menp] POS:DT POS:NNP POS:VBZ POS:IN POS:DT POS:NN POS:IN POS:NNS POS:CC POS:NNS POS:MD POS:VB POS:JJ POS:IN POS:DT POS:NNS POS:CC POS:IN POS:DT POS:NN POS:IN POS:NNS POS:VBG POS:JJ POS:NNS POS:CC POS:NNS POS:MD POS:VB POS:TO POS:VBG POS:NNS POS:. 
[sentNum: 372]<Annotation Id="24499" Type="Sentence" StartNode="70493" EndNode="70686">The intention of this new guideline is to provide both guidance and flexibility for women about when to start and stop screening mammography and how frequently to be screened for breast cancer.PreferredName:intent SemanticType:[qlco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:New SemanticType:[tmco] PreferredName:Providing (action) SemanticType:[acty] PreferredName:To SemanticType:[qlco] PreferredName:Pliability SemanticType:[qlco] PreferredName:Spatial guidance for medical procedure SemanticType:[clna] PreferredName:To SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Stop (qualifier value) SemanticType:[tmco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Frequent SemanticType:[tmco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NN POS:VBZ POS:TO POS:VB POS:DT POS:NN POS:CC POS:NN POS:IN POS:NNS POS:IN POS:WRB POS:TO POS:VB POS:CC POS:VB POS:VBG POS:RB POS:CC POS:WRB POS:RB POS:TO POS:VB POS:VBN POS:IN POS:NN POS:NN POS:. 
